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Bacteria must be able to respond and rapidly adapt to their environment. Historically, this has 
been studied in the context of two-component systems (TCS). TCS are composed of a sensor histidine 
kinase that upon activation autophosphorylates a conserved histidine residue and then transfers this 
phosphate to a response regulator at a conserved aspartate residue.  This phosphorylation event leads to 
dimerization of the response regulator and its subsequent activation, which in many cases, is 
transcriptional activation. In addition to this classical signaling paradigm, bacteria also contain eukaryotic-
like serine/threonine kinases (eSTK). In the past decade these kinases and their partner eukaryotic-like 
phosphatases have been characterized. However, their in vivo substrates still remain largely unknown.  
         My thesis project describes how eukaryotic-like serine/threonine kinases regulate classical two-
component systems involved in cell wall metabolism. In my first project, the Bacillus subtilis eSTK PrkC 
phosphorylates the essential response regulator WalR. This modification enhances WalR activity and has 
pronounced transcriptional and physiological effects.  I have also shown that this mechanism of regulation 
is conserved in the clinically relevant pathogen Staphylococcus aureus.  My second project focuses on 
the role of Enterococcus faecalis eSTK IreK and its phosphorylation of the VanB-type vancomycin 
resistance histidine kinase VanS. My evidence suggests that threonine phosphorylation of IreK is required 
for full induction of the VanRS regulon genes and subsequently full vancomycin resistance. Together, 
these projects highlight how threonine phosphorylation of classical two-component systems is an 
important mechanism of regulation. Finally, I have done work with eSTKs from gram-negative bacteria 
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Chapter 1. General Introduction 
 
1.1 Bacterial Cell Wall  
 
All bacteria contain a rigid cell wall that is critical for cell shape and also prevents lysis due to turgor 
pressure. This essential structure is composed primarily of peptidoglycan. This mesh like structure 
completely encapsulates bacteria, and is termed the sacculus. Coordination of the synthesis and 
degradation of peptidoglycan is required for successful cell growth and daughter cell separation.  
Inhibition of these processes results in cell death, underlying the importance of this structure in 
maintaining viability. Bacteria invest a lot of resources into maintaining their cell wall and responding to 
cell wall stress. My thesis discusses strategies Bacillus subtilis, Staphylococcus aureus, and 
Enterococcus faecalis use to respond to cell wall stress and regulate cell wall metabolism. The 
essentiality of this structure is exploited by the immune system to recognize bacterial pathogens and is 
also the target of antibiotics that inhibit these cellular processes.  
The topology and structure of peptidoglycan in Gram-positive and Gram-negative bacteria is quite 
distinct. In Gram-negative bacteria, a thin layer of peptidoglycan is sandwiched between the outer and 
inner membranes. Cryo-transmission electron microscopy of Escherichia coli and Pseudomonas 
aeruginosa has revealed the peptidoglycan layer to be 6nm and 2.5nm thick respectively [167]. This is in 
stark contrast to what is observed for Gram-positive bacterium such as Bacillus subtilis [168] and 
Staphyloccus aureus [169] using the same technique, which is much thicker and ranges from 15-30 nm 
thick. In Gram-positive bacteria there is no outer membrane and peptidoglycan is the outermost layer in 
the cell. The ability to isolate sacculi after sodium dodecyl sulfate boiling of bacterial cells in both Gram-
negative [93] and Gram-positive bacteria [15] highlights the rigidity of this structure and the important 
structural role peptidoglycan plays in determining cell shape [286]. The coordination of synthesis and 
degradation to insert new material into the peptidoglycan mesh is a highly regulated process that involves 




1.1.1 Peptidoglycan Biosynthesis 
Peptidoglycan synthesis is a complex process that involves approximately 20 coordinated reactions 
[24]. It involves the synthesis of the nucleotide precursors in the cytoplasm, synthesis of lipid-linked 
intermediates on the cytoplasmic face, and subsequent flipping and polymerization of mature 
peptidoglycan on the outer leaflet of the membrane. Mature peptidoglycan consists of linear glycan 
strands cross-linked by short peptides [222]. These strands are composed of alternating N-
acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) residues linked to a pentapeptide chain 
[276] (Figure 1.1.2).  
Peptidoglycan biosynthesis begins in the cytoplasm where UDP-GlcNAc is converted from the 
glycolysis intermediate, fructose-6-phosphate, through four successive enzymatic steps. These reactions 
are carried out by the activities of glucosamine-6-phosphate synthase (GlmS), phosphoglucosamine 
mutase (GlmM), glucosamine-1-phosphate acetyltransferase and N-acetylglucosamine-1-phosphate 
uridyltransferase activities by the GlmU bifunctional enzyme [24]. The pathway for UDP-GlcNAc 
biosynthesis in bacteria is distinct from the pathway found in eukaryotes, where this molecule is used for 
chitin and glycoproteins.  
The conversion of UDP-GlcNAc to UDP-MurNAc is the first committed step towards the generation 
of the peptidoglycan polymer. It involves a two-step addition-elimination mechanism that is catalyzed by 
the cytoplasmic enzymes MurA [162] and MurB [27, 28]. Sequential assembly onto UDP-MurNAc by the 
Mur family of ligases results in the generation of the Park nucleotide (Figure 1.1.1). These ligases are 
structurally similar and involve binding of the UDP-MurNAc substrate in the N-terminal domain, an ATP 
binding domain, and C-terminal amino-acid binding domain. UDP-MurNAc is modified by the addition of 
L-alanine (MurC), D-glutamic acid (MurD), meso-diaminopimelic acid or L-lysine (MurE) and the dipeptide 
D-Ala-D-Ala (MurF) [247]. The third position of the pentapeptide stem is variable between Gram-negative 
and Gram-positive bacteria. While most Gram-positive bacteria contain an L-lysine at this third position, 
the Gram-positive spore former Bacillus subtilis that will receive considerable attention throughout this 





Figure 1.1.1 Structure of Park Nucleotide.  
 
Figure 1.1.1 Structure of Park Nucleotide. Adapted from Smith et al, 2006 [247].The Mur ligases modify 
UDP-MurNAc resulting in the Park nucleotide. Shown is meso-DAP at the third position of the stem 




 While the previous steps were entirely cytoplasmic, after the generation of the Park nucleotide 
precursor, the remaining steps occur at the membrane. It involves the key lipid, undecaprenyl phosphate 
(C55-P), also known as bactoprenol. In addition to its role in peptidoglycan biosynthesis, this lipid is also 
required for the biosynthesis of lipopolysaccharides [214], enterobacterial common antigen [220], capsule 
polysaccharides [269], and teichoic acids [283]. In peptidoglycan biosynthesis, the integral membrane 
protein MraY catalyzes the transfer of the MurNAc-pentapeptide to bactoprenol yielding Lipid I.  Lipid I is 
a substrate of the cytoplasmic enzyme, MurG [226], which catalyzes the transfer of the GlcNAc moiety 
from UDP-GlcNAc to Lipid I by forming a β 1-4 linked disaccharide, Lipid II [35] (Figure 1.1.2). After 
generation of Lipid II, this molecule has to be flipped across the membrane to generate a mature 
peptidoglycan polymer. The flippase activity has been attributed to the essential integral membrane 
protein FtsW in E. coli [176].  
 After Lipid II has been flipped to the extracellular space, it is now integrated into the 
peptidoglycan polymer by the activity of penicillin binding proteins (PBPs). PBPs are divided into two 
functional categories; the high molecular mass (HMM) PBPs and the low molecular mass (LMM) PBPs. 
HMM PBPs catalyze the polymerization of the glycan strand and insertion into the pre-existing cell wall. 
[33, 94, 231] HMM PBPs possess both transpeptidase and transglycosylase activity. Transglycosylation 
involves the polymerization of glycan strands by the formation of β 1-4 glycosidic bonds between the 
GlcNAc and MurNAc moiety of Lipid II [235]. Transglycosylation leads to parallel glycan strands. These 
  
4 
long glycan strands can be integrated into the peptidoglycan framework by the transpeptidation activity of 
HMM and LMM PBPs. The pentapeptides that are perpendicular to the sugar backbone are cross-linked 
between glycan strands and allows for the cross-linking of mature peptidoglycan. The coordination of 
transpeptidation and transglycosylation activity results in the formation of the peptidoglycan sacculus that 
completely surrounds the bacterium.  
 





























Figure 1.1.2 Peptidoglycan Biosynthesis. Reproduced from Allison Fay’s Thesis (2010). The gray 
hexagon depicts UDP-GlcNAc, which is converted to UDP-MurNAc (black hexagons) by the enzymes 
MurA and MurB. The Mur ligases (MurC to MurF) generate the Park nucleotide which is attached to the 
lipid carrier bactoprenol by the enzymatic activity of the integral membrane protein MraY to generate Lipid 
I. Lipid I is then a substrate of MurG, which attaches GlcNAc to generate Lipid II. This is flipped across 
the membrane where it is inserted into the peptidoglycan framework by PBPs through their 
transglycosylation and transpeptidation activities.  




1.1.2 Antibiotics That Target Peptidoglycan Biosynthesis 
Due to the essential nature of the bacterial cell wall and its conserved structure, many antibiotics 
target enzymes or precursors in the peptidoglycan biosynthesis pathway.  The antibiotic of the most 
historical significance is penicillin. It was discovered in 1929 to kill bacterial cells. Subsequent analysis 
demonstrated that penicillin was able to inhibit peptidoglycan crosslinking [294]. Penicillin was shown to 
bind to PBPs [91] by mimicking the terminal D-Ala-D-Ala residue found in peptidoglycan precursors [264]. 
The high antimicrobial effectiveness of penicillin led to further development of β-lactam antibiotics, such 
as cephalosporins, however these molecules bind to PBPs with variable efficiency and can lead to 
subsequent resistance [11, 52, 300]. A narrow spectrum β-lactam that receives considerable attention 
due to its resistance in Staphylococcus aureus is methicillin [186]. 
In addition to β-lactams, which prevent transpeptidation of peptidoglycan precursors, many cell 
wall antibiotics target enzymes in the intracellular steps. While there are many antibiotics, I will discuss 
those relevant to this thesis. The first step in the pathway is blocked by the antibiotic fosfomycin, which is 
an irreversible inhibitor of MurA [125].  This inhibition is due to the generation of a thiol adduct between 
fosfomycin and Cys115 within the active site of MurA [163]. Mutation of Cys115 to an aspartate residue 
conferred resistance to fosfomycin [130]. Mycobacterium tuberculosis resistance to fosfomycin is due to 
the presence of an aspartate at this position. Sensitivity to fosfomycin could be achieved by engineering a 
M. tuberculosis MurA Asp115Cys variant [54].  
In addition to fosfomycin, several other classes of antibiotics target the intracellular peptidoglycan 
biosynthesis steps. D-cycloserine is an irreversible inhibitor of alanine racemase, the enzyme that 
generates the D-Ala-D-ala substrate that is utilized by the MurF ligase to complete the UDP-MurNac-
pentapeptide [145]. In addition to the inhibition of alanine racemase, several antibiotics target lipid-linked 
steps. Tunicamycin is a competitive inhibitor of MraY [38], although it is also a potent inhibitor of teichoic 
acid biosynthesis by blocking the incorporation of N-acetylglucosamine from UDP-GlcNAc into teichoic 
acid polymers [210, 296]. Further upstream from MraY, bacitracin inhibits bacterial cell wall synthesis 
through sequestration of bactoprenol [253].  
Once Lipid II is flipped across the membrane it becomes a target of glycopeptides [218]. This 
class of antibiotics consists of both vancomycin and teicoplanin. They function by binding to the terminal 
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D-Ala-D-Ala residue and blocking both transglycosylation and transpeptidation steps. This class of 
antibiotics is the last resort antibiotic for methicillin-resistant Staphylococcus aureus (MRSA) [205]. 
Emerging resistance to vancomycin has become an increasing clinical health problem in MRSA and 
vancomycin-resistance Enterococci [51].  
 
1.1.3 Cell Wall Hydrolases 
Cell wall hydrolases (autolysins) are lytic enzymes that can digest bacterial peptidoglycan [275]. 
Peptidoglycan is considered to be a rigid structure, due to its ability to prevent osmotic lysis and cell 
shape. The peptidoglycan polymer is quite dynamic as it must be expanded during cell growth and 
reshaped during cell division or differentiation. While the peptidoglycan biosynthesis machinery has been 
extensively studied, the autolysins are less well characterized. However, it has been proposed that these 
autolysins can selectively remove peptidoglycan and are involved in cell growth, cell wall turnover, 
peptidoglycan maturation, cell division, separation, motility, chemotaxis, genetic competence, protein 
secretion, differentiation, and pathogenicity [80, 81, 248]. However unregulated peptidoglycan 
degradation and cell lysis can be lethal to cells. Therefore, the expression and activity of these enzymes 
must be tightly regulated.  
The important role autolysins play in normal cell growth and division can be seen by genetic 
analysis of autolysins in various bacteria. Due to the limited number of hydrolases in S. pneumoniae, 
there is little functional redundancy and deletion of the cell wall hydrolase, PcsB, is lethal [22]. The 
essentiality of the response regulator, VicR, is due to its regulation of this essential cell wall hydrolase 
[187]. In contrast to S. pneumoniae, there is functional redundancy in autolysins in B. subtilis [248]. This 
functional redundancy has made it difficult to determine the physiological significance of individual 
autolysins. However, combining mutations has led to one well-studied case of synthetic lethality. This 
involves the enzymes CwlO and LytE, which are both regulated by the essential two-component system, 
WalRK. The synthetic lethality results in loss of D,L-endopeptidase activity at the lateral cell wall [103]. 
The inability to cleave the peptidoglycan polymer between D-Glu and mesoDAP prevents the insertion of 




In order for cells to successfully multiply and differentiate, it requires the coordinated activity of 
the peptidoglycan synthesis machinery and autolysins. Deregulation of autolysins can be very detrimental 
to the cell and ultimately lead to cell lysis. The importance in regulating cell wall metabolism is reflected 
by the fact that many signaling systems regulate various components of this pathway although how these 
systems actually work mechanistically remains unclear. In the later sections I will be describing both two-
component systems and eukaryotic-like Ser/Thr kinases that have been shown to regulate cell wall 
metabolism and adapt to cell wall stress.  
  
1.2 Two-Component Systems 
 
Bacteria must be able to sense and respond to environmental stimuli. Two-component systems 
are classical signaling systems composed of a sensor histidine kinase and a cognate response regulator 
(Figure 1.2). Sensor histidine kinases are usually membrane bound, and upon sensing of a ligand, 
undergo a conformational change that leads to the autophosphorylation on a conserved histidine residue. 
After autophosphorylation, the histidine kinase is able to transfer this phosphate group to a conserved 
aspartate residue within the receiver domain of the response regulator. Phosphorylation of this conserved 
aspartate residue leads to dimerization and activation of the response regulator. Response regulators are 
modular proteins with a conserved receiver domain that interacts with its cognate histidine kinase, and an 
effector domain. In many cases, and in the two-component signal transduction systems I will be 










Figure 1.2 Schematic of Two-Component Signal Transduction 
 
Figure 1.2. Two-Component Signal Transduction. Schematic representing the membrane bound 
histidine kinase that upon sensing of an environmental stimulus leads to structural changes within the 
histidine kinase and autophosphorylation at the conserved histidine residue. The histidine kinase 
phosphorylates the receiver domain at the conserved aspartate (D53). This leads to activation of the 
response regulator. In addition to kinase activity, histidine kinases also possess dual phosphatase activity 
and are also able to dampen the response.   
 
1.2.1 Histidine Kinases 
 Sensor histidine kinases are critical for interpreting the environment and relaying this information 
to the response regulator by phosphorylation. Histidine kinases contain a conserved kinase core with 
highly divergent sensing domains [252]. All histidine kinases contain a dimerization and histidine 
phosphotransfer domain (DHp) and a C-terminal catalytic and ATP-binding domain (CA) [5, 203, 251]. 
The DHp and CA domain compose the histidine kinase core and is structurally distinct from serine and 
threonine kinases. The dimerization domain of histidine kinases forms anti-parallel four helix bundles that 















Thermatoga maritime HK853 was solved in 2005 and for the first time showed the physical interactions 
between the DHp and CA domains of an intact histidine kinase [161]. 
 In addition to the intracellular kinase domain, many histidine kinases contain other protein 
domains within the cytoplasm. One commonly found domain is the HAMP domain. Its name derives from 
the observation that they are found in histidine kinases, adenylyl cyclases, methyl-accepting chemotaxis 
proteins, and some phosphatases [10, 291]. In sensor histidine kinases, HAMP domains lie near the 
membrane and undergo conformational changes that transmit signals from the extracellular domain to the 
autokinase domain [204]. Structural data suggests that the HAMP domains induce a helical rotation, 
which can serve as a signal transduction mechanism for kinase activation or inactivation [111].  
 Another common domain found in both extracellular and intracellular domains of histidine kinases 
is the PAS (Per-Arnt-Sim) domain. Nearly half of all PAS domain containing proteins are histidine kinases 
[104]. However, their conservation at the primary sequence level is poor, therefore making it difficult to 
annotate PAS domains [278]. While historically it has been considered to be a cytoplasmic sensing 
domain, the location of PAS domains within extracellular folds of sensor histidine kinases has become 
appreciated in recent years [45]. PAS domains are ubiquitous in bacterial signaling proteins and are 
thought to either initiate a cellular signaling response or respond to physical or chemical signals [104].  
 Information is relayed from the extracellular input domain to the intracellular kinase domain 
through a transmembrane helix and a cytoplasmic linker. The linker consists of a coiled coil-like domain 
that is thought to promote intramolecular association upon activation, and is critical for proper signal 
transduction. Mutational analysis of the well-studied Escherichia coli histidine kinase EnvZ linker region 
nicely illustrated that while the linker is not required for enzymatic activity or dimerization, it is required for 
proper signal transduction [202]. Modification of the linker through either amino acid substitutions or 
deletions altered the ratio of kinase and phosphatase activity, and resulted in a constitutively active 
phenotype. These data point to the important role that the linker region plays in propagating information 
from the periplasmic receptor domain to the cytoplasmic signaling domain.  
 The ability of sensor histidine kinases to detect signals is quite divergent. There is a high degree 
of variability in topology, transmembrane domains, and domain architecture within the histidine kinase 
super family [138]. Using these criteria, which predict the mechanism of sensing and signal transduction, 
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there are three primary groups of sensor histidine kinase signal perception: periplasmic or extracellular 
sensing histidine kinase, sensing within transmembrane helices, and cytoplasmic sensing histidine 
kinases that can be either soluble or membrane anchored [166]. The largest subgroup consists of the 
periplasmic or extracellular sensing histidine kinases. These histidine kinases contain a C-terminal 
extracellular domain that is flanked by 2 transmembrane helices. It is thought that ligand binding to the 
extracellular domain is how the signal is perceived; however, the structural details of how this signal is 
propagated still remain elusive. The histidine kinases that I will be discussing throughout the remainder of 
this thesis belong to this subgroup.   
1.2.2 Phosphatase Activity of Histidine Kinases 
 
 In addition to the activity of sensor histidine kinases to phosphorylate substrates, they can also 
serve as phosphatases of their cognate response regulator. This fine-tuning of histidine kinase and 
phosphatase activity upon signal perception is what modulates the amount of phosphorylated response 
regulator in the cell. This can readily be observed in vitro, however there is still considerable debate about 
the in vivo role of histidine kinase phosphatase activity [129]. Phosphatase activity has been well studied 
using the Escherichia coli EnvZ/OmpR two-component system, which regulates outer membrane 
expression of the OmpF and OmpC porins.  
 Considerable biochemical and biophysical experiments have been performed on EnvZ/OmpR to 
characterize the relevance of in vivo phosphatase. One issue is the ability of the histidine kinase EnvZ to 
interact with OmpR after it has been phosphorylated and bound to DNA. This was addressed using 
fluorescent anisotropy experiments in which the dissociation constant for OmpR~P in the presence or 
absence of ompC DNA were measured. The binding affinities were unaltered and the authors believe that 
a ternary complex is likely to form in vitro and in vivo [7, 170].  Additionally, affinity constants were 
determined for EnvZ binding to OmpR or OmpR~P using fluorescence resonance energy transfer [131]. 
Interestingly, EnvZ has a 3-fold diminished affinity for OmpR~P compared to OmpR. While the 
biochemical and biophysical data do not rule out the possibility of EnvZ mediated dephosphorylation of 
OmpR, genetic evidence suggests that mutations in EnvZ can stimulate its phosphatase activity and 
leads to a phenotype that Is more severe than a ΔenvZ strain [224]. While the in vivo role of EnvZ 
mediated dephosphorylation of OmpR is still a contentious subject, other in vivo evidence has suggested 
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that phosphatase activity of histidine kinases is important to reduce cross-talk between two-component 
systems [97].  
 The mechanism of response regulator dephosphorylation by histidine kinases is thought to occur 
by nucleophilic attack of the aspartyl phosphate of the response regulator. The orientation of the histidine 
kinase and the response regulator in the Thermatoga maritime HK853/RR468 co-crystal [44], which will 
be further discussed in Section 1.3.4, supports this hypothesis. The conserved histidine residue, which is 
required for autophosphorylation and phosphotransfer, does not appear to be required for phosphatase 
function, implying that the mechanism is not a reverse phosphotransfer mechanism [239, 244]. Amino 
acid substitutions along the α1 helix of the DHp domain of the histidine kinase CrdS from Myxococcus 
xanthus, identified the glutamate adjacent to the conserved histidine residue to be required for kinase 
activity, and a conserved threonine/asparagine five amino acids C-terminal to be required for 
phosphatase activity in vitro and in vivo [290]. These mutations were introduced into other HisKA proteins, 
and the conserved function of these residues suggests that histidine kinases utilize a common 
mechanism for sensor histidine kinase and phosphatase activity. These data together suggest the 
important role of histidine kinase phosphatase activity in regulating the phosphorylation level of the 
response regulator. 
 
1.2.3. Response Regulators 
 Response regulators are the substrates of histidine kinases, and phosphorylation serves as a 
molecular switch to generate an adaptive response. Response regulators contain a conserved N-terminal 
receiver domain, which accepts the phosphate from the histidine kinase at a conserved aspartate residue 
(D53). There is a variable linker region that connects the receiver domain to the C-terminal effector 
domain. In the majority of cases, the C-terminal effector domain is a DNA binding domain, however, a 
diverse array of enzymatic functions can be attributed to other response regulator effector domains [251]. 
Upon phosphorylation by its cognate histidine kinase, the receiver domain undergoes a conformational 
change that is propagated to the effector domain. In addition to phosphorylation by histidine kinases, 
certain response regulators can undergo phosphorylation with small molecule phosphodonors both in 
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vitro and in vivo [171]. Crystal structures now exist of receiver domains unphosphorylated or in the 
presence of phosphoaspartyl analogs, as well as several structures of full-length response regulators. 
 The receiver domain of the response regulator consists of a conserved aspartate residue that is 
the site of autophosphorylation and phosphotransfer from its cognate histidine kinase. This domain is 
highly conserved among response regulators. A sequence alignment of response regulators shows the 
high degree of conservation even across response regulator subfamilies (Figure 1.2.3) [281]. They 
consist of alternating β-strands and α-helices that fold into a central five-stranded parallel β-sheet 
surrounded by α-helices. 
Figure 1.2.3 Sequence Alignment of Response Regulator Receiver Domains  
 
Figure 1.2.3. Sequence Alignment of Response Regulator Receiver Domains. Reproduced from 
Shuishu Wang, 2012[281]. PhoP, PrrA, and MtrA from M. tuberculosis, DrrB from T. maritima, PhoB from 
E. coli, Spo0F from B.subtilis, FixJ from S. meliloti. Top 5 sequences are from the OmpR/PhoB subfamily. 
Spo0F is a single domain response regulator. FixJ is a NarX/FixJ subfamily member. Highlighed in blue 
are identical residues. Highlighted in red are identical residues within the OmpR/PhoB subfamily 
response regulators. Highlighted in gray are moderately conserved sequences across all response 
regulators.  
 
The phosphorylation site, a conserved aspartate residue, lies within an acidic pocket comprised 
of β1 and β3. These conserved acidic side chains are involved in binding of a divalent cation, which is 
essential for the phosphorylation reaction [36]. The α1 helix of the response regulator interacts with its 
cognate histidine kinase, and therefore one would predict a lower degree of conservation within this 
region [44]. The α4-β5-α5 interface has also been shown to be in contact with the histidine kinase.  
 In addition to its interaction with the histidine kinase, the α4-β5-α5 interface is thought to be 
important for phosphorylation regulation of response regulator activities [280]. This interface is considered 
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to be the physiologically relevant dimerization interface upon phosphorylation mediated conformational 
changes [156, 265]. The importance of this interface for response regulator activity was shown in B. 
subtilis PhoP by mutating residue R113, which is buried within this dimerization interface [48]. While 
PhoP was still a substrate of PhoR phosphorylation, it was unable to undergo phosphorylation-mediated 
dimerization or DNA binding, suggesting that phosphorylation is not sufficient for phosphorylation 
mediated dimerization.  
  The α4-β5-α5 interface of the response regulator receiver domain is also important for interaction 
with its effector domain.  These contacts can serve as an important point of regulation. There are 
currently six full-length response regulator structures, and even though the receiver domain and DNA 
binding domains are highly conserved, there is considerable diversity in domain arrangement [21]. Full-
length proteins and receiver domain only constructs were analyzed for response regulator 
autophosphorylation activity. Interestingly, in Mycobacterium tuberculosis MtrA, where extensive 
interdomain contacts are present in the crystal structure, there was highly diminished autophosphorylation 
of the full length protein [21]. These data suggest that docking of the DNA-binding domain to this interface 
acts as a competitive inhibitor for response regulator activation. In all cases, removal of the DNA binding 
domain restored response regulator autophosphorylation activity. It should be noted that there was no 
difference in kinetics in histidine kinase phosphorylation of full-length or receiver domain only response 
regulator constructs. Therefore, the authors speculate that interdomain contacts may serve to insulate 
response regulator activity from small molecule phosphodonors in vivo.  
 
1.2.4 Two-Component System Partner Specificity  
Bacteria contain pairs of two-component systems that respond to a diverse array of 
environmental conditions. While some organisms contain only several pairs, there are bacteria like 
Myxococcus xanthus that contains upward of 272 genes that encode for two-component system proteins 
[150]. On average bacteria have 54 TCSs, based off bioinformatics analysis of 457 sequenced bacterial 
genomes [49]. Even given the large number of two-component systems within a bacterium, there is 
surprisingly little in vitro or in vivo cross talk between two-component systems.  
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Structural insight has been gained into partner specificity originally from the co-crystal structure of 
Spo0F-Spo0B from B. subtilis [302]. However, the implications of this structure remained unclear as 
Spo0B lacked autokinase activity. Almost a decade later the first co-crystal of a catalytically active 
histidine kinase and its cognate response regulator receiver domain was generated from Thermatoga 
maritima HK853 and RR468 (Figure 1.2.4) [44].   The atomic detail gathered in this structure showed that 
RR468 interacted with HK853 by inserting its α1 helix and β5-α5 loop into the four helix bundle histidine 
containing phosphotransfer (DHp) domain to generate a six helix bundle. Furthermore, the β3-α3 loop 
makes transient interactions with the C-terminal catalytic and ATP-binding (CA) domain. It should be 
noted that direct contacts within these domains were also conserved within the Spo0B-Spo0F co-crystal 
[147], confirming the previous implications from the Spo0B/Spo0F co-crystal.  
 
Figure 1.2.4. Co-crystal of T. maritima Two-Component System 
 
Figure 1.2.4. Co-crystal of T. maritima Two-Component System. Adaptation of PDB ID: 3DGE [44]. In 
different shades of blue are two histidine kinase (HK 853) monomers in complex with the receiver 
domains of the response regulator (RR468) shown in different shades of orange. 
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Building off this structural data and the vast amounts of sequencing data gathered from various 
bacterial organisms, investigators have used bioinformatics and computational approaches to analyze 
two-component signal specificity. Secondary and tertiary structural differences in histidine kinases and 
response regulators are minimal, suggesting that fidelity is achieved on the primary sequence level. By 
using the two co-crystals mentioned above as well as bacterial genomes, statistical approaches have 
been applied to determine the interface between a histidine kinase and its cognate response regulator in 
the absence of an atomic crystal structure.  
Co-variance based approaches were initially used to probe histidine kinase and response 
regulator interactions; however, this relied on the frequency of an amino acid at a specific position without 
taking into account the local context. Another major drawback to this approach was that the evolutionary 
constraints on individual amino acids could arise from both direct and indirect interactions [260]. Direct 
Coupling Analysis improved upon co-variance analysis by adding a global inference parameter to identify 
direct interactions [288]. This method has been successful in identifying direct contact residues between 
histidine kinases and response regulators as well as the dimerization surface within response regulators. 
This type of analysis can allow investigators to identify residues at the interaction interface between two-
component signaling proteins without an atomic resolution crystal structure. 
Based off insights from both biochemical and computational approaches, researchers have 
altered the specificity of histidine kinases for their cognate response regulators in both in vitro and in vivo 
settings [43, 147, 246]. These data suggest that a handful of amino acid residues are necessary for 
substrate recognition. This can help explain why these two-component system signaling transduction 
modules while so well conserved on a three-dimensional level, are able to discern its appropriate cognate 
signaling protein. In conclusion, mutational analysis at this protein-protein interface can have profound 
consequences for protein-protein interaction and signaling.  
 
1.3 WalRK Two-Component System 
 The WalRK two-component system, formerly known as YycFG, was originally identified as 
essential in the gram-positive soil dwelling bacterium Bacillus subtilis [77]. It is the only essential pair in B. 
subtilis out of 34 [78]. Due to its essentiality and high conservation among low G+C% gram-positive 
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bacteria, including clinically relevant pathogens such as Enterococcus faecalis, Streptococus pneumoniae, 
and Staphylococcus aureus [70], it has received considerable attention (Figure 1.3).  
The response regulator WalR is essential in all cases [77, 100, 164, 263, 279]. Due to its 
essentiality, several crystal structures of WalR receiver domains [29, 305] and of the WalR DNA-binding 
domains [64, 197, 268] from various organisms have been generated. While the individual domains have 
been studied extensively, there is currently no full-length structure of WalR. The structures of the 
truncated WalR proteins show that WalR is a member of the OmpR/PhoB family of response regulators 
and contains a helix-turn-helix DNA binding domain. WalR orthologs display a high level of amino acid 
sequence identity (>70%), particularly in the DNA binding domain [70]. This conservation reflects the 
WalR DNA recognition motifs that have been found in several bacteria. WalR binds two hexanucleotide 
direct repeats separated by five nucleotides. The consensus sequence for both B. subtilis and S. aureus 
is 5’- TGTWAH-N5-TGTWAH – 3’ [68, 108].  There are minor variations within this consensus sequence 
for S. pneumoniae [189]. It has also been shown that WalR activates and represses gene expression in B. 
subtilis dependent on the distance of the WalR binding site from the promoter [30]. 
M. tuberculosis response regulator MtrA [21] is the closest structural homolog of WalR. MtrA and 
WalR receiver domain dimers are distinctly oriented towards each other. They are positioned at a 50 
degrees rotation around an axis perpendicular to the α4-β5-α5 interface, relative to canonical 
OmpR/PhoB receiver domain dimers [21].  Furthermore, MtrA has substantial interdomain contacts 
between the receiver domain and the DNA binding domain that cause low rates of autophosphorylation 
by the small molecule phosphodonor, phosphoramidate. Structural similarities between MtrA and WalR 
hint that extensive interdomain contacts inhibit autophosphorylation of full-length WalR. This is in 
agreement with reports suggesting that B. subtilis and S. aureus WalR cannot autophosphorylate with 
acetyl phosphate [85].  In agreement with this model, Zhao et al reported they could get 
autophosphorylation of B. subtilis WalR receiver domain only with the small molecular phosphodonor, 
carbamoyl phosphate [305]. 
WalK, the histidine kinase, is essential in most, but not all species. While the intracellular domain 
architecture of WalK orthologs is highly conserved, the extracellular sensing domain can be divided into 
two concrete categories. In cases when WalK is essential, the accessory proteins YycH and YycI are 
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present (Figure 1.3) and WalK contains a large 154 amino acid extracytoplasmic loop, which is predicted 
to contain a PAS domain [259]. In contrast, the non-essential WalK ortholog in S. pneumoniae, VicK, has 
only a short 12 amino acid extracellular peptide and a single transmembrane helix [188]. Due to its lack of 
essentiality in S. pneumoniae, considerable work has been performed to characterize the role of the 
intracellular domains that are common among all WalK orthologs. For example, while it is unknown what 
the intracellular PAS domain is sensing, in vitro biochemical experiments demonstrated its contribution to 
WalK phosphatase activity towards WalR [98]. Furthermore, the role of PAS domain mediated 
phosphatase activity could be verified in vivo, as the WalK histidine kinase, is not essential in S. 
pneumoniae [284].  
 
Figure 1.3 Structural Organization of WalRK Operon in Low G+C% Gram-positive Bacteria. 
  
Figure 1.3. Structural Organization of WalRK Operon in Low G+C% Gram-positive Bacteria. 
Adapted from Türck et al [271] WalR (YycF/ VicR), the response regulator, and WalK (YycG/ VicK), the 
histidine kinase, are conserved across all low G+C% gram-positive bacteria. However, accessory proteins 
within the operon are variable. Indicated in yellow are essential proteins. Black bars indicate 
transmembrane helices. Functions are indicated below the proteins. RR= response regulator, SK= sensor 
histidine kinase, NR= negative regulator of histidine kinase function, β-lac = similarity to enzyme super-




The accessory proteins YycH and YycI are only found in bacteria that contain a WalK ortholog 
with two transmembrane helices and an extensive extracellular loop. Both of these proteins have been 
crystalized, and despite having only 10% sequence identity, they are structurally similar [228, 257]. They 
both contain a N-terminal anchored transmembrane domain and interact with WalK in a tertiary complex. 
In-frame deletion of either YycH or YycI leads to 10-fold increase in WalRK activity as measured by the 
transcription of the canonical WalR target gene yocH [256, 258]. Even though both YycH and YycI 
contain extracellular domains, their transmembrane helices are sufficient to complement for a ΔyycH or 
ΔyycI strain. These data suggest that it is the transmembrane helices that are important for regulating the 
activity of the essential histidine kinase, WalK [259]. 
While YycH and YycI directly interact with WalK, the function of YycJ remains more enigmatic. 
Hidden Markov Model predictions suggest that YycJ is a member of the metallo-β-lactamase superfamily 
[70]. In B. subtilis, deletion of yycJ affected colony morphology and led to an accumulation of secondary 
mutations that prevented sporulation [258]. The phenotypes for modulating YycJ (VicX) are much more 
striking in Streptococcal species. In S. pneumoniae, overexpression of yycJ in a murine intraperitoneal 
infection model decreased virulence [279] and a yycJ null allele attenuated bacterial growth in a 
respiratory tract infection model [263]. In S. mutans, inactivation of yycJ led to deregulated WalRK two-
component signal transduction resulting in a slower doubling time, reduced oxidative stress tolerance, 
altered biofilm formation, and reduced genetic competence [236]. The data from the Streptococcal 
species suggest that YycJ negatively regulates WalRK activity, however the phenotypes are not so 
straight forward in Bacillus and Staphylococcal species.  
The last gene in the WalRK operon, YycK, is present only in Listeria and Bacillus. Bioinformatics 
predicts that it encodes an HtrA-type serine protease. In L. monocytogenes, YycK plays a role in heat, 
acid, and penicillin stress response and pathogenesis [250]. However, no phenotype has been observed 
for YycK in B. subtilis [256]. Until more experiments are performed to investigate the in vivo role of YycK, 




1.3.1 WalRK Regulon 
Due to the essentiality of both the histidine kinase WalK and the response regulator WalR in B. 
subtilis, determination of its regulon in vivo has remained challenging. A novel hybrid regulator approach 
that fused the phosphate regulon PhoP receiver domain to the WalR DNA binding domain provided the 
first glimpse into WalR regulon genes [108]. This chimeric protein allowed Howell et al to push the system 
towards an “on” state by growing B. subtilis cells in phosphate starvation conditions, which is known to 
activate PhoR, the cognate histidine kinase of PhoP. This allowed for heterologous expression of WalR 
regulon genes that could be compared to the high phosphate “off” state. These initial in vivo experiments 
identified yocH, a cell wall hydrolase, as a WalR target. Electrophoretic Mobility Gel Shift Assays (EMSA) 
confirmed that WalR specifically bound to the yocH promoter. Furthermore, DNase1 footprinting of yocH 
and the essential cell division gene, ftsZ, which had been previously identified as a WalR target gene [85], 
allowed for the first identification of WalR binding sites.  
WalRK regulon genes have also been studied by placing the entire WalRK operon under 
isopropyl- β-D-thiogalactopyranoside (IPTG)-inducible control in B. subtilis [30] and S aureus [68, 69]. 
The advantage of this approach is that the strains are viable in the presence of inducer, but one can 
generate a conditional deletion of the operon, by removing IPTG. Several caveats of this approach are 
that the operon is no longer under native regulation and that depletion of WalRK may lead to indirect 
transcriptional effects. Nevertheless, this approach has proved to be a powerful method to identify WalR 
regulon family members. Many of the genes identified are cell wall modifying enzymes such as 
hydrolases and amidases. Furthermore, virulence genes in both S. aureus and S. pneumoniae have been 
identified as WalR target genes. WalRK regulon genes and their function that can be identified by 
transcriptomic analysis are provided in Table 1.4.1 for B. subtilis and S. aureus. More recently, in vivo 
chromatin immunoprecipitation (ChIP) experiments have identified 22 loci that are WalR target sites in B. 
subtilis [227]. Many of these new loci did not appear in transcriptomic studies of WalR, and this is 
suggested to be the result of deviation from the canonical WalR binding site and co-regulation with other 
regulators such as other two-component systems, alternate sigma factors, and other transition state 




Table 1.3.1 WalRK Regulon Genes in B. subtilis & S. aureus 
 
B. subtilis  
Gene Control by WalR Direct Effect Function Ref. 
yocH + Yes CW hydrolase [108] 
lytE + Yes CW hydrolase [30] 
cwlO (yvcE) + Yes CW endopeptidase [30] 
tagAB - Yes Teichoic acid biosynthesis [108, 109] 
tagDEF - Yes Teichoic acid biosynthesis [108, 109] 
yjeA (pdaC) - Yes Peptidoglycan deacetylase [30] 
yoeB (iseA) - 
Yes 
Posttranslational regulator of 
autolysins 
[30] 
ykvT ND Yes CW hydrolase [108] 
ydjM + Yes CW associated protein [108] 
Des - Yes Fatty acid desaturase [30] 
S. aureus 











isaA + Yes CW transglycosylase [69] 
sceD + ND CW transglycosylase [69] 
ssaA + Yes CW amidase [69] 
SA0620 + ND CW amidase [69] 
SA2097 + ND CW amidase [69] 
SA2353 + ND CW amidase [69] 
SA0710 + ND CW amidase [69] 
ebpS + ND Elastin binding protein [69] 
sdrD + ND Fibrinogen binding protein [69] 
 
 
Table 1.3.1 WalRK Regulon Genes in B. subtilis & S. aureus. Control by WalR shows whether WalR 
activates or represses transcription of the target gene. Direct Effect implies EMSA or other in vitro assay 
showing WalR binds to the promoter. ND=not determined. CW= cell wall.  
 
 
Several of the genes that are negatively regulated by WalR, tagAB and tagDEF, are teichoic acid 
biosynthesis genes that are known targets of the PhoPR two-component system under phosphate 
limitation conditions [110]. In vivo evidence has shown that expression of WalR regulon genes under 
phosphate limiting conditions is dependent on the presence of the sensor histidine kinase, PhoR [109] 
and that PhoPR-mediated induction of the phosphate limitation response is diminished in the absence of 
WalRK.  However, in vitro PhoR mediated phosphorylation of WalR was much weaker than WalK 
mediated phosphorylation of WalR [109]. Mutational analysis of WalRK and PhoPR two-component 
systems shows the importance of amino acid positions within α1 helix of the DHp histidine kinase domain 
  
21 
and the α1 helix of the response regulator. Modification of these residues allowed for robust 
phosphotransfer from WalK or PhoR to its non-cognate response regulator [120].  The in vivo cross-talk 
of PhoR and WalR underscores the importance of WalR regulon genes in maintaining cell wall 
homeostasis and is a unique example of in vivo cross-talk among two-component systems. 
Cell wall homeostasis is the major role of the WalRK two-component system. In S. pneumoniae, 
essentiality of the WalRK has been traced to its regulation of a non-redundant cell wall hydrolase, PcsB 
[187]. However, the gene or genes responsible for its essentiality in B. subtilis or S. aureus have not been 
identified [30, 69]. Phenotypic analysis of genes within the WalRK regulon in B. subtilis was undertaken to 
determine which gene or combination of genes was required for essentiality [30]. Single deletions in yocH, 
ydjM, cwlO, lytE, yoeB, and yjeA are all viable. Double mutations of the genes positively regulated by the 
WalRK regulon were also generated, and the only synthetic lethal pair was cwlO and lytE.  This was later 
determined to be the result of lack of D,L-endopeptidase activity of the lateral cell wall [103]. However, 
ectopic expression of cwlO and lytE was insufficient to suppress WalRK essentiality. So in contrast to S. 
pneumoniae, essentiality of WalRK in B. subtilis and S. aureus is polygenic in nature. This multigenic 
essentiality has made WalRK a very attractive drug target, due to the decreased rate at which 
suppressors could arise and specificity within low G+C% gram-positive bacteria [293]. Platforms to 
develop novel antimicrobials specific for WalR or WalK have been undertaken by various groups [96, 132, 
195, 196, 212]. To this end, understanding the WalRK regulon and the reason for WalRK essentiality 
remain an important priority.   
Beyond cell wall homeostasis, the WalRK two-component system has been linked to cell division. 
B. subtilis WalR has been reported to modulate the transcription of the essential cell division protein ftsAZ 
[85] and to bind to its promoter [108]. In addition to the proposed transcriptional regulation of ftsAZ, WalK 
has been reported to interact with FtsZ on a protein-protein level. Immunofluorescence analysis of 
exponentially growing B. subtilis showed that WalK and FtsZ co-localize at the division site, and WalK 
localization is dependent on FtsZ [86]. In addition, WalR localization to the nucleoid, which would be 
expected for an activated response regulator, was abrogated when WalK was no longer localized to the 
division site. The localization of WalK at the division site is distinct from its accessory proteins YycH and 
YycI, which are found in spotty patches throughout the cell membrane [87]. Furthermore, WalK was 
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shown to interact by bacterial two-hybrid with other proteins within the divisome including Pbp2B, FtsL, 
and DivIB, [87]. These localization studies suggest a model that WalK is inactive when associated with its 
accessory proteins YycH and YycI, and only upon localization to the division septum is WalK active. This 
allows for coordination of cell wall homeostasis with cell division.   
 
1.3.2 WalRK Two-Component System and Antibiotics 
 Since the WalRK two-component system can be induced by treatment with cell wall antibiotics, 
WalK localizes to the divisome, and WalRK regulates genes involved in cell wall homeostasis, the 
proximal inducing signal is likely a molecule related to cell wall synthesis [70]. In particular, treatment of 
wild-type B. subtilis cells with the antibiotic vancomycin, which binds Lipid II and prevents peptidoglycan 
maturation, leads to up-regulation of genes negatively regulated by WalRK and the down-regulation of 
genes positively regulated by WalRK [42]. Vancomycin treatment effectively turns off WalRK activity. This 
phenotype is also seen in antibiotics that target early stages of peptidoglycan precursor synthesis, 
bacitracin and fosfomycin [115, 165].  In contrast, antibiotics that target later stages in peptidoglycan 
synthesis, such as beta-lactams, activate the WalRK two-component system [115]. Compiled, these data 
hint that WalRK may be sensing the cell wall intermediate Lipid II.  Inhibiting earlier stages in 
peptidoglycan synthesis titrates the amount of cell wall precursor, and therefore lowers the amount of 
available Lipid II. Furthermore, by inhibiting penicillin binding proteins by beta-lactams, transglycosylation 
and transpeptidation reactions are blocked, and therefore Lipid II is no longer being utilized, causing Lipid 
II levels to increase. The current model in the field is that WalK is sensing the cell wall intermediate Lipid 
II. If this model is valid, this suggests that when cells are not rapidly dividing, WalK is inactive and WalR is 
not being phosphorylated. However, localization of WalR and WalK in stationary phase has not been 
performed to support this model, and there is no biochemical evidence for the direct interaction of WalK 
with Lipid II. 
The importance of WalRK in monitoring cell wall integrity is reflected in the prevalence of 
mutations within the WalRK operon in clinical isolates of vancomycin-intermediate Staphylococcus aureus 
(VISA), which display decreased sensitivity to vancomycin. Glycopeptide resistance in methicillin-resistant 
Staphylococcus aureus (MRSA) has become an emerging clinical threat [40] and a survey of 39 globally 
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distributed VISA strains, identified mutations with the WalRK operon at a frequency of 61% [241].  A 
single amino acid deletion within the ATPase domain of WalK, when moved into a clean background, was 
sufficient to lead to cell wall thickening as measured by electron microscopy [241]. Hyperactivation of the 
WalRK two-component system either by overexpression of the operon [119] or deletion of YycH, a 
negative regulator of WalK [182], leads to enhanced resistance to vancomycin. In addition to 
misregulation of WalK, non-synonymous amino acid substitutions are also prevalent in the response 
regulator, WalR [99]. While we do not know the physiological significance of these mutations in all cases, 
their prevalence within clinical isolates suggest that modulating the activity of the WalRK two-component 
system has profound effects on the bacterial cell wall. By modifying cell wall architecture, bacteria are 
able to overcome negative selection by antibiotics such as vancomcyin.  
 
1.4 VanRS Two-Component System 
The VanRS two-component system consists of the sensor histidine kinase, VanS, and response 
regulator, VanR. The presence of the VanRS two-component system in bacteria leads to high-level 
resistance to vancomycin and/or teicoplanin [107]. The dissemination of the transposons harboring the 
VanRS two-component system regulatory genes and the glycopeptide resistance structural genes is an 
acute public health problem, as vancomycin is the front-line therapy for treating infections by Gram-
positive pathogens, such as MRSA [46, 205, 262, 287]. Vancomycin works by binding the C-terminal D-
alanine D-alanine (D-Ala D-Ala) pentapeptide precursors, critical building blocks in generation of the 
bacterial peptidoglycan polymer. This inhibits cell growth by blocking both the transglycosylation and 
transpeptidation steps [218]. 
There are currently six types of vancomycin resistance modules that have been described in 
Enterococci [51] that rely on the VanRS two-component system. The VanA-type resistance found on 
theTn1546 transposon element leads to high-level resistance to glycopeptides and is induced upon 
treatment with vancomycin and teicoplanin. The VanC [71], VanE [1], and VanG-type [60, 173] 
resistances produce terminal D-Ala-D-Ser precursors that result in a 6-fold decreased affinity for 
vancomycin. VanD-type resistance is due to constitutive production of peptidoglycan precursors ending in 
D-Ala-D-Lac [59, 61, 63].  In contrast, the VanB-type vancomycin resistance module only responds to 
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vancomycin and leads to inducible high-level expression of vancomycin resistance, and will be the focus 
of experiments described herein.  
The VanB-type vancomycin resistance module that will be characterized in Chapter 5 is located 
on the Tn1549 transposon element [90]. It consists of the VanSB sensor histidine kinase and the VanRB, 
response regulator (Figure 1.4). Upon sensing of vancomycin, the system is able to regulate the 
transcription of its own two-component system genes in an amplifying loop [62].  It is also able to regulate 
transcription of the vancomycin resistance genes that modify the peptidoglycan from D-Ala-D-Ala 
precursors to D-Ala-D-Lac precursors [75]. This requires the concerted action of a dehydrogenase VanHB 
that converts pyruvate to D-lac, and a ligase, VanBB, with altered specificity compared to the host Ddl 
ligase. In addition to modifying the target of vancomycin, the resistance module also removes susceptible 
targets.  Endogenous cell wall precursors that have a terminal D-Ala residue are removed through the 
concerted action of D,D-dipeptidase activity (VanXB ) and D,D-carboxypeptidase activity (VanYB ) [14]. 
Altering the host cell wall has a substantial fitness cost to bacteria and the successful dissemination of 
VanB-type vancomycin is dependent on the low level expression of VanRS in the absence of vancomcyin, 
and its ability to quickly adapt in its presence [82]. 
VanSB has been characterized as a bifunctional sensor histidine kinase and phosphatase in vitro 
[58]. In vivo deletion of VanS in both S. coelicolor and E. faecium resulted in constitutive expression of the 
vancomcyin resistance genes [13, 114]. Further work in S. coelicolor showed that deletion of the acetyl 
phosphate synthesis genes in combination with VanSSc ablated this constitutive expression [114]. These 
results suggest that VanRSc is able to use acetyl phosphate in vivo as a small molecule phosphodonor to 
autophosphorylate and activate transcription of its regulon genes. Thus, in the absence of inducer 
(vancomcyin), VanS acts as a phosphatase to maintain basal expression of VanRS (Figure 1.4).  Further 
evidence that points to the important in vivo role of VanS phosphatase activity, is the identification of a 
clinical isolate that is defective in phosphatase activity and leads to constitutive glycopeptide resistance 
[58]. This isolate was fully functional in VanSB autophosphorylation and VanSB to VanRB phosphotransfer. 
Identification of a T237K amino acid substitution in the HisKA domain of VanSB led to constitutive 
activation[20]. This residue has been demonstrated to be required for phosphatase activity [290]. 
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Modulation of the phosphatase activity of VanS can have profound effects on the transcriptional output of 
the VanRS regulon.  
 
Figure 1.4 Regulation of VanRSB Two-Component System 
 
Figure 1.4. Regulation of VanRSB Two-Component System. Reproduced from Courvalin, 2005 [51]. In 
the absence of inducer, VanS dephosphorylates VanR. In its presence VanR is phosphorylated and binds 
to the promoters PRB to initiate transcription of the two-component system genes and PYB to initiate 
transcription of the vancomycin resistance genes.  
 
 
How the VanRSB TCS actually senses vancomycin, however, still remains unclear. There is 
considerable debate in the field whether vancomycin is a direct ligand for VanSB or VanSB is measuring 
the presence of vancomcyin indirectly through interaction with cell wall intermediates that accumulate or 
degrade upon antibiotic treatment [107]. Recent work in Streptomyces coelicolor used a photoprobe of 
vancomycin to demonstrate direct interaction of vancomycin with VanSSC [136]. While their probe picked 
up VanSSc, it also picked up other membrane proteins in both E. coli and S. coelicolor membrane 
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fractions. Furthermore, VanSB is significantly divergent from VanSSc with only 15% structural pairwise 
identity [107].  
Efforts to decipher the signal perceived by VanSB have been undertaken by stimulating VanB 
strains with various classes of antibiotics and determining the ability to induce vancomycin resistance 
genes. In contrast to VanA-type resistance, which was able to induce expression of VanX in response to 
all antibiotics that inhibit transglycosylation, regardless of their structure or mode of function, VanB-type 
was only responsive to treatment with vancomycin [19]. This in vivo induction data suggests that VanS 
might directly interact with vancomycin. Further evidence supporting this comes from the identification of 
gain of function amino acid substitutions in the external sensor domain of VanS that allow for induction by 
the structurally similar glycopeptide teicoplanin [19].   
 
1.5. Eukaryotic-like Serine/Threonine Kinases in Gram-Positive Bacteria 
 The ability of bacteria to respond and to adapt to their environment has historically been studied 
in the context of two-component systems and their His/Asp modifications. However, phosphoproteomics 
analysis of bacterial species over the past decade has revealed the presence of extensive serine, 
threonine, and tyrosine phosphorylation modifications. In B. subtilis, approximately 200 proteins have 
been identified in three independent studies [76, 151, 155]. Historically, serine and threonine 
phosphorylation was studied in the Ser/Thr kinases HPr [137], SpoIIAB [183], RbsT, and RbsW [298]. 
These kinases play important roles in the regulation of sporulation and sigma B activity, the major sigma 
factor involved in stress response. However, these kinases belong to a distinct family of kinases, GHKL 
[72].  More recently, whole genome sequencing has indicated that many bacteria contain proteins with 
eukaryotic-like signaling domains [18, 206, 303]. For example, Hank’s type bacterial eukaryotic-like 
serine/threonine kinases (eSTKs) have extensive sequence homology in their kinase domains with their 
eukaryotic counterparts. [101]. These eSTKs are structurally and functionally distinct from other serine 
and threonine kinases that are present in bacteria. While many of the Gram-positive eSTKs regulate 
essential bacterial processes, the kinases themselves are usually not essential, although M. tuberculosis 
PknA and PknB are essential [79, 126, 230]. Deletion of these kinases is not strictly essential in other 
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bacterium under laboratory conditions, however, they play significant roles in viability in stationary phase 
in both B subtilis [88, 238] and other streptococcal species [113, 123, 215]. In many cases their Gram-
negative counterparts have not been as extensively characterized. 
  The conserved eSTK kinase domain consists of 12 subdomains that fold into a two-lobed 
catalytic core structure with the active site lying within the deep cleft [135]. The first eSTK crystal structure 
of Mycobacterium tuberculosis PknB provided substantial evidence that the bacterial homologs were 
structurally and mechanistically conserved with mouse cyclic AMP dependent protein kinase (PKA), a 
canonical family member of the eukaryotic Ser/Thr kinase super family [159, 198, 301]. There is a high 
degree of conservation within the intracellular kinase domain. However, these eSTK domains are often 
associated with an additional input or signaling domain [142]. Particularly in bacterial genomes that 
contain a high number of eSTKs such as myxobacterial species [207] and Streptomyces coelicolor [208] 
there is a high variety of functional domains. Some of these domains are ligand-binding domains, 
repetitive domains for protein interaction roles, and in some cases enzymatic domains. However, in many 
cases the ligands or protein interaction partners remain unknown.  
One domain associated with eSTKs in Gram-positive bacteria that has been well characterized is 
the extracellular domain comprised of variable PASTA (pencillin-binding protein and Ser/Thr kinase-
associated) repeats [299]. Hints as to the ligand for these PASTA domains were originally obtained from 
studying the structure of PBP2X from Streptococcus pneumoniae [95].  The structure includes a molecule 
of the β-lactam antibiotic cefuroxime, which is structurally analogous to unlinked peptidoglycan, 
suggesting that PASTA repeats bind peptidoglycan. This was confirmed in vivo by showing that the 
PASTA repeats of B. subtilis PrkC was required for peptidoglycan mediated spore germination [237].  
Since the in vivo discovery of peptidoglycan as the ligand for the B. subtilis eSTK PrkC, further 
structural studies have been performed to determine the mechanistic details. The crystal structures from 
Mycobacterium tuberculosis PknB [25] and Staphylococcus aureus PknB [200] show that unlike PBP2X, 
the PASTA domains are in an extended linear conformation. This led the authors to propose a ligand-
induced dimerization model in which peptidoglycan leads to dimerization of the PASTA domains. 
Dimerization of the extracellular PASTA domains is propagated through the transmembrane domain and 
leads to dimerization and autophosphorylation of the cytoplasmic kinase domain (Figure 1.5).  
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Figure 1.5 Activation Model of eSTKs. 
 
Figure 1. 5 Activation Model of eSTKs. Reproduced from Pereira et al [206]. Schematic of M. 
tuberculosis PknB with its four extracellular PASTA repeats (depicted in orange) with its two-lobed 
conserved eSTK domain. Upon sensing of peptidoglycan fragments, the linear PASTA repeats dimerize 
which leads to intracellular dimerization of the kinase domain, which leads to autophosphorylation and 
subsequently transphosphoryation of PknB substrates.  
 
 
Direct evidence showing the interaction of peptidoglycan with PASTA repeats from B. subtilis 
PrkC was recently shown by nuclear magnetic resonance (NMR) studies using muropeptides [249]. This 
study was also able to identify a residue within the C-terminal PASTA domain, R500, which was shown to 
be required for binding to the DAP moiety within the muropeptide. Consolidation of the data from 
homologous eSTKs, demonstrate that PASTA domains bind to peptidoglycan fragments with specificity. 
This is the only eSTK protein family in prokaryotes where the ligand has been well characterized. Taking 
advantage of this knowledge, I chose to study the physiological role of these eSTKs in B. subtilis, S. 
aureus, and E. faecalis. 
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1.5.1 Regulation of Bacterial eSTKs by Staurosporine 
The high structural homology between eukaryotic Ser/Thr kinases and bacterial eSTKs suggests 
that small molecule modulators of eukaryotic kinase activity would also be effective against their bacterial 
eSTK counterparts. The best characterized molecule is the small competitive ATP inhibitor staurosporine 
[223]. A co-crystal of mouse PKA catalytic subunit and staurosporine showed that staurosporine bound to 
the adenosine pocket and mimics adenosine binding through polar and nonpolar interactions with enzyme 
residues [211].  Several amino acids within the kinase active site also serve as a binding pocket for 
staurosporine. Thr183 is one of these residues and is an important determinant of staurosporine 
sensitivity in bacterial eSTKs.  
Staurosporine and its analog KT5720 are potent inhibitors of the M. tuberculosis PknD kinase 
domain in vitro [174].  The essential M. tuberculosis PknB is inhibited by ~25 µM staurosporine in vivo 
[79] making it a not particularly good inhibitor. However, mutation of the M. tuberculosis PknB active site 
to be “PknD-like” which involved introducing both Met145Leu and Met155Val substitutions conferred low 
nanomolar inhibition. Since Met155 is actually in the same position as Thr183 of murine PKA, a bulky 
amino acid may not provide enough space for staurosporine docking in the active site.  This is further 
confirmed by in vitro analysis of Staphylococcus epidermidis Stk1, which contains a Phe at this position, 
and was only inhibited at high micromolar concentrations [154]. In contrast, staurosporine was shown to 
be active against the B. subtilis eSTK PrkC in vivo at low micromolar concentrations [237, 238]. This data 
shows that while there is a high conservation among the bacterial eSTKs, different amino acid residues 
within the active site is sufficient to confer resistance to the small molecule eukaryotic kinase inhibitor, 
staurosporine. 
 
1.5.2 Bacillus subtilis PrkC 
 There are three Hank’s type eSTKs in the B. subtilis genome. YabT contains a short 
transmembrane domain and intracellular kinase domain and is expressed specifically during sporulation 
[73]. YbdM (PrkD) does not contain a transmembrane domain or obvious sensor input domain, and its 
role remains unclear [158]. B. subtilis PrkC was first identified as an eSTK by inspection of the B. subtilis 
genome [240]. PrkC is co-transcribed and overlaps with its partner eukaryotic-like serine/threonine 
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phosphatase, PrpC [88]. While transcriptomic data has shown that it is expressed throughout the life 
cycle of B. subtilis [118, 191], the promoter and the transcription factor(s) responsible for its expression 
remain unknown.  In rich medium, the prkCΔ1 strain generated by Gaidenko et al, has a pronounced 
stationary phase defect in liquid culture as measured by cell density (OD600) and by enumeration of 
colony forming units [88]. To further dissect the functional significance, they utilized a σB reporter gene, 
ctc-lacZ, as σB regulates a large stationary phase regulon in B. subtilis [37]. They noticed a significant 
drop in β-galactosidase expression in the prkCΔ1 strain. However, no further mechanistic data was 
provided to explain the link between PrkC and σB. These preliminary experiments suggested that PrkC 
had an important role in stationary phase.  
Further characterization also revealed important roles of PrkC in post-stationary phase 
developmental processes [158].  B. subtilis sporulates under conditions of nutrient limitation to generate 
an endospore that is resistant to heat treatment at 80° C for 20 minutes [190]. The sporulation efficiency 
of wild-type versus a marked deletion strain of prkC, Δprkc::kan, was determined by counting the number 
of heat resistant spores versus viable bacterium induced to sporulate by resuspension. There was a 
greater than 2-fold reduction in sporulation efficiency in the ΔprkC mutant [158].  The same phenotype 
was observed following introduction of a K40R mutation in the eSTK kinase domain that is known to be a 
critical residue for enzymatic activity. To further characterize the sporulation defect, the levels of alkaline 
phosphatase, an enzyme whose production is associated with stage II of B. subtilis sporulation, was 
measured [74]. There was no substantial difference in alkaline phosphatase production in wild-type 
versus Δprkc::kan cultures. The stage in sporulation in which PrkC is important was not further 
investigated.  
 In addition to the ability to undergo sporulation, certain B. subtilis strains are also capable of 
generating biofilms. Wild-type and Δprkc::kan cultures were grown in Belitsky medium and the amount of 
bacterial growth that adhered to the polyvinyl chloride microtiter plates was quantified by crystal violet 
staining. The authors saw a reproducible and significant reduction in biofilm formation [158]. They 
furthermore also showed through a prkC-lacZ fusion and western blotting, that PrkC was transcribed and 
expressed throughout the formation of the biofilm. While PrkC is not essential for growth in B. subtilis, its 
importance for regulating post-exponential developmental processes in B. subtilis is clearly demonstrated 
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by its severe stationary phase lysis phenotype, its reduced sporulation efficiency, and diminished capacity 
to generate biofilms.  
 During these initial experiments, the ligand for PrkC remained unknown. However, with more 
evidence suggesting PASTA domains bind to peptidoglycan fragments, the Dworkin lab demonstrated 
that PrkC was necessary and sufficient to induce peptidoglycan-mediated spore germination. 
Peptidoglycan was isolated by either boiling with 4% sodium dodecyl sulfate [92] or by harvesting cell free 
supernatants. Peptidoglycan fragments are released by growing cells as cell wall hydrolases and 
amidases digest the mature peptidoglycan mesh to insert new peptidoglycan monomers [67] and are 
therefore abundant in the media. These data showed that PrkC was required for germination with either 
purified peptidoglycan or cell-free supernatants [237]. It was also shown that PrkC only responded to 
peptidoglycan containing a DAP residue at position 3 of the stem peptide. Complementation of ΔprkC 
with S. aureus PknB was sufficient to germinate spores in the presence of L-Lys containing peptidoglycan. 
Another important finding was that PrkC was sensitive to the small molecule modulators bryostatin, a 
kinase stimulator, and staurosporine, a competitive inhibitor of the kinase domain. This paper 
demonstrated that PASTA domains are likely to bind to peptidoglycan fragments in vivo and are able to 
distinguish between DAP and L-Lys residues.  
 PrkC has also been shown to regulate transcription of the cell wall hydrolase, YocH [238]. Shah 
et al showed by RT-PCR analysis that peptidoglycan-mediated yocH induction was dependent on PrkC. 
YocH also regulates its own transcription in a PrkC-dependent fashion. In contrast to all of the previous 
experiments described in this section, which involve post-stationary phase developmental processes, 
these experiments were performed during early logarithmic growth in the rich medium, LB. This further 
emphasizes the important role PrkC has in regulating cell wall processes in B. subtilis throughout growth. 
However, it was unclear how a membrane-bound eukaryotic-like Ser/Thr kinase regulates transcription. 
This is one of the central topics of my thesis.  
 In addition to these in vivo studies of PrkC function, in vitro biochemical studies have been 
performed to determine substrates of PrkC based off phosphoproteomic analysis performed in vivo. One 
study in particularly, showed in vitro that PrkC can phosphorylate proteins involved in basic metabolism 
[209]. However, the physiological significance of these modifications remains unclear. In most cases, the 
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threonine or serine residue(s) that has been phosphorylated has not been mapped. And in the absence of 
this information, interpreting the consequences of phosphorylation and its potential physiological impact 
on bacterial fitness is difficult.  
 
1.5.3 Staphylococcus aureus PknB 
 Staphylococcus aureus is an important clinical pathogen that can cause clinical symptoms 
ranging from skin infections to toxic shock syndrome. Analysis of the S. aureus N315 genome revealed 
an eSTK with the conserved amino-terminal eSTK kinase domain, transmembrane domain, and 3 
extracellular PASTA repeats [194]. The gene was originally coined stk1 (serine threonine kinase 1), but is 
now referred to as PknB, due to its high structural homology with M. tuberculosis PknB [194]. To 
determine if this ORF had autokinase activity, recombinant protein was generated and 
autophosphorylated in the presence of γP32- ATP [55]. Phosphoamino acid analysis was performed and 
showed PknB to autophosphorylate primarily on threonine residues. This was the first biochemical 
evidence that the PrkC homolog in S. aureus was a kinase.  
Genetic analysis of pknB has been performed in a variety of laboratory and clinical isolates of S. 
aureus. The deletion in strain 8325-4 showed delayed growth in defined RPMI 1640 medium. This was 
found to be attributable to a purine biosynthesis defect that could be restored by addition of adenine to 
the medium [55]. This effect on purine biosynthesis was also seen via transcriptomic studies of a ΔpknB 
strain in S. aureus 8325 [66]. In addition to transcriptomic effects, they were able to show PknB 
phosphorylation of PurA, adenylosuccinate synthase, in vitro. They showed mechanistically that this 
phosphorylation led to 2-fold diminished activity of PurA.  This purine biosynthesis defect has only been 
observed in S. aureus strains of the 8325 lineages and not in other S. aureus strains [194].  
 Deletion of pknB also results in various phenotypes related to cell wall homeostasis. The ΔpknB 
mutant shows a general trend of hypersensitivity to cell wall antibiotics of various classes. In strain 8325-4, 
the ΔpknB mutant shows increased sensitivity to fosfomycin, an antibiotic inhibiting MurA, the first step in 
the peptidoglycan biosynthesis [55]. In contrast, in S. aureus 8325, the ΔpknB had only a 2-fold increased 
sensitivity to fosfomycin [66]. However, in this genetic background, the ΔpknB strain was significantly 
more sensitive to tunicamycin, an inhibitor of MraY. Deletion of pknB in S. aureus N315, a methicillin-
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resistant strain, resulted in hypersensitivity to the β-lactam family of antibiotics, such as cefotaxime and 
ceftriaxone [26]. This sensitivity to only β-lactams was further confirmed in the methicillin resistant strain 
COL and community-acquired MRSA strain USA300 [261]. Furthermore, ΔpknB is more resistant than the 
parental strain to Triton-X-100 induced lysis [55, 261]. The modulation in sensitivity of the ΔpknB mutation 
in various S. aureus genetic backgrounds to cell wall acting antibiotics and Triton-X-100 induced autolysis, 
suggest that PknB plays an important roll in coordinating cell wall architecture. 
 The importance of PknB in cell wall homeostasis has been further characterized in the methicillin 
resistant strain COL and the community-acquired methicillin resistance S. aureus strain USA300 [261]. 
They sought to determine if there was a connection between PknB and the alternative sigma factor, σB, 
which is responsible for stress response, including oxidative stress. It has been published that the 
antibacteriacidal effects of β-lactams is exerted partially through the production of reactive oxygen 
species [282]. They observed that while supplying σB in trans was not capable of suppressing 
hypersensitivity to β-lactams, it was capable of restoring growth at elevated temperatures. This genetic 
analysis suggests that there is either a direct or indirect effect of PknB regulation on σB.  
 TEM analysis of the ΔpknB mutant showed weak electron dense, and fragile looking membranes, 
in contrast to those seen in the isogenic parental control [26]. The role of PknB in the regulation of cell 
wall metabolism was further confirmed through microarray analysis of the ΔpknB strain that showed a 
significant up-regulation of the VraRS two-component system regulon [66]. This regulon consists of genes 
involved in cell wall homeostasis and cell wall biosynthesis [144]. The role of PknB in cell wall metabolism 
was further validated by a metabolomics analysis, which found that peptidoglycan metabolites were 
differentially represented in the ΔpknB strain compared to wild type at various stages of growth [152].  
 Thus, while PknB has a consistent role in cell wall metabolism in various S. aureus strains, PknB 
has a conflicting role in murine pathogenesis models. Using a murine model of hematogenous 
pyelonephritis (renal infection) mice were infected with wild type or ΔpknB mutant S. aureus 8325-4 
bacteria [55]. Pathogenesis was scored by enumeration of renal bacterial loads and histopathological 
analysis. As compared to the isogenic parent strain, the ΔpknB mutant had a 2-log decrease in CFU and 
only displayed minimal lesions with decreased infiltration with neutrophils. However, in contrast to this 
study, S. aureus Newman or its ΔpknB mutant [39] had similar rates of killing in a murine model of sepsis, 
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even though the ΔpknB mutant displayed hyperhemolysis.  An additional study using a ΔpknB mutant in 
USA300 showed hypervirulence in a murine cutaneous model of infection [261]. This hypervirulence was 
attributed to an enhanced agr response in the ΔpknB mutant. These three studies show conflicting roles 
for PknB in murine pathogenesis models.  It should be noted that different murine and S. aureus strains 
were used in the studies and could account for the contradictory conclusions.  Furthermore, the 
observation that PknB interplays with σB, which has shown to interact with PknB to regulate MgrA [270], 
a global regulator of virulence and multidrug resistance transporters, may account for some of the 
differences between the lab strains and clinical isolates. 
 
1.5.4 Enterococcus faecalis IreK 
 Enterococci are low G+C% gram-positive bacteria that primarily live in the gastrointestinal tract of 
animals. This interaction is not always benign, and there is considerable interest in understanding the 
biology of E. faecalis.  The genome of E. faecalis V583 was mined to identify genes encoding Ser/Thr 
kinase domains, and a homolog to B. subtilis PrkC was found [139]. Initial publications describing this 
gene kept the name prkC, due to its homolog with B. subtilis, however subsequent phenotypic analysis of 
its function led to the name ireK [141].  
A clean deletion of ireK in E. faecalis strain OG1RF exhibited a growth defect in tryptic soy broth, 
but not in brain heart infusion media, or semi-defined medium MM9YEG [139]. The initial characterization 
showed increased hypersensitivity of the ΔireK mutant to broad-spectrum cephalosporins that could be 
complemented in trans. Complementation of this phenotype was dependent on the kinase activity of IreK, 
as no complementation was observed in the K41R mutation, which has previously been shown to ablate 
kinase activity in the eSTK homolog, PrkC in B. subtilis [141]. Not all β-lactams exerted the same 
magnitude of hypersensitivity, such as ampicillin, which can inhibit all PBPs effectively. In contrast, 
cephalosporins have a low affinity for the enterococcal PBP5, suggesting that PBP5 can still undergo 
transpeptidation and lead to high level resistance to these compounds [181, 221]. Further analysis of 
cephalosporin sensitivity showed that expression of MurAA in trans enhanced cephalosporine resistance 
in a ΔireK mutant [274].  
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Due to the enhanced sensitivity of the ΔireK mutant to cell wall antibiotics, scanning electron 
microscopy of the isogenic parental strain and the ΔireK mutant was performed. While in BHI, there was 
no morphological differences, in tryptic soy broth, 10% of the ΔireK mutant cells had cell ghosts and 
massive lesions within the cell wall, consistent with the previously observed growth defects [139]. The 
ΔireK mutant had enhanced sensitivity to bile and was unable to persist in the mouse intestine [139]. 
These observations show that IreK is important for cell wall metabolism and homeostasis, and in the 
absence of IreK, E. faecalis is unable to adapt to cell wall stress.  
 
1.6 Eukaryotic-like Ser/ Thr Phosphatases in Gram-Positive Bacteria 
 The need for dedicated phosphatases in bacteria was not initially appreciated as the 
phosphohistidine and phosphoaspartyl residues found within two-component signal transduction systems 
undergo relatively rapid hydrolysis [105]. However, phosphorylated serine and threonine residues are not 
as labile, and are thought to require the dedicated activity of a phosphatase to remove the 
phosphorylation and quench the signaling cascade [4, 303]. Homologs of four eukaryotic protein 
phosphatase superfamilies are present in bacteria:  conventional and low molecular weight protein 
tyrosine phosphatase, phosphoprotein phosphatases (PPP), and metal dependent phosphatases (PPM) 
[128, 240]. I will not further discuss the tyrosine phosphatases, which have been recently reviewed [23]. 
The PPP family of Ser/Thr phosphatases can also dephosphorylate phosphohistidine and 
phosphotyrosine residues [23]. While PPP family members have been annotated for bacteria, most are 
dual-specificity phosphatases in vitro.  
 The Ser/Thr Mg2+ or Mn2+ dependent phosphatases of the PPM family contain a conserved 
domain with eukaryotic PP2C that contains 11 to 13 signature motifs and eight conserved amino acids [2, 
32, 128, 240]. Within this family are two subfamilies, which are differentiated based off the presence of 
motifs 5a and 5b [304]. The subfamily, which contains all 13 signature motifs, is the cognate 
phosphatases to the eSTKs described above and will be further discussed. This PPM family of 
phosphatases has no known inhibitors, and therefore bacteria can be used as a powerful tool to probe 
their function in vivo.  
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 Human PP2C contains a central β-sandwich comprised of two five-stranded antiparallel β sheets 
that are flanked by a pair of antiparallel α helices [53]. Dephosphorylation is thought to occur by metal-
activated nucleophilic attack of the phosphorous atom. Due to the high degree of active site residue 
conservation among eukaryotic and bacterial homologs, this dephosphorylation mechanism is considered 
conserved. There are three additional α helices in the human PP2C structure that are absent in the 
crystal structures of bacterial PP2C homologs. The crystal structures of Mycobacterium tuberculosis PstP 
[285], Mycobacterium smegmatis MspP [285], Streptococcus agalactiae STP [217], and 
Thermosynechococcus elongatus PphA [232] show a nearly identical catalytic domain, however, there 
are key differences to the human PP2C structure. One key difference is the coordination of three metal 
ions within the active site of the bacterial structures, compared to only two seen in PP2C. Secondly, the 
bacterial homologs do not contain a conserved His residue which was shown to be critical in human 
PP2C for hydrolysis [53]. In contrast, the bacterial homologs contain a methionine residue at that position, 
except in the case of MspP, which contains a phenylalanine. The last and most striking difference is that 
the flap subdomain is further away from the active site. Mutagenesis of the flap subdomain in PphA 
resulted in a decrease in enzymatic activity [232], suggesting this flap may facilitate substrate binding and 
turnover.  
 Unlike their eukaryotic counterparts, bacterial eSTPs do not contain an obvious input domain. 
The question of how eSTPs, which are often co-transcribed with their cognate eSTK, are regulated both 
transcriptionally and post-translationally is unknown. However, their importance in regulating their 
cognate eSTK is well illustrated by the fact that deletion of S. pneumoniae PhpP is nonviable, except 
when deleted simultaneously with its cognate eSTK, StkP [199]. Also like eSTKs, they regulate diverse 
processes from cell wall division and maintenance in Mycobacterium [177], development in Myxococcus 
xanthus [266], to translation machinery in Listeria monocytogenes [12]. In the following sections I will 
discuss more in depth what is known about the eSTPs that regulate the conserved PASTA domain 




1.6.1 Bacillus subtilis PrpC 
PrpC is a PP2C eukaryotic-like Ser/Thr phosphatase that regulates the eSTK, PrkC (Section 
1.5.2). Sequence analysis of prpC revealed conserved signature motifs and amino acids known to bind to 
metal ions and the phosphate group that are characteristic of PP2C PPM phosphatases [240]. 
Recombinant PrpC was active against phosphorylated PrkC in vitro and was expressed throughout log 
and stationary phase cultures [193]. ΔprpC strains have enhanced stationary phase survival in contrast to 
B. subtilis ΔprkC mutant strains that have a strong stationary phase lysis phenotype [88]. Like the ΔprkC 
mutant strain, the ΔprpC strain also showed reduced sporulation efficiency and biofilm formation. 
However, unlike the sporulation deficiency characterized for ΔprkC, the ΔprpC strain was unable to 
generate alkaline phosphatase, suggesting the defect is before stage II of sporulation [158]. There was no 
observed role for PrpC in peptidoglycan-mediated germination [237].  
Its ability to regulate PrkC in vivo was shown by studying the PrkC-dependent transcriptional 
regulation of yocH. Overproduction of PrpC prevented peptidoglycan-mediated yocH induction. This 
overproduction phenotype was not observed in PrpC D36N, which is an inactivating mutation in a 
conserved catalytic site residue [238]. This data suggests that PrpC can regulate PrkC activity in vivo. 
While there is no biochemical or genetic evidence demonstrating that PrpC dephosphorylates PrkC 
substrates, it might be expected that PrpC not only regulates the activation state of PrkC, but also turns 
off the signaling cascade by dephosphorylating PrkC substrates. 
One substrate that has been observed in vitro and in vivo to be subject to PrpC activity is the HPr 
phosphotransfer system, where the differential migration by native gel electrophoresis of Ser~P HPr, was 
reversed by recombinant PrpC [243]. Furthermore, HPr that was purified from B. subtilis lysates from 
ΔprpC cultures contained a higher fraction of Ser~P HPr than the wild-type lysates. However, they were 
not able to determine the physiological relevance of PrpC-mediated dephosphorylation.  
 
1.6.2 Staphylococcus aureus Stp1 
Like PrpC, S. aureus Stp1 is co-transcribed and translationally coupled with its partner eSTK, 
PknB (Section 1.5.3) [26]. Deletion of stp1 in methicillin resistant S. aureus strain N315 leads to thickened 
cells as observed by TEM [26]. This same study also observed increased resistance to lysostaphin, 
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however, there was no difference in sensitivity observed with any antibiotic. Metabolomics data showed a 
differential representation of metabolites involved in nucleotide metabolism and cell wall precursor 
metabolites as compared to the isogenic wild type and ΔpknB strains [152].  While the phenotype for the 
Δstp1 is not as striking in many of these assays as that observed for the ΔpknB mutant, it is consistent 
with the interpretation that Stp1 opposes the role of PknB.  
This role of Stp1 in opposing PknB was observed in a virulence model of S. aureus. The Δstp1 
mutant in S. aureus Newman was identified in a screen for genes involved in hemolysis. There was 
decreased hemolysis expression observed in this background that could be explained by diminished hla 
expression, the gene encoding α-toxin [39]. A Δstp1 mutant was severely attenuated in a mouse model of 
sepsis, which is in sharp contrast to the lack of phenotype observed for the ΔpknB strain in this same 
genetic background.  
 
1.6.3 Enterococcus faecalis IreP 
 Similar to its bacterial homologs discussed in the previous two sections, IreP is immediately 
upstream of its eSTK, IreK (Section 1.5.4).  Recombinant IreP exhibited manganese-dependent 
phosphatase activity in the presence of p-nitrophenyl phosphate and was able to dephosphorylate 
autophosphoryated IreK [141]. A clean deletion of ireP in both E. faecalis OG1RF and T1 genetic 
backgrounds resulted in hyperresistance to cephalosporins, which is the opposing phenotype observed 
for the ΔireK strain in these genetic backgrounds. This increased resistance was dependent on the 
presence of its cognate eSTK, IreK. This enhanced resistance to cephalosporins came at a substantial 
fitness cost to E. faecalis. When co-culture competition experiments were performed in Mueller Hinton 
Broth, the ΔireP strain was rapidly outcompeted, even during only 1 dilution and even when 90-95% of 
the starting co-culture inoculum contained the ΔireP mutant.   These experiments reveal an important role 
for IreP in regulating IreK kinase activity and that these mutants play important roles in cell wall 




1.7 Eukaryotic-like Ser/Thr Kinases in Gram-Negative Bacteria 
 Unlike the gram-positive eSTKs described above (Section 1.5) that are Hank’s type eukaryotic 
Ser/Thr kinase homologs [101], the majority of Gram-negative bacteria do not contain these conserved 
sequence motifs and amino acids [240]. A noticeable exception to this is the gram-negative 
developmental bacterium, Myxococcus xanthus, that contains hundreds of eSTKs including Hank’s type 
eSTKs [116]. The gram-negative cyanobacterium Synechococcus elongatus contains a variable number 
of Ser/Thr kinase domains depending on the strain [89]. One of these eSTKs Is a Hank’s type eSTK, 
coined PrkE, and has been shown to be involved in regulating the circadian clock by interacting with the 
sensor histidine kinase, CikA, by yeast two-hybrid [157]. This interaction with classical two-component 
systems made this kinase particularly interesting to study for me, as the underlying theme of this thesis is 
the interplay between eSTKs and two-component systems.  
In addition to studying Hank’s type eSTKs in Gram-negative bacteria, I also sought to study 
bacterium that lacked these family members. The most well studied eSTK in Gram-negative bacteria is 
Escherichia coli HipA. It is a member of the phosphatidylinositol 3/ 4 kinase superfamily and its kinase 
activity is required for persister formation [50, 234]. The closest structural homolog is the eukaryotic 
CDK2 [106]. However, the structural superimposition showed very poor alignment suggesting that HipA 
might be a new class of kinase [112]. While HipA in E. coli is part of a toxin/antitoxin system, it became 
apparent through genome mining that hipA homologs were present in other genomes. I focused on 
Caulobacter crescentus due to its complex cell cycle, and differentiation into dimorphic cell types of a 
stalked and swarmer cells. Due to the role of eSTKs in Gram-positive and M. xanthus in regulating 
differentiation, I sought to work with the C. crescentus HipA homologs. I knew their expression was 
variable throughout the life cycle of C. crescentus [172], however no other biochemical or genetic data 
has been published in the literature.  
Eukaryotic-signaling proteins in Gram-negative bacteria, while not always highly conserved with 
Hank’s type eSTKs, share strong structural homology with other eukaryotic Ser/Thr kinase family 
members. In addition to the variability within the intracellular kinase domains, the sensor input domains 
are often uncharacterized [272]. Gram-negative eSTKs have been linked to virulence in P. aeruginosa 
[179], persister formation in E. coli [50], and developmental process in M. xanthus [180]. These eSTKs 
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and eSTPs are abundant in Gram-negative and Gram-positive bacterial genomes and the roles they play 
in physiological development of bacterium further remains to be elucidated. 
 
1.8 Convergence of Eukaryotic-like Ser/Thr Kinases and Classical Two-Component Systems 
 An emerging, though rather under developed them in the literature, is that two-component 
systems and eSTK/eSTPs do not function in isolation but rather these signaling paradigms converge to 
regulate the same processes. An advantage to this convergent regulation is that phosphohistidine and 
phosphoaspartyl modifications are more labile, while phosphothreonine and phosphoserine modifications 
are much more stable and could allow for different kinetic regulation of the same pathway. One example 
of this convergent regulation occurs in Myxococcus xanthus [117]. This bacterium grows unicellulary and 
forms large swarms of cells under nutrient rich conditions. However, upon nutrient limitation these cells 
aggregate and form fruiting bodies. These fruiting bodies generate metabolically inert myxospores if 
conditions are still unfavorable. Fruiting body formation and sporulation are under control of the global 
transcription factor, FruA. FruA expression is controlled through the activity of another transcription factor, 
MrpC that itself is positively regulated by the MrpA/B two-component system in response to nutrient 
limitation [255]. Threonine phosphorylation of MprC by the eSTK Pkn14 reduced MrpC’s affinity for its 
own promoter and that of the global regulator FruA [185]. To add another layer of complexity, the eSTK 
Pkn14 seems to be activated by the phosphorylation of a membrane bound eSTK Pkn8 [184]. This 
negative regulation of fruiting body formation by MrpC threonine phosphorylation results in enhanced 
levels of MrpC and faster development in either a Δpkn8 or Δpkn14 strain background. In this example, 
the well-coordinated timing required for fruiting body formation and sporulation is fine-tuned through the 
convergence of the MrpA/B two-component system and the eSTKs Pkn8/Pkn14, which have antagonistic 
effects.  
 Another example in which threonine phosphorylation antagonizes the activity of the two-
component system is the regulation of cytoxin expression in Group B Streptococcus (GBS) [216]. S. 
agalactiae Stk1 was shown to be important for the regulation of β-hemolysin expression. This phenotype 
is dependent on the two-component system response regulator CovR that acts as a transcriptional 
repressor of β-hemolysin expression [122, 146]. Further analysis showed that Stk1 phosphorylated CovR 
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at Thr65. By utilizing the phosphomimetic T65E they were able to show deceased autophosphorylation of 
the response regulator by the small molecule phosphodonor acetyl phosphate and abolished DNA 
binding of CovR by EMSA and DNase1 cleavage. These experiments propose a mechanism by which 
Stk1 phosphorylation of CovR prevents phosphorylation by its cognate histidine kinase CovS and leads to 
an inactivated form of CovR [153]. Conversely CovR phosphorylation at the conserved aspartate residue 
within the receiver domain reduces the level of threonine phosphorylation. While the ligand of the cognate 
His kinase CovS remains unknown, this regulation provides a model in which virulence genes are finely 
tuned to the appropriate environmental conditions.    
 An example where a two-component system and eSTK cooperate to positively enhance the 
activity of the response regulator is the dormancy (DosR) regulon in M. tuberculosis [47]. The eSTK PknH 
has been previously shown to regulate growth in murine models and respond to nitric oxide (NO) stress in 
vitro. An unbiased mass spectrometry proteomics approach identified proteins that were differentially 
expressed in the M. tuberculosis ΔpknH strain versus the isogenic parental control. A substantial portion 
of the DosR regulon was downregulated in the ΔpknH samples [277]. The DosR regulon is positively 
regulated by the DosR/ DosS/ DosT three-component system under hypoxic conditions [143, 225]. The 
overlap of these signaling paradigms in regulating an adaptive response to NO suggested that PknH 
might functionally interact with DosR, the response regulator. PknH interacted with DosR in a protein 
fragment complementation assay and phosphorylated DosR in in vitro kinase assays [47]. PknH 
phosphorylation of DosR at T198 and T205 in conjunction with DosS phosphorylation at the conserved 
aspartate in the receiver domain cooperatively enhanced DosR binding to promoters [47]. While the 
mechanism by which this threonine phosphorylation alters the activity or the structure of the response 
regulator is not known, full activation of the DosR regulon appears to require input from both the sensor 
histidine kinase DosS and the eSTK PknH.  
 eSTKS can also directly phosphorylate TCS histidine kinases. For example, the B. subtilis sensor 
histidine kinase DegS is a substrate of the eSTKs YabT and YbdM [121]. In vitro evidence showed that 
phosphorylation by YbdM stimulated DegS phosphotransfer to its cognate response regulator, DegU. A 
S76D phosphomimetic exhibited enhanced autophosphorylation and DegU phosphotransfer. The authors 
analyzed a degS S76D allele in vivo and observed both reduced transformation efficiency and fewer cells 
  
42 
expressing the PcomK-gfp transcriptional fusion by microscopy.  These observations suggest that this 
histidine kinase is hyperactive in vivo and results in increased levels of DegU~P. They also monitored a 
DegU regulon genes that was positively regulated by DegU~P.  They observed increased yvcA promoter 
activity in the degS S76D and in the YbdM overexpression strain compared to wild type or the degS S76A 
allelic replacement strain. This shows that histidine kinases can be directly targeted by eSTKs and this 
can lead to modulation of their autophosphorylation activity and their ability to phosphotransfer.  
  These examples illustrate that threonine or serine phosphorylation is capable of modifying 
classical two-component systems by either antagonizing their activity or synergistically enhancing their 
activity. Thus, while bacteria often only have a few eSTKs, the potential cross-talk with the tens to 
hundreds of two-component systems in bacterial genomes suggests that signaling interaction networks 
are much more intertwined and not as linear as appears when they are studied in isolation.  
 
1.9 Scope of This Dissertation 
 The underlying theme of this dissertation is to understand the role of eSTKs in regulating cellular 
processes and specifically, to investigate the interaction between eSTKs and two-component systems. In 
my first set of experiments I sought to understand how a membrane-bound eSTK, PrkC in B. subtilis, was 
able to regulate the transcription of the cell wall hydrolase, yocH. Previous literature suggested that yocH 
was a WalRK regulon gene and additionally its transcription is regulated in a PrkC-dependent fashion. In 
Chapter 3, I examine how PrkC is able to interact with the WalRK two-component system to alter 
transcription of yocH and other WalRK regulon genes. In Chapter 4, I extend our findings of T101 
phosphorylation to other B. subtilis response regulators and determine if the specific regulation of WalR is 
conserved in the clinically relevant Gram-positive bacterium, Staphylococcus aureus.  
 In Chapter 5, I investigate if IreK, the PrkC homolog in Enterococcus faecalis, is able to respond 
to cell wall fragments and feed into the VanRS two-component system. In contrast with the PrkC-WalR 
interaction, IreK did not phosphorylate VanR, the response regulator, but rather the histidine kinase, 
VanS. By utilizing staurosporine, the eukaryotic small molecule kinase inhibitor, I was able to show 
inhibition of VanRS regulon induction in vivo in response to vancomycin stimulation. These data suggest 
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a novel therapeutic option for the sensitization of VanB-type vancomycin resistance enterococci to 
vancomycin treatment.  
 In addition to our focus on understanding these modifications in vitro and in vivo, I also sought to 
establish conditions to study eSTKs from Gram-negative bacteria in vitro, which will be addressed in 
Chapter 6. I focused on the C. crescentus HipA homologs that have not been characterized or previously 
shown to be active kinases. In addition, through collaboration with Dr. Michael Rust at the University of 
Chicago, I developed in vitro conditions to study Synechococcus elongatus PrkE and its potential 




















Chapter 2. Materials and Methods 
2.1 B. subtilis Transformation and DNA manipulation 
Plasmids (listed in Appendix B) were constructed using standard methods unless otherwise noted. 
All PCRs were performed using Phusion High-Fidelity Polymerase (NEB). B. subtilis PCRs were 
performed at an annealing temperature of 50°C. In cases when efficient digestion of PCR products wasn’t 
obtained, gel-extracted PCR products were cloned into commercially available pJET1.2/blunt (Fermentas).  
Strains used for Gram-positive bacteria and E. coli protein expression are listed in Appendix A. B. subtilis 
trpC2 was obtained from Chet Price [88]. B. subtilis PY79 was obtained from the Losick Laboratory at 
Harvard University. Undomesticated 3610 was obtained from Daniel Kearns at Indiana University at 
Bloomington. B. subtilis was either transformed with 10 µl of plasmid DNA or 1-2 µl of genomic DNA using 
the two-step method [102]. Oligos used are listed in Appendix C. Genomic DNA was prepared using the 
Wizard Genomic DNA Purification Kit (Promega). I used 50 mM EDTA and 1mg/ml lysozyme and treated 
culture pellets for 10 minutes at 37°C to break down the Gram-positive cell wall. With S. aureus I also 
added 1mg/ml lysostaphin. The rest of the protocol was according to manufacturer’s instructions.  
 
2.2 Transposon Mutagenesis with pMarB Himar1 transposase 
 JDB 1786 was transformed with pMarB transposon (JDE 1344) using standard methods. 
Kanamycin resistant transformants were grown overnight in 3ml of LB + 10µg/ml kanamycin at 30°C. In 
the morning, the strain was plated onto LB agar + 10µg/ml kanamycin and allowed to incubate at 50°C, 
the restrictive temperature, in the presence of H2O in order to prevent desiccation of the plates. The 
following morning plates were sprayed with 10mg/ml 4-methylumbelliferyl-β-D Galactopyranoside in 
DMSO (Sigma) using a Martini Mister. After 2 minutes, plates were visualized using a UV light box. Any 
colonies that appeared dark were re-streaked and confirmed for erythromycin sensitivity, kanamycin 




2.3 Inverse PCR to Identify Transposon Hits 
 Strains that met the above criteria in 2.2 were grown in LB to generate genomic DNA. To identify 
insertion sites I adapted a protocol from Bae et al [17]. 1 µg of genomic DNA (gDNA) was digested with 
0.5 µl of Taqα1 restriction enzyme (NEB) for 1 hour at 65°C. The reaction was heat inactivated by 
incubation at 80°C for 20 min. Digested genomic DNA was used as a substrate for ligation with T4 DNA 
ligase (NEB) that was performed overnight at room temperature, using 10 µl of Taqα1-digested gDNA as 
the substrate. This was PCR purified and used as a template for PCR using primers LG28 and LG29. 
PCR products were gel extracted and submitted for sequencing using primer LG28 or LG29.  
 
2.4 Expression of Recombinant Proteins Under T7 Promoter 
 This protocol applies to all B. subtilis, S. aureus, and E. faecalis recombinant proteins in pET 
derivative vectors (Novagen) unless otherwise indicated. Cultures were inoculated directly from the 
glycerol stock and grown overnight at 37°C in LB with the appropriate amount of antibiotic. The following 
morning they were diluted 1:500 into fresh LB + antibiotic(s) and grown at 37°C to an OD600 of 0.7-1. 
Cultures were allowed to cool for 10 minutes at RT and an aliquot was taken as a pre-induction lysate. 
Cultures were induced with 1mM IPTG and allowed to induce for 3 hours at room temperature.  A post-
induction lysate was also taken. Cultures were centrifuged at 5,000g for 10 min to pellet cells. 
Supernatants were decanted and pellets were stored at -80°C prior to purification. Pre and post-induction 
lysates were run on an SDS-PAGE gel to confirm protein expression. S. elongatus PrkE was also done 
using this procedure, except after induction with 1mM IPTG, the cultures were allowed to induce at 30°C.  
 
2.5 Purification of 6xHis-tagged Recombinant Proteins 
Proteins were purified by resuspending frozen pellets in lysis buffer and allowing cultures to sit on 
ice with intermittent vortexing for at least 30 minutes. Lysis buffer consisted of 50mM Tris pH 7.5, 300mM 
NaCl, 30mM imidazole, 1mg/ml lysozyme, and 1mM PMSF. After adequate lysing on ice, lysates were 
sonicated for 45 seconds total ‘on’ time with cycles of 5 seconds ‘on’ and 30 seconds ‘off’’. After 
sonication, 5 µg/ml of DNase1 and 3mM MgCl2 were added to lysates. Lysates were rotated on a nutator 
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for 15 minutes at 4°C. Lysates were cleared by centrifugation at 15,000g for 30 minutes at 4°C. Ni-NTA 
resin (Qiagen) was equilibrated with wash buffer. Wash buffer consists of 50mM Tris pH 7.5, 300mM 
NaCl, and 30mM imidazole. Cleared lysates were incubated with Ni-NTA resin in empty protein columns 
(Pierce). Cleared lysates were incubated with the resin at 4°C for at least 1 hour on a nutator. Lysates 
were allowed to flow by gravity. Resin was washed three times with 10 column volumes of wash buffer. 
Proteins were eluted with step-wise increasing concentrations of 100mM imidazole. Elution buffer 
consisted of 50mM Tris pH 7.5, 300mM NaCl, and 100-500mM imidazole. Proteins were loaded onto 
SDS-PAGE and fractions chosen to dialyze overnight. Proteins were dialyzed overnight in 10 kDa MWCO 
mini-dialysis cups (Pierce) at 4°C. eSTKs/eSTPs were dialyzed in 50mM Tris pH 7.5, 150mM NaCl, 5% 
glycerol, and 1mM DTT. WalK was dialyzed into 50mM Tris pH8, 200mM KCl, 5% glycerol, and 0.5mM 
DTT. Proteins were quantified using the spectrophotometer.  
 
2.6 In vivo Biotinylation of WalK 
 To generate in vivo biotinylated WalK for Surface Plasmon Resonance Experiments, JDE 1779, 
which contains WalK-Avitag (pLG140), pRSFDuet-GroLGroS (pLG143) and pBirA (Avitag), was 
expressed for purification. Cultures were grown from the glycerol stock in TYH media with 100 µg/ml 
ampicillin, 30 µg/ml chloramphenicol, and 50 µg/ml kanamycin overnight at 37°C. The following morning 
cultures were diluted 1:500 in fresh TYH media with 100 µg/ml ampicillin and 50 µg/ml kanamycin and a 
final concentration of 0.5% glucose to an OD600 of 0.7. After which 10ml of 5mM biotin solution along with 
1mM IPTG was added to the flask. 12 mg of D-biotin was added to warmed (via microwave) 10mM bicine 
buffer (pH 8.3) and filter sterilized to generate the 5mM biotin solution. Cultures were pelleted by 
centrifugation after 3 hour induction at room temperature, and stored at -80°C until purification. Pre and 
post-induction lysates were taken to confirm expression by SDS-PAGE.  
 
2.7 Cleavage of 6xHis-SUMO using ULP1 Protease 
 N-terminal 6xHis-SUMO fusion proteins were cleaved by addition of a 1:1000 dilution of ULP1 
protease. This can be done in as little as 2 hours at 4°C or can also be done overnight at 4°C 
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simultaneously while dialyzing proteins after Ni-NTA purification. To remove the 6xHis-SUMO from the 
untagged protein, the ULP1-digested preps were incubated with Ni-NTA resin at for at least one hour at 
4°C. Flow through was collected (which except for WalR contains the protein), and then subsequent 
washes of 50mM Tris pH7.5, 150mM NaCl, and 30mM imidazole are used to gently elute any protein that 
is sticking to the resin. I additionally do elutions with 50mM Tris pH7.5, 150mM NaCl, and 500mM 
imidazole, to ensure that all protein has been recovered. I took the individual fractions and loaded them 
for visualization by CBB staining. Appropriate fractions were re-pooled and dialyzed in dialysis buffer for 1 
hour at room temperature before proteins were used in functional assays. Alternatively, the second round 
of dialysis can be done overnight at 4°C.  
 
2.8 Purification of Strep-tag II or Biotinylated Proteins  
 Strep-Tactin Superflow 0.2ml columns (IBA) or Streptactin Superflow Plus (Qiagen) resin was 
used to purify proteins that had a Strep-tag II or Biotin tag. The proteins that were handled this way were 
T7-PrpC-strep-tag II (JDE1715), T7-PrpC D36N-strep tag II (JDE1903) and WalK-Biotin (JDE 1779). 
Frozen pellets were resuspended in lysis buffer and allowed to incubate on ice for at least 30 minutes 
with intermittent vortexing. Lysis buffer consists of 100mM Tris pH 7.5, 150mM NaCl, 1mM EDTA, 0.5mM 
DTT, 1mg/ml lysozyme, and 1mM PMSF. Lysates were sonicated for 45 seconds total time with cycles of 
5 seconds ‘on’ and 30 seconds ‘off’’. After sonication, 5 µg/ml of DNase1 and 3mM MgCl2 were added to 
lysates. Lysates were rotated on a nutator for 15 minutes at 4°C. Lysates were cleared by centrifugation 
at 15,000g for 30 minutes at 4°C. Cleared lysates were added to the column or onto the resin that had 
been pre-equilibrated with wash buffer and allowed to flow through by gravity, or incubate on the resin for 
at least 1 hour at 4°C. Wash buffer consisted of 100mM Tris pH 7.5, 150mM NaCl, 1mM EDTA, and 
0.5mM DTT. To elute strep-tag II or biotinylated proteins from the column or resin, 200 µl of elution buffer 
was added, five times. Elution buffer contained 100mM Tris pH 7.5, 150mM NaCl, 1mM EDTA, 2.5mM 
desthiobiotin, and 0.5mM DTT. PrpC and PrpC D36N were dialyzed into 20mM Tris pH 7.5, 50mM NaCl, 
1mM MnCl2, 0.5mM DTT, and 5% glycerol. WalK-biotin was dialyzed into WalK dialysis buffer, like what 




2.9 In vitro Kinase Assay of Eukaryotic-like Ser/Thr Kinases 
 eSTK kinase reactions were performed in a PrkC kinase buffer that consisted of 50mM Tris-HCl 
pH 7.5, 50mM KCl, 10mM MgCl2, and .5mM DTT. A 5X version of this buffer was generated to add to 
reactions. All reactions were performed in the presence of 400µM cold ATP and 2 µCi of γp32-ATP. eSTK 
was used at a final concentration of 2 µM and substrates were added at a final concentration of 4 µM, 
unless indicated otherwise. Reactions were incubated at 37°C for 30 min. 5X SDS-PAGE buffer was 
added to the reactions and subsequently boiled at 95°C for 5 min. Samples were run on a 12% SDS-
PAGE gel and dried for 30 minutes at 80°C in a gel dryer. Dried gels were exposed to a phosphoscreen 
and visualized using a Typhoon Scanner (GE Healthcare).  
 
2.10 In vitro Phosphatase Assay of Eukaryotic-like Ser/Thr Phosphatases 
 To perform in vitro phosphatase assays, the eSTK (PrkC or IreK) was incubated with substrates 
(WalR or VanS) in a 100 µl kinase reaction including 2 µM eSTK and 4 µM substrate, 500 µM cold ATP 
and 4 µCi γP32-ATP in kinase buffer. Kinase buffer consisted of 50mM Tris pH 7.5, 50mM KCl, 10mM 
MgCl2, 10mM MnCl2, .5mM EDTA, and .25mM DTT. Reactions were incubated for 30 minutes at 37°C. 
Kinase reaction was split into 4 X 25 µl reactions. One reaction was stopped with 5X SDS-PAGE buffer. 
The other reactions were spiked with 1 µl of 1mM staurosporine in DMSO to inhibit eSTK activity. 
Recombinant phosphatase (PrpC, PrpC D36N, IreP) was spiked at 2µM final concentration. Reactions 
were incubated for 1 hour at 37°C. Reactions were stopped by addition of 5X SDS-PAGE loading dye and 
incubated at 95°C for 5 minutes. Samples were run on a 12% SDS-PAGE gel and dried for 30 minutes at 
80°C in a gel dryer. Dried gels were exposed to a phosphoscreen and visualized using a Typhoon 
Scanner (GE Healthcare). 
 
2.11 WalK Kinase Assay 
 Reactions that were performed with WalK were done with its own kinase buffer with a final 
concentration of 100mM Tris pH 8, 200mM KCl, 4mM MgCl2, 0.5mM DTT, 0.1mM EDTA, and 3.5% 
glycerol. For kinetic experiments, 50 µl reaction volumes were used in order to be able to remove aliquots. 
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4 µM WalK (JDE 1601) and 4µM WalR (JDE 1591) or WalR T101D (JDE 1706) were incubated at room 
temperature with 1mM cold ATP and 176 nM γP32-ATP. Aliquots were removed at indicated times and 
stopped by addition of 2X SDS-PAGE loading buffer. Samples were not boiled.  
 In reactions when I sought to address the contribution of T101~P to the kinetics of WalK kinase 
activity, I performed an in vitro eSTK kinase assay with 4 µM WalR and 1µM PrkC for 30 minutes in a 
25µl reaction volume at 37°C. 1 µl of 1mM staurosporine (in DMSO) was added to inhibit PrkC activity. 
The previous reaction was spiked with 2.5 µl of 1M Tris pH8, 7.5µl 1M KCl, 5µl 5X WalK buffer, 4µM 
WalK (JDE1601) and 8µCi γP32-ATP to a total 50 µl reaction volume. Samples were withdrawn at 1 min, 
5min, and 15 minutes. To ensure I was observing phosphoaspartyl modifications and not 
phosphothreonine modifications, samples were incubated at 95°C for 5 minutes. 
 
2.12 WalK Phosphatase Assay 
WalK kinase reaction was performed with 1µM WalK-Biotin (JDE1779) and 10 µM WalR (JDE 
1591), WalR T101D (JDE 1706) and WalR T101~P (JDE 1604) in a 200 µl reaction volume in 1X WalK 
kinase buffer and 250 µM cold ATP and 20 µCi (~220nM) γP32-ATP. After 30 minutes at room 
temperature, samples were incubated on 40 µl of 50% Ni-NTA resin in a 1ml Pierce spin centrifugation 
column and incubated on ice for 1 hour. Samples were washed 3X 700 µl of 50mM Tris, 150mM NaCl, 
30mM imidazole wash buffer. WalR D53~P* was eluted 2X with 100 µl of 50mM Tris, 150 mM NaCl, and 
500mM imidazole buffer. Elution 1 was put through a ZebraSpin Desalting Column 7kDa (Pierce). 85 µl 
was added to a 125 µl total reaction volume with or without 2µM PrkC (JDE 1582) in the presence of 
400µM cold ATP in 1X PrkC kinase buffer. PrkC kinase reaction was performed for 30 minutes at room 
temperature. Samples were then desalted and added to new tube containing 5X WalK kinase buffer, and 
2µM WalK-6his (JDE 1601). Phosphatase activity was measured by taking indicated time points and 
stopping samples by addition of 5X SDS-PAGE loading buffer. Samples were run on a 12% SDS-PAGE 
gel and dried for 30 minutes at 80°C in a gel dryer. Dried gels were exposed to a phosphoscreen and 




2.13 Intrinsic Stability of WalR D53~P 
WalK kinase reaction was performed with 1µM WalK-Biotin (JDE1779) and 10 µM WalR (JDE 
1591), WalR T101D (JDE 1706) and WalR T101~P (JDE 1604) in a 200 µl reaction volume in 1X WalK 
kinase buffer and 250 µM cold ATP and 20 µCi (~220nM) γP32-ATP. Reactions were allowed to continue 
for 25 minutes at RT. Samples were incubated on 50 µl of Ni-NTA magnetic agarose beads (Qiagen) for 1 
hour on ice. Samples were washed 3X 700 µl of 50mM Tris, 150mM NaCl, 30mM imidazole wash buffer. 
Wash buffer was removed by using a magnetic stand and pipetting away the wash buffer. WalR D53~P* 
was eluted from the magnetic beads 2X with 100 µl of 50mM Tris, 150 mM NaCl, and 500mM imidazole 
buffer. Fraction that contained the highest amount of signal by the Geiger counter was used to put 
through the desalting column, to remove imidazole. After desalting, 100 µl was added to 5X WalRK buffer 
to generate 1X WalK kinase reaction conditions. Samples were incubated at 37°C for indicated time 
points and reactions were stopped by addition of 5X SDS-PAGE loading dye. Samples were run on a 
12% SDS-PAGE gel and dried for 30 minutes at 80°C in a gel dryer. Dried gels were exposed to a 
phosphoscreen and visualized using a Typhoon Scanner (GE Healthcare). 
 
2.14 WalR Receiver Domain Autophosphorylation with Carbamoyl Phosphate 
 WalR receiver domain (JDE2394 digested with ULP1 protease) was incubated with 30mM 
carbamoyl phosphate for 2 hours at room temperature in 1X WalK kinase buffer. Samples were stored on 
ice before running Native PAGE electrophoresis.  
 
2.15 Native PAGE Electrophoresis of WalR and WalR REC 
This protocol was provided from personal communication with Patricia Casino based off Casino 
et al [44]. Kinase assay samples or protein samples were run by adding 4X Native Loading Dye: 62.5mM 
Tris pH 6.8, 30% glycerol, and .01% bromophenol blue. Protein gels consisted of 375mM Tris pH 
8.8, .05% APS, 1:1000 dilution of TEMED, and either 12% or 15% acrylamide. Running buffer consisted 
of 25mM Tris and .192M glycine. Note that no SDS should be in the sample buffer, gels, loading buffers, 
or electrophoresis buffer. Gels were pre-run for 1 hour at 4°C at 100V. Gels were run for at least 5-6 
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hours at 100V in the cold room to obtain good separation. After electrophoresis, protein gels were stained 
with Coomassie Brilliant Blue. Gels were destained with 40% Destain Solution.  
 
2.16 PyocH Electrophoretic Mobility Shift Assay  
 I generated a Biotin-PyocH promoter by amplifying with primers LG205 and LG223 (contains 
5’Biotin) from PY79 genomic DNA. 300 base pair fragment was purified by gel extraction and quantified 
by spectrophotometer. Final EMSA conditions consisted of 50 ng/µl poly di:dC (Pierce), 10ng Biotin- PyocH 
probe, 1% glycerol, and buffer 10mM Tris pH 7.4, 50mM NaCl, 5mM EDTA, and 20mM DTT. PrkC kinase 
reactions and WalK kinase reactions were performed as described previously and spiked into the EMSA 
reactions. WalR was added to EMSA reactions and allowed to incubate for 20 minutes at room 
temperature. 6X DNA loading dye was added to samples.  
 Samples were loaded onto 6% 0.5X TBE Native PAGE gel that had been pre-run at 100V for 1 
hour at 4°C. Samples were run for 2 hours at 100V at 4°C. The gel was transferred to a Biodyne B (Pall) 
membrane by wet transfer in 0.5X TBE buffer at 100V for 1 hour. Membrane was cross-linked using 
Optimal Crosslink setting on the Symington Lab’s UV Crosslinker. Membrane was visualized using the 
LightShift Chemiluminescent EMSA Kit (Pierce) according to manufacturer’s instructions.  
 
2.17 Surface Plasmon Resonance (by Dr. Phini Katsamba) 
 While I provided proteins for these experiments, the Biacore was run by Dr. Phini Katsamba from 
Dr. Lawrence Schapiro Lab at Columbia University Medical Center. WalK-Biotin was captured on a 
streptavidin SA chip ~ 460 RU. Binding of WalR wt, WalR T101D and WalR T101~P proteins over a 
protein range of 20-0.3125 µM in a PBS buffer supplemented with 0.1 mg/mL BSA and 0.005% Tween 20 
was monitored. 
 
2.18 Reverse Phase HPLC Analysis of WalR 
 Reverse Phase HPLC analysis was performed in collaboration with Paul O’Brien, PhD Candidate 
in Dr. Arthur Palmer’s Lab in the Department of Biochemistry and Biophysics at Columbia University 
Medical Center. Buffer A consisted of water and Buffer B consisted of 99.9% acetonitrile with 0.1% 
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trifluoroacetic acid. We used a Jupiter C4 300Å 5 micron 4.6mm X 250mm column on a Walters 600 
HPLC Machine and a Walters 2487 UV detector in Dr. Virginia Cornish’s Laboratory in the Department of 
Chemistry at Columbia University. We ran a program at 1ml/min with starting conditions of 9.1% 
acetonitrile and 90.9% H20 for 10 min and then ramped to 82% acetonitrile and 18% H20 over 55 
minutes. I prepared samples by performing in vitro kinase assays using 15µM WalR or WalR T101S and 
3µm PrkC with 100µM ATP in PrkC kinase buffer for 2hours at 37°C. For D53~P I performed a WalK 
kinase assay with 15µM WalK and 3µM WalR or WalR T101S with 100µM cold ATP. For doubly 
phosphorylated samples, 120 µl of desalted PrkC kinase reactions were added to 3µM WalK in a WalK 
kinase reaction with 100µM ATP. 20µl of sample was injected onto the column. Elution times indicated 
are the peak of the protein profile.  
 
2.19 Phosphopeptide Identification by Mass Spectrometry (provided by Dr. Mary Ann Gawinowicz) 
In-gel Digestion of Coomassie-stained Bands: Gel bands were transferred to pre-digested tubes 
and 100 µl 0.01M DTT/0.1M Tris, pH 8.5 was added. The tube was placed in a heating block at 55° for 1-
2h.  After cooling the tube to room temperature, the liquid was removed and replaced with 10 µl 0.03M 
iodoacetamide/0.1M Tris, pH 8.5.  This was allowed to react for 30 min. in the dark after which the liquid 
was removed and the gel was washed as described below. Gel bands were prepared for digestion by 
washing twice with 200 µl 0.05M Tris, pH 8.5/ 30% acetonitrile for 20 minutes with shaking, and once with 
100 µl acetonitrile for several minutes until the gel was opaque white.  After removing the acetonitrile, the 
gel pieces were dried for 20-30 min. in a Speed-Vac concentrator. Gels were digested by adding 0.10mg 
modified trypsin (sequencing grade, Roche Molecular Biochemicals, Indianapolis, IN) in 50 µl 0.025M Tris, 
pH 8.5, or enough volume to completely hydrate the gel. The tubes were placed in a heating block at 32° 
and left overnight. Peptides were extracted with 2X 50 µl 50% acetonitrile/2% TFA and the combined 
extracts were dried in the Speed-Vac and dissolved 20 µl 0.1% formic acid. 5 µl aliquots were analyzed 
by LC-MS/MS. 
ESI-LC-MS/MS: LC-MS/MS analysis was done on a Waters Ultima Q-Tof hybrid quadrupole/time-
of-flight mass spectrometer with a nanoelectrospray source. Capillary voltage was set at 1.8kV and cone 
voltage 32V; collision energy was set according to mass and charge of the ion, from 18eV to 50eV. 
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Chromatography was performed on an LC Packings HPLC with a Dionex C18 PepMap column (15 cm x 
75 mm) using a 90-minute linear acetonitrile gradient with flow rate of 200 nl/ min. Raw data files were 
processed using the MassLynx ProteinLynx software and .pkl files were submitted for searching at 
www.matrixscience.com using the Mascot algorithm. Search parameters were as follows: Database, 
SwissProt 2010_10; taxonomy, Bacillus subtilis; enzyme, trypsin; variable modifications, 
Carbamidomethyl (C), Oxidation (M), Phospho (ST), Phospho (Y); max missed cleavages, 2; peptide 
mass tolerance, 1.2 Da; fragment mass tolerance, 0.6 Da. 
2.20 Analysis of B. subtilis WalR Allelic Replacement Strains  
 For stationary phase lysis on plates, strains were streaked directly from the glycerol stock onto LB 
agar and allowed to grow overnight at 37°C. The following morning plates were removed from the 
incubator and allowed to sit at ambient temperature for 3 to 4 days. Plates were visualized on the gel box 
using white light to facilitate visualization of the transparent colonies.  
This is the protocol for visualization of PyocH-GFP transcriptional reporter expression. After 
transformation, strains were re-patched with the appropriate antibiotics and then patched onto LB agar 
plates. After an overnight incubation at 37°C to allow for growth, plates were allowed to sit on the bench 
for a day to allow for PyocH expression from the ‘wild-type’ ΔprpC strain and visualized on a UV light box 
using a long wave UV light. 
 
2.21 Construction of B. subtilis 3610 Strains  
 B. subtilis 3610 strains were generated by performing SPP1 phage transduction of PY79 or trpC2  
strains based off a protocol provided by Dr. Richard Losick’s Lab at Harvard University. Donor lysates are 
generated by growing a single colony in 2 ml of TY media for at least 6 hours at 37°C. TY media is 
generated by adding 10ml 1M MgSO4 and 1ml 0.1M MnS04, after autoclaving, into 1 liter of LB or LB 
agar. Near the end of the growth, melt TY soft agar and aliquot 3mls into tubes (approximately 50 °C). If it 
is too hot it will kill the cells. Make serial dilutions of SPP1 phage and mix 200 µl dense culture with 100 µl 
of phage dilutions (diluted in TY media). Incubate for 15 minutes statically at room temperature. Add the 
donor/phage mixture to 3ml aliquot of TY soft agar and overlay onto TY agar plates. Let them incubate 
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upright overnight at 37°C. The following day harvest lysates by picking a plate that contain standard 
looking plaques and scrape off the overlay into 5ml of TY media. Transfer to a 50ml falcon tube and 
vortex. Spin at 5,000g for 10 min to remove the agar. Treat supernatants with 5µg/ml DNase1. Let stand 
for 10 min at room temperature. Filter lysates through a .22-micron syringe filter and store phage stock at 
4°C. For transduction grow recipient culture in 2-3ml of TY for approximately 5-6 hours, so the culture is 
very dense. Mix recipient culture with phage stock using the ratios of 10 µl phage to 990 µl recipient 
culture or 100 µl phage to 900 µl recipient culture. Vortex phage/ recipient culture mix and allow to 
incubate for 30 minutes at 37°C statically. Centrifuge at 5,000g for 10 minutes and pour off supernatant. 
Resuspend pellet and plate onto LB selective media with 10mM sodium citrate. For tetracycline 
transduction, sodium citrate is not necessary.  
 
2.22 Biofilm and Pellicle Formation in B. subtilis 3610 
 To generate pellicles, cultures are grown from a single colony in 3 ml of LB at 37°C to an OD600 of 
1.0. They are diluted 1:1000 into MSgg media and cultures are allowed to sit statically at room 
temperature. I commonly used 10ml volumes into an individual well of a 6-well sterile cell culture dish. For 
solid agar biofilms, cultures are grown up from a single colony in 3ml of LB to an OD600 of 1.0 and 3 µl are 
spotted directly into the center of MSgg agar plates. Plates are incubated at 30°C for the desired time. To 
make 1 liter of MSgg biofilm media add 5ml of 0.1M phosphate buffer, 20 ml of 0.5M MOPS pH7, 2ml of 
0.1M MgCl2, 0.5 ml 0.01M MnCl2, 0.1ml 1mM ZnCl2, 0.02ml 10mM thiamine, 0.5ml 10mg/ml 
phenylalanine, 0.5ml 10mg/ml tryptophan, 0.5ml 10mg/ml threonine, 1ml of 50% glycerol and 5ml of 10% 
glutamate. These are mixed together and filter sterilized. After sterilization, 1 ml of 5mM FeCl3 and 0.7ml 
0.1M CaCl2 are mixed in to the sterile media. In order to generate solid media, the concentrations are 
doubled and mix 1:1 with 2X agar in water.  
 
2.23 Immunoprecipitation of WalR-Flag 
 Under native conditions, JDB 3580, 3582, and 3584 were grown in LB to a desired time point. In 
preliminary experiments I chose OD600 of 5.0, as this is the time point I have observed differences in 
WalRK gene expression. For formaldehyde cross-linking experiments I adapted a method previously 
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used by Fukushima et al [86].  I spun down the cultures and resuspended them in 32 mM sodium 
phosphate buffer with 1.33% formaldehyde for 30 minutes at room temperature. I washed these pellets 2 
times with 1X PBS. The only difference between formaldehyde treated cultures and non-treated samples 
was that I used an Emulsiflex for 3 times at 15,000 psi to burst open B. subtilis cross-linked cultures after 
performing the lysis buffer step. Samples were resuspended in 2X SMM buffer with 1mg/ml lysozyme for 
30 minutes at 37°C. After generation of protoplasts, I resuspended the protoplasts in Lysis Buffer, which 
consists of 50mM Tris pH 7.5, 150mM NaCl, 1% NP-40, 3mM MgCl2, 5µg/ml DNase1, and 1mM PMSF. I 
let samples incubate on ice for 1 hour with vortexing. M2-Flag Magnetic Beads (Sigma) were equilibrated 
in wash buffer: 50mM Tris pH 7.5 and 150mM NaCl. After incubation on ice for 1 hour, samples were 
centrifuged at 15,000g for 30 minutes to clear the lysate from membranes and cellular debris. Cleared 
lysates were incubated on the resin overnight at 4°C. The following morning washes were done with 10 
times the column volume of beads used. After washing, magnetic beads were incubated with 3X flag 
peptide (150ng/µl) in 50mM Tris pH 7.5 and 150mM NaCl for 30 minutes at room temperature. 5X SDS-
PAGE loading dye was added to a final concentration of 1X. Half of the sample was split to observe the 
extent of crosslinking in formaldehyde treated samples. Beads were also boiled in 2X SDS-PAGE buffer 
with no β-mercaptoethanol or DTT for 3 minutes at 95°C to remove proteins attached to the beads, 
without breaking apart the Flag antibody that is conjugated to the magnetic beads. Samples were run on 
an SDS-PAGE gel and then transferred in 1X Transfer Buffer at 60V for 60 minutes using a wet transfer 
in standard transfer buffer to a nitrocellulose membrane. After transfer the membrane was blocked with 
PBS-T and milk, and allowed to incubate for 30 minutes at room temperature. The blot was washed 3X 5 
minutes with PBS-T. After which the membrane was allowed to incubate overnight with the monoclonal 
anti-Flag-HRP conjugate (Sigma) in a 1:1000 dilution in PBS-T. The following morning the membrane 
was washed with 3X 5 minute washes with PBS-T and visualized using Super Signal Horse Radish 
Peroxidase (Pierce). The blot was exposed to film and processed with an X-Omat (Kodak).  
 
2.24 RNA Extraction and cDNA Synthesis: B. subtilis and E. faecalis   
B. subtilis cultures were grown as indicated and then mixed with equal volume of ice-cold 100% 
methanol. Cultures were vortexed immediately and spun down at 15,000g at 4°C for 15 minutes. Pellets 
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were stored at -80°C for at least one overnight before proceeding with purification. E. faecalis cultures 
were stabilized with Bacterioprotect Reagent (Qiagen) according to manufacturer’s instructions and 
stored at -80°C for at least one night. RNA was extracted using the Mechanical Disruption Protocol in the 
Qiagen RNEasy MiniKit. RNA was quantified using the NanoDrop (ThermoScientific) and was 
subsequently treated with DNAse1 (NEB) for 15 minutes at 37°C. After DNAse1 treatment, 5mM EDTA 
was added and DNAse1 was inactivated by treatment at 75°C for 10 min. 200ng of DNAse treated RNA 
was used as a template in FirstAid cDNA Synthesis Kit (Fermentas) using random hexamer primers 
according to manufacturer’s instructions.   
 
2.25 Real Time Quantitative PCR Analysis of Transcripts 
qPCR primers were designed using Primer3Plus online qPCR primer tool. All products are 
between 70-150 bp with an annealing temperature of 60°C. 3 primer sets were ordered for each locus in 
order to identify primers with high efficiency and low presence of primer dimers. RT-qPCR was performed 
in 20 µl reaction volumes of 1X Perfecta SYBR-Green (Quanta) using 5 µl of a 1:200 dilution of cDNA as 
input. A final concentration of primers (0.1 µM) was used for all experiments. RT-PCR was performed on 
a Biorad iCycler with cycle parameters of: 95°C 3 min, 95°C 10 seconds, 60°C 30 seconds, for 35 cycles. 
Technical triplicates were used and averaged to generate Ct values. Minus reverse transcriptase controls 
were performed to ensure efficient DNase treatment. Melting curves were also generated to confirm 
specific PCR products. Water controls were also used to check for primer dimers. Data was analyzed 
using delta delta CT normalizing to 16S rRNA.  
 
2.26 Construction of S. aureus Allelic Replacement Strains  
I used the pIMAY vector system recently developed by Monk et al [178]. I obtained the vectors 
with permission from the authors from Dr. Luciano Marraffini at Rockefeller University. Vectors pLG328, 
pLG329, pLG334 and pLG335 were generated using a Sequence and Ligation Independent Cloning 
(SLIC) approach as provided by Dr. Ian Monk in personal communication. pIMAY Fwd and pIMAY Rev 
were used to amplify pIMAY from 10ng of template using Phusion PCR with annealing temperature of 
50°C and 2 min extension time. 1µl of Dpn1 was added to the 50 µl PCR and incubated for 2 hours at 
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37°C. This was purified by the Qiagen PCR Purification Kit. Our insert PCR product and pIMAY PCR 
product were separately treated in a 40 µl total reaction containing 4 µl of NEB Buffer 2, 2µl 100mM DTT, 
4µl 2M Urea, 1µg of DNA and 1µl of T4 DNA Polymerase (NEB) and incubated at 23°C for 20 min. 2 µl of 
0.5M EDTA was added and the reaction was incubated at 75°C for 20 minutes to stop the reaction. I 
annealed pIMAY and the insert using 5µl of vector and 5µl of insert using 65°C for 10 min, and stepwise 
decrease from 65°C to 25°C with a minute hold for each degree. The reaction was precipitated with pellet 
paint (Novagen) and transformed into E. coli DC10B. I engineered a silent AatII restriction into the WalR 
cloning site to facilitate screening of transformants. This AatII site was generated by SOE PCR with 
LG666/LG673 and LG667/LG672 using outside primers LG666 and LG667 on either S. aureus 8325 or 
clinical isolate 8007 genomic DNA. To generate mutations, mutagenesis primers LG579/580 were used to 
generate T101S on pLG328 and LG640/641 to generate S101T on pLG329.  Vectors were electroporated 
into S. aureus 8325 or 8007 using 0.1cm electroporation cuvettes with a setting of pulse 21 kV/cm, 100 Ω 
and 25uF. Selection was done according to the original publication and screened by colony PCR with 
IM151/IM152 to detect for replicating plasmids.  
 
2.27 S. aureus Strains - Stationary Phase & Hemolysis 
 Stationary Phase Lysis: Cultures were streaked directly from glycerol onto Trytic Soy Agar (BD) 
and allowed to grow overnight at 37°C. After one overnight incubation at 37°C, strains were allowed to 
remain at room temperature. After 7 days, there is a clear difference between wild type (JDB 3399) and 
ΔpknB (JDB 3400). Pictures were taken with a GeneFlash (Syngene Bio Imaging) gel box using white 
light.  
 Hemolysis: Strains were streaked directly from glycerol stocks onto Trypticase Soy Agar (TSAII) 
with 5% Sheep Blood (BD BBL). After one overnight at 37°C, plates were stored at 4°C for an additional 





2.28 VISA Characterization of S. aureus Strains (by Madeleine Sowash/ Dr. Anne-Catrin Uhlemann) 
E-tests : The vancomycin MIC for each strain was determined using both vancomycin and dual 
vancomycin-teicoplanin E-test strips (bioMérieux, France). Strains were grown overnight in Brain-Heart 
Infusion (BHI) broth (Becton Dickinson, Inc. [BD]) at 37oC with 220 rpm shaking. Cultures were diluted 
1/100 and grown to 0.5 and 2.0 McFarland, respectively for vancomycin and vancomycin-teicoplanin E-
tests, before streaking a lawn on BHI agar (BD) plate. After placement of E-test strips, plates were 
incubated at 35oC and MIC results were recorded at 24 hours and 48 hours. Mu3 and Mu50 were used as 
the hVISA and VISA controls, respectively.  
Population Analysis Profile (PAP):  Strains were grown overnight in BHI broth at 37oC with 220 
rpm shaking. Cultures were centrifuged at 3000 rpm for 10 minutes. Pellets were resuspended in 
phosphate buffered saline (PBS) to 0.5 O.D., followed by serial dilution to 10-4. Fifty microliters of the 10-4 
dilution were spiral plated onto BHI agar with the following vancomycin (Sigma) concentrations: 0.0µg/mL, 
0.5µg/mL, 1µg/mL, 1.5µg/mL, 2µg/mL, 2.5µg/mL, 3µg/mL, 4µg/mL and 8µg/mL. Fifty microliters of the 10-
3 dilution were spiral plated onto BHI agar with the following vancomycin concentrations: 2µg/mL, 
2.5µg/mL, 3µg/mL, 4µg/mL and 8µg/mL. Plates were incubated at 35oC, and colonies were counted at 24 
hours and 48 hours. Mu3 and Mu50 were used as the hVISA and VISA controls, respectively. 
“The log10 CFU/ml was plotted against the vancomycin concentration, and an area under the 
time-concentration curve (AUC) was calculated using GraphPad Prism software. The AUCtest/AUCMu3 
ratio was calculated, and strains were categorized as VSSA, hVISA, and VISA according to this ratio as 
follows: VSSA, <0.9; hVISA, 0.9 to 1.3; VISA, >1.3.” [99]. 
 
2.29 In vitro Inhibition by Staurosporine  
 To perform in vitro staurosporine inhibition assays I used 1µM kinase in their respective kinase 
buffer conditions with 11nM (0.5µCI) γP32-ATP and no cold ATP. For eSTKs, these reactions were 
incubated for 30 minutes at 37°C. 1mM In Solution Staurosporine (Calbiochem) was diluted with DMSO 
to keep the level of DMSO constant throughout the reactions. For histidine kinases, these reactions were 
incubated for 30 minutes at room temperature. Samples were stopped by addition of 5X SDS-PAGE 
loading dye and equal amounts of sample were run on a 12% SDS-PAGE gel. Gels were dried and 
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exposed to a phosphoscreen and visualized by Typhoon Phosphoimager. DMSO only control was used 
to determine the uninhibited kinase levels. Inhibition was determined by quantifying gel lanes with ImageJ 
and comparing them to the DMSO only control.  
 
2.30 Construction of E. faecalis IreK Complementation Strains 
 The protocol, strains, and plasmids were obtained from Dr. Danielle Garsin at the University of 
Texas Medical School at Houston. I SOE’d the L. lactis P23 promoter to the RBS and ORF of IreK. This 
was inserted into pSD15 by conventional cloning. This was digested with Xma1 (NEB) and cloned into 
pRV1 digested with the same. It should be noted that pRV1 must be propagated at 30°C in EC1000 in 
BHI + 300 µg/ml erythromycin. This cloning step is very inefficient, so I used the NEB Quick Ligase Kit 
and transformed 10 µl into 300µl of EC1000 competent cells made by the Rubidium Chloride Method 
(NEB). pRV1 derivative vectors (pLG364, pLG371, pLG372 and pLG373) were electroporated into E. 
faecalis CK111. CK111 strains were conjugated to JDB3539 and allowed to conjugate for at least 6 hours 
at 37°C on .22 micron polycarbonate membranes (Osmonics K02BP02500) on BHI agar plates. The filter 
containing the conjugation was dislodged and vortexed with sterile PBS before platting onto BHI with 10 
µg/ml erm, 200 µg/ml X-gal in DMSO, and 25 µg/ml fusidic acid to counter-select for the donor strain.  
Colonies are re-streaked onto BHI agar with 10 µg/ml erm and 200 µg/ml X-gal in DMSO to select for 
single cross-over events. To induce double cross-over, a single colony was resuspended in PBS and 
plated onto MMY9EG agar supplemented with 10mM p-Cl-Phe (Sigma) and 200 µg/ml X-gal in DMSO. 
White colonies should contain double crossover events and should be confirmed by PCR and sequencing.  
 
2.31 Staurosporine and Vancomycin Treatment of E. faecalis JH2-2::TN1549 
 JH2-2::TN1549 (JDB 3368) which was obtained from Dr. Patrice Couvalin at the Pasteur Institute 
was streaked for single colonies from a glycerol stock on BHI agar. After one overnight at 37°C, an 
individual colony was taken and grown in BHI media until an OD600 of 0.7. At this point cultures were 
either pre-treated for 10 minutes with 10µM staurosporine or DMSO mock or simultaneously added with 
2µg/ml vancomycin to stimulate the VanRS regulon. Samples were allowed to incubate for 10 minutes 
  
60 
after vancomycin addition and were stopped by addition of 2 volumes of RNA Bacterioprotect Reagent 
(Qiagen).   
 
2.32 MIC Characterization of VRE Strains  
 Strains were isolated on brain heart infusion (BHI) agar and then grown in BHI broth at 37°C. The 
MICs of glycopeptides were determined by the method of E-test after 24 h of incubation on BHI. The E-
test system (bioMérieux, Marcy l'Etoile, France) comprises a predefined and continuous concentration 
gradient of antimicrobial agent which, when applied to inoculated agar plates and incubated at 37°C, 
creates an ellipse of microbial inhibition. The MIC is determined where the ellipse of inhibition intersects 
the strip and the MIC corresponds to the graduation at the intersection with the strip. 
2.33 VanS Kinase Assay 
 VanS kinase assays were conducted in buffers with 50mM Tris pH7.5, 50mM KCl, 10mM MgCl2, 
2mM MnCl2, 0.5mM DTT as previously performed [58]. VanS autophosphorylation experiments with 2 µM 
VanS (JDE 1985) or 2 µM VanS T223D (JDE 2881) were performed in 100 µl reaction volume in the 
presence of 100 µM cold ATP and 10 µCi γP32-ATP. VanS was allowed to autophosphorylate at room 
temperature for indicated time points. Reactions were stopped by the addition of 5X SDS-PAGE loading 
dye. For experiments to monitor VanS to VanR phosphotransfer a 25 µl kinase reaction with 10 µM VanS 
or VanS T223D was allowed to incubate with 400µM cold ATP and 5µCi γP32-ATP for 30 minutes at room 
temperature. These kinase reactions were diluted into a 100 µl reaction with 1X final kinase buffer and 
10µM VanR (JDE1985). To measure the rate of phosphotransfer, samples were taken at indicated 
intervals and stopped by the addition of 5X SDS-PAGE loading dye.  
 For experiments in which I was assessing the influence of IreK phosphorylation on VanS kinetics, 
I performed an eSTK kinase reaction with 1µM IreK and 10µM VanS (JDE 1985) or 10 µM VanS T223A 
(JDE 2880) in PrkC kinase buffer using 100µM cold ATP. After incubation at 37°C for 2 hours, these 
samples were desalted and staurosporine was added to inhibit IreK activity. Samples were then diluted 
into VanS kinase reaction conditions in the presence of 5µCi γP32-ATP and samples were taken at 
indicated time points. To ensure I had completely inhibited IreK activity, I split samples and incubated 
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them at 95°C for 5 minutes, to ensure I was not looking at phosphothreonine rather than phosphohistidine 
modifications. Samples were run for 1hour at 150V in a 12% SDS-PAGE protein gel, dried for 30 minutes 
at 80°C, and exposed to a phosphoscreen for 1 hour. Screen was scanned with a Typhoon Scanner (GE 
Healthcare). 
 
2.34 VanR Autophosphorylation with Radiolabelled Acetyl Phosphate 
The generation of radiolabelled acetyl phosphate (AcP) was obtained through personal 
communication with Dr. John Kirby at the University of Iowa. 5X AcP buffer consisted of 125mM Tris pH 
7.4, 300mM KoAc, 50mM MgCl2. For 10 µl of radiolabelled AcP, 2 µl of 5X AcP buffer, 10 µCi γP32-ATP 
and 1U E. coli acetate kinase (Sigma) are incubated for at least 1 hour at room temperature. Adding 2.5 
µl of ~100µM VanR (JDE 1985) directly to 7.5 µl of AcP* mix was used to generate VanR D53~P. This 
reaction was allowed to incubate for 1 hour at room temperature. This was scaled up to perform VanS 
phosphatase assays.  
 
2.35 VanS Phosphatase Assay 
 VanS phosphatase assays were conducted in buffers with 50mM Tris pH7.5, 50mM KCl, 10mM 
MgCl2, 2mM MnCl2, 0.5mM DTT as previously performed [58]. VanR  (JDE 1985) was allowed to 
autophosphorylate with AcP* (Section 2.30). After autophosphorylation VanR was put through a 
ZebraSpin Deslating Column 7kDa MWCO (Pierce) to remove excess γP32-ATP. Meanwhile, either 10 
µM VanS (JDE 1986) or 10 µM VanS T223A (JDE 2880) were incubated with 2 µM IreK (JDE 2003) for 2 
hours at 37°C to enhance the population of threonine phosphorylated VanS.  Once VanR was labeled at 
D53, 5µM VanS/IreK , VanS T223A/ Irek, VanS, or VanS T223D were incubated with 25 microliters of 
VanR D53~P  in a 50 µl reaction volume. Aliquots were taken at indicated time points and stopped by the 
addition of 5X SDS-PAGE loading dye. Samples were run for 1hour at 150V in a 12% SDS-PAGE protein 
gel, dried for 30 minutes at 80°C, and exposed to a phosphoscreen for 1 hour. Screen was scanned with 




2.36 Staining of Phosphoproteins by Pro-Q Diamond Blot Stain 
 Protein samples are run on a 12% SDS-PAGE gel for 1 hour at 150V. Near the end of the run, a 
PVDF membrane was activated with methanol for several seconds and then incubated in 1X Transfer 
Buffer for 10 min. Transfer was done at 4°C or with an ice pack at 60V for 60 min. After transfer PVDF 
membranes were stained with Pro-Q Diamond Phosphoprotein Blot Stain (Molecular Probes) according 
to manufacturer’s instructions. For enhanced reproducibility, follow all incubation steps for the exact 
amount of time indicated. Also, a nitrocellulose protein membrane is not a substitute for PVDF membrane 
in this case.  
 
2.37 C. crescentus HipA Homolog Protein Purification: Denaturing Conditions & Refolding 
Conditions 
 For strains JDE 2145 (CC2386), 2146 (CC2770), and 2147 (CC2735) cultures were expressed 
from pBad24 derivative vectors and induced with 0.2% arabinose at 37°C for 3 hours. After standard 
purification procedures and after clearing the lysate, I took this pellet, which contains both the membrane 
fraction and inclusion bodies. This protocol was adapted from Holly Wolcott, PhD candidate in the 
Department of Biochemistry and Biophysics at Columbia University Medical Center. The pellet was 
washed three times in 20 ml of Tris Wash Buffer with Triton (50mM Tris pH 7.5, 10mM EDTA, 50mM DTT, 
500mM NaCl, 2.5% Triton X-100). This step removes the membranes from the inclusion bodies. After 
three washes, this step is repeated using Tris Wash Buffer except that the Triton X-100 is omitted. The 
inclusion body was then resuspended in freshly made 6M guanidine HCl, 50mM Tris pH 8 overnight at 
4°C. The following morning the resolubilized inclusion body is spun down for 20 minutes at 15,000g to 
remove cellular debris.  
 The inclusion body is quantified using the spectrophotometer and diluted with 6M guanidine HCl 
in 50mM Tris pH 8 to a final protein concentration of 1mg/ml. A panel of refolding buffers was made with 
55mm Tris, 21mM NaCl, .88mM KCl, 1mM MgCl2, 1mM DTT and differing amounts of the denaturants 
Guanidine HCl and L-arginine. The final concentrations used can be seen in Figure 6.3.2.1. 10 µl was 
added to 950 µl of renaturing buffer and vortexed. This was repeated until a total of 50 µl of 1mg/ml 
inclusion body had been added. Samples were allowed to incubate overnight at 4°C. The following 
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morning, samples were spun at 15,000g for 30 minutes at 4°C to remove aggregates. The supernatant 
was split and half was taken to perform TCA precipitation, to determine which refolding buffer worked 
best. Of the fractions that looked promising, the other half was dialyzed into eSTK dialysis buffer and 

























Chapter 3. The Essential Response Regulator, WalR, is a Substrate of the Eukaryotic-like Ser/Thr 
Kinase & Phosphatase PrkC & PrpC in B. subtilis 
 
3.1 Introduction  
Previous experiments from the Dworkin Lab showed that the eukaryotic-like Ser/Thr kinase, PrkC 
was able to regulate transcription of the cell wall hydrolase, yocH [238]. It was further shown in vivo that 
overexpression of PrpC, the cognate eSTP, inhibited induction of peptidoglycan-mediated PrkC-
dependent yocH expression. However, the mechanism underlying the ability of PrkC, a membrane-bound 
Ser/Thr kinase, to mediate these transcriptional effects remained elusive (Figure 3.1). In addition to the 
regulation of yocH expression by PrkC, it is also positively regulated by the WalRK two-component 
system [108]. It contains canonical WalR binding sites and WalR binds to PyocH in vitro [108] and in vivo 
[227].  
Interplay between the PASTA-domain containing eSTK and the WalRK two-component system 
has also been reported in other Gram-positive bacteria. In Streptococcus pneumoniae, deletion of the 
cognate eSTK, StkP, showed a significant down-regulation of genes known to be regulated by the WalR 
homolog, VicR [229]. In Staphylococcus aureus, deletion of PknB resulted in down-regulation of several 
known WalRK regulon genes [66]. This transcriptomic data mirrors the regulation of yocH that is seen in 
B. subtilis. This suggests that the cross talk between the PASTA domain containing eSTK and the 
essential two-component system, WalRK, is likely conserved.  
There are three scenarios that could explain how PrkC and its homologs are able to mediate 
these effects. The first scenario would be by direct interaction with the WalRK essential two-component 
system, which positively activates yocH expression in B. subtilis [108]. A second possible scenario is that 
PrkC phosphorylates proteins involved in cell division, like has previously been shown for M. tuberculosis 
PknB [126, 201] and S. agalactiae Stk1 [242]. These modifications would activate the WalRK two-
component system, which senses changes in cell wall metabolism. A third scenario would be PrkC 





Figure 3.1 Model of YocH Induction 
 
 
Figure 3.1. Model of YocH Induction. Adapted from Shah et al [238].  YocH, the cell wall hydrolase 
auto-regulates its own expression in a PrkC-dependent fashion. However, how PrkC mediates these 
transcriptional effects is unknown and this is highlighted by the question marks. 
 
 
3.2 Transposon Screen to Identify Novel Factors That Regulate PyocH Expression 
 I initially took an unbiased reverse genetics approach to identify factors that modulate PyocH 
expression. I took advantage of the high level of yocH expression seen in a ΔprpC background. A former 
post-doc in the lab, Dr. Ishita Shah, generated a PyocH -lacZ transcriptional fusion. In order to visualize 
PyocH -lacZ expression on LB agar plates, I sprayed the compound 4-methylumbelliferyl-β-D 
Galactopyranoside (MUGal). MUGal is a substrate for β-galactosidase and releases the compound  
methylumbelliferone, which can be visualized by a UV light box [254]. In order to confirm that I could see 
differential expression of PyocH -lacZ I plated a mixture of JDB 1786, ΔprpC amyE:: PyocH -lacZ and JDB 
1787 ΔprkC amyE:: PyocH -lacZ (Figure 3.2.1). I used this as a proof of principle that PrkC-dependent yocH 





























Figure 3.2.1 Visualization of PyocH-lacZ Reporter Activity. Mixture of JDB 1786, ΔprpC amyE:: PyocH -
lacZ and JDB 1787 ΔprkC amyE:: PyocH -lacZ. Strains were each grown from a single colony in 3ml LB at 
37°C to an OD600 of 0.5. Strains were mixed 1:1 and plated at 10-5 dilution.  Colonies were plated on LB 
agar and allowed to incubate overnight at 37°C. Plate was visualized the following day using approx. 200 
microliters of 4-methylumbelliferyl-β-D-galactopyranoside(10 mg/ml in DMSO) using a Martini Mister. 
Compound allowed to incubate for 2 minutes prior to observing under UV light. 
 
 
I utilized the mariner-based transposon system that has previously been used in B. subtilis [149]. 
I utilized the pMarB plasmid, which drives Himar1-mariner transposase expression under the σB promoter. 
This system utilizes a temperature sensitive shuttle vector that was able to replicate at 30°C but not at the 
restrictive temperature of 50°C. Furthermore, the kanamycin resistance gene is flanked by the Himar1 
specific inverted terminal repeats. To screen for replicating plasmid, there is also an erythromycin 
resistance cassette. After incubation at elevated temperatures on LB + 10µg/ml kanamycin, transposition 
should occur randomly throughout the genome. In order to confirm that transposition was working as 
previously published, I screened for sporulation deficient B. subtilis, since this is a non-essential process, 
by patching KanR colonies on DSM. I obtained a similar frequency of hits as reported in the original 
publication.  
In order to identify transposon hits, I performed an inverse PCR approach based off Bae et al [17]. 
I obtained hits in prkC and lacZ, which would be expected if I was investigating PrkC-dependent PyocH -
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lacZ expression. I also obtained a hit in yocI, whose sequence was actually contained within the PyocH -
lacZ transcriptional fusion construct. The 11 additional hits, however, did not identify any other 
transcription factors or DNA binding proteins (Table 3.2).  It should be noted that the screen was not 
saturated. As with all screens, I realized that no essential genes would be obtained. This screen was 
performed simultaneously with directed approaches to determine if PrkC directly interacted with the 
essential two-component system, WalRK.  
Table 3.2 Hits from Transposon Mutagenesis of PyocH -lacZ Reporter 
Gene Function 
yocI   ATP-dependent DNA helicase, immediately upstream of yocH  
lacZ    
prkC  Eukaryotic-like Ser/Thr Kinase  
glgC  Glucose-1-phosphate adenylyltransferase  
gltT  H+/Na+-glutamate symport protein 
gpsA  NAD(P)H-dependent glycerol-3-phosphate dehydrogenase  
ybfN  Unknown  
yckA  Similar to amino acid ABC transporter (permease) 
ydcD  20 bp upstream from ydcDE operon (MazF/PemK endoribonuclease/inhibitor) 
yesM  TCS sensor kinase  
yfnI  Probable transmembrane glycoprotein; similar to anion-binding protein 
yrkO  Unknown (10 coiled/coil regions) putative integral membrane protein 
ywbN  Unknown function, twin-arginine protein secreted in a Tat-dependent fashion 
ywCA  Similar to Na+-dependent symport  
 
Table 3.2 Hits from Transposon Mutagenesis of PyocH -lacZ Reporter.  Transposon sites were identified by 
inverse PCR as hits that resulted in loss of PyocH -lacZ reporter expression by pMarB mediated 
transposition of JDB 1786.  
 
3.3 PrkC Phosphorylates WalR at T101 in vitro  
 In parallel to the Tn-based screen, I also took a biochemical approach to determine if PrkC was 
able to phosphorylate WalR or WalK. I generated and purified N-terminal 6xHis-PrkC kinase domain only 
(PrkCKD), full length C-terminal 6xHis -tagged WalR, C-terminal 6xHis tagged cytoplasmic domain only of 
WalK. It should be noted that WalK does not express well unless it is co-expressed with the GroLGroS 
chaperone from E. coli.  I was unsure if PrkC would phosphorylate the response regulator, WalR, or the 
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histidine kinase, WalK. So I incubated PrkC with both proteins. Even though WalK does not 
autophosphorylate robustly in PrkC kinase buffer, to ensure I was not visualizing phosphohistidine or 
phosphoaspartyl modifications, samples were boiled at 95°C for 5 min. I did not observe any 
transphosphorylation of WalK (data not shown), however I observed robust transphosphorylation of WalR 
by PrkC under these conditions. 
 To further understand this modification, I submitted an in vitro kinase assay sample of WalR that 
had been incubated with PrkC to the Columbia Protein Core Facility. To identify the site of 
phosphorylation, Dr. Mary Ann Gawinowicz performed mass spectrometry analysis. She identified one 
phosphopeptide, which was found to include T101, which is located at the dimerization interface of the 
receiver domains. To confirm that this was the only site of modification and also to determine the 
specificity at which PrkC phosphorylates this residue, I generated protein constructs that had either serine, 
which is the most chemically conserved amino acid substitution, or alanine, which should no longer be 
phosphorylated by a Ser/Thr kinase. These proteins were stable and expressed robustly. I repeated the 
kinase assay with the panel of wild type WalR (JDE 1591), WalR T101A (JDE 1708), and WalR T101S 
(JDE 1713). PrkC was no longer able to phosphorylate WalR T101S or T101A, suggesting that PrkC is 
very specific to threonine phosphorylation.  
Figure 3.3.1 PrkC Phosphorylates WalR at T101 in vitro  
 
Figure 3.3.1 PrkC Kinase Assay with WalR, WalR T101S or WalR T101A. Kinase assays were 
performed for 30 minutes at 37°C. 2µM PrkC (JDE 1582) was incubated with 4µM of WalR (JDE 1591), 
WalR T101S (JDE 1713) and WalR T101A (JDE 1708).  






3.4 PrkC Phosphorylates WalR In a Heterologous E. coli Expression System  
 In order to verify by a different method that PrkC was able to phosphorylate WalR, I took 
advantage of the pETDUET dual expression vector (Novagen). This vector allows for the simultaneous 
induction and expression of two proteins off the same vector in E. coli BL21 (DE3). I then probed whether 
WalR that had been co-expressed with PrkC was phosphorylated in vivo. I took advantage of Pro-Q 
Diamond Phosphoprotein Stain of PVDF membranes to stain for phosphoproteins. This stain is not 
specific to phosphothreonine and phosphoserine, therefore I made sure to boil the sample as previous 
reports of WalR receiver domain only constructs reported phosphorylation at the conserved D53 after 
purification from E. coli [305]. While this method can also be used to probe lysates, I took advantage of 
the presence of 6xHis tags on both proteins to purify WalR, PrkCKD, or WalR and PrkCKD simultaneously. 
After running an SDS-PAGE gel I transferred this to a PVDF membrane and stained the blot with Pro-Q 
Diamond Stain (Figure 3.4.1).  
 To ensure that I was not overexposing the membrane after staining, I loaded a Peppermint Stick 
which is a ladder that contains both unphosphorylated and phosphorylated protein bands. This allows for 
proper scaling of the image and avoidance of false positives. I observed robust staining of PrkCKD. This 
suggests that PrkCKD is catalytically active in vivo and is able to autophosphorylate at multiple threonine 
residues within its active site using this heterologous system. As a negative control I purified WalR 
without co-expression with any kinase. I could barely visualize staining by Pro-Q diamond staining, which 
confirms that boiling of the sample was sufficient to remove any minor population of D53~P WalR that 
might have previously existed. Upon co-expression of PrkCKD and WalR I was able to visualize WalR 
staining by Pro-Q Diamond staining. This provided further evidence that WalR was a bona fide in vivo 









Figure 3.4.1 In vivo Phosphorylation of WalR by PrkCKD in E. coli  
   
Figure 3.4.1 PrkCKD Phosphorylates WalR in E. coli. E.coli strains JDE 1582, 1591, and 1604 were 
expressed with 1mM IPTG and proteins purified. Elutions were run on an SDS-PAGE gel and then 
transferred to a PVDF membrane. The PVDF membrane was stained with Pro-Q-Diamond stain, which 
stains all phosphorylated proteins. As a control for scaling, I included the Peppermint Stick ladder, which 




3.5 WalR T01~P Is a Substrate of PrpC 
 I wanted to test in vitro if WalR was also a substrate of PrpC, the cognate eSTP to PrkC. I slightly 
modified the kinase assay buffer conditions as PrpC is a manganese-dependent PP2C phosphatase, and 
my original PrkC kinase buffer lacked manganese. To perform the phosphatase assay I phosphorylated 
WalR with PrkCKD in vitro with radiolabelled-ATP. After 30 minutes, I spiked the reactions with 
staurosporine, which has previously been shown to inhibit PrkC [237]. I wanted to establish conditions 
where PrkCKD was not still actively autophosphorylating and transphosphorylating WalR. I then spiked the 
reactions with 2 µM recombinant PrpC and incubated for another hour at 37C. I also performed in parallel 
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reactions that did not contain PrpC at all or contained PrpC D36N, which was shown to be catalytically 
dead in vivo [238].  
 
Figure 3.5.1 PrpC Dephosphorylates PrkC and WalR T101~P in vitro 
 
 
Figure 3.5.1 PrpC Dephosphorylates PrkC and WalR T101~P in vitro. In vitro phosphatase assay of PrpC 
against PrkCKD and WalR T101~P.  After performing a kinase assay, this reaction was split into four 
reactions. The first aliquot was stopped immediately, the other three reactions were spiked with either 
PrpC (JDE 1715), PrpC D36N (JDE 1903), or left untreated. These reactions were allowed to incubate for 
1 hour at 37°C. Wild-type PrpC was able to dephosphorylate PrkCKD and WalR T101~P. PrkCKD 
consistently migrates lower after dephosphorylation. The PrpC D36N protein still retained some catalytic 
activity, however, this was much reduced in comparison to the PrpC lane.  
 
 While I observed significant loss in signal for WalR T101~P when incubated with PrpC under 
these conditions, it was not complete. I believe that there are two reasons for this observation. Although I 
attempted to shut down PrkC activity with staurosporine, PrkC still remains active in the phosphatase 
assay conditions, as can be observed through enhanced signal for both PrkCKD and WalR in the mock 
control lane compared to the PrkCKD + WalR lane. Secondly, the slow in vitro efficiency of PP2C-like 
eukaryotic phosphatases has been previously reported in the literature. As a control, I included a 
PrkC 
WalR 
PrkC WalR PrkC	  +
	  WalR 





catalytically dead variant of PrpC D36N. However, in vitro, it still retained some catalytic activity, 
intermediate between wild-type PrpC and the mock control reaction. One way to enhance the differences 
seen could be by removing excess γP32-ATP from the reaction by a desalting column in order to eliminate 
further transphosphorylation and autophosphorylation by PrkCKD. Another interesting observation is that 
dephosphorylation of PrkCKD by PrpC results in a differential migration on SDS-PAGE gel. One 
explanation is that upon dephosphorylation of threonine residues within the active site there is a 
significant conformational change within the protein. Conformational changes have been reported in 
crystal structures of Hank’s type kinases in both active and closed conformations [301].  
 
3.6 Transcriptomic Analysis of WalRK Regulon Genes 
 I now wanted to determine if there was differential expression of WalRK regulon genes in vivo. I 
performed RT-qPCR analysis of WalRK target genes that are known from the literature to be both 
positively and negatively regulated [30]. Since I knew from the transposon screen that I could obtain high 
levels of yocH expression in stationary phase in a ΔprpC::tet background, I grew JDB 3 and JDB 2482 to 
an OD600 of 5.0. At this point there is no substantial difference between the growth curves of the wild-type 
and ΔprpC strains.  
 
 
Table 3.6.1 WalRK Regulon Expression in Stationary Phase 
 
  Positive Regulation Negative Regulation 
  cwlO lytE yocH yoeB yjeA 
wt  1 ± 0.08 1 ± 0.07 1 ± 0.05 1 ± 0.04 1 ± 0.07 
ΔprpC 2.19 ± .01 2.5 ± 0.04 26.67 ± 0.61 0.04 ± .02 0.06 ± 0.03 
 
Table 3.6.1 WalRK Regulon Expression in Stationary Phase. Cultures were grown to stationary phase 
(OD600 of 5.0) and RNA was harvested and qRT-PCR analysis performed. Genes positively regulated are 
indicated in green and genes that are negatively regulated by the WalRK two-component system are 
indicated in red. In the ΔprpC background we see increased activation of positively regulated genes and 





 In a ΔprpC background PrkC is no longer regulated by its cognate eSTP and I would expect 
hyperactivation of PrkC and a substantial fraction of WalR to be phosphorylated at T101. I only saw 
subtle differences for the genes cwlO and lytE. However, in addition to their regulation by WalRK they 
have now been reported to regulated by the σI regulators in B. subtilis [227]. I observed robust expression 
of yocH as expected, suggesting that our qPCR analysis was working. Furthermore, I saw robust 
repression of two genes repressed by WalRK. These genes are important in regulating cell wall 
autolysins: yoeB which has been shown to post-translationally inhibit the D,L-endopeptidases cwlO and 
lytE [9, 297] and yjeA (pdaC) which has been shown to be a peptidoglycan deacetylase and important for 
prevention of lysozyme mediated cell lysis [134]. This evidence indicated that the in vitro biochemical 
studies that identified WalR as a substrate of PrkC/PrpC had in vivo physiological significance.  
 In addition to this data revealing that the WalRK regulon was differentially expressed in a ΔprpC 
background, the pattern also provided a hint that threonine phosphorylation of WalR increased the activity 
of the protein. It should be noted that these cultures were taken in stationary phase, when there is 
minimal cell division and WalK is largely inactive [70]. By increasing the activity of WalR through 
threonine phosphorylation, this could be a way for cells to regulate cell wall metabolism, even in a 
situation with limited WalR D53~P.  
   
3.7 Characterization of WalR Allelic Replacement Strains in B.subtilis  
 In order to confirm that this threonine modification was essential for the ΔprpC mediated 
transcriptional changes, I decided to make allelic replacement strains in B. subtilis. The essentiality of 
both WalR and WalK made generation of these strains non-trivial. Luckily, I was able to generate walR 
T101A and walR T101S in vivo. In the first attempt at generating the allelic replacement strain, I inserted 
an additional copy of WalR under its own promoter at the ectopic locus amyE and deleted the 
endogenous copy of WalR with a kanamycin resistance cassette (JDB 3095 and JDB 3110). However, I 
observed substantial polar effects of the downstream regulon genes, WalK, YycH, YycI, and YycJ in a 
preliminary microarray performed in collaboration with Ashlee Bates in Patrick Eichenberger’s Lab at NYU. 
Therefore I sought to generate a strain where I could avoid substantial polar effects on the WalRK operon. 
While these strains were not further characterized, they did demonstrate that while WalR is essential, the 
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threonine modification is non-essential. This was in agreement with the non-essentiality of the eSTK, 
PrkC.  
 To eliminate polar effects on downstream operon genes, I constructed two different strains. The 
first strain inserted a kanamycin resistance gene upstream of the WalRK operon that was transcribed in 
the direction of a terminator and away from the WalRK operon to eliminate any unwanted polar effects 
(Figure 3.7.1). This left the entire WalRK regulon under its endogenous promoter. This strain construction 
was similar to that observed in a paper studying the role of a DNA binding domain mutation in WalR, 
WalR R204C in B. subtilis L-forms [65]. In the homology regions used for double crossover, I engineered 
the T101A or T101S amino acid substitutions. This was the strain that was further used to characterize 
the role of WalR T101~P in vivo on regulon gene expression. To confirm no unwanted mutations were 
introduced, I sequenced both WalR and WalK. I also generated a strain with KanR cassette upstream of 
the regulon with no amino acid substitutions in the flank to serve as an isogenic control.  
 
Figure 3.7.1 Allelic Replacement Strain of walR T101A or walR T101S 
 
 
Figure 3.7.1 Allelic Replacement Strain of walR T101A or walR T101S. Kanamycin resistance 
cassette was inserted upstream of the promoter of the WalRK and oriented into the terminator directly 
upstream. This allowed for inclusion of T101A or T101S incorporation into the homology flank used to 
generate this strain.  
 
 
3.7.1 WalR T101A or T101S Exhibit Stationary Phase Lysis Phenotype 
 To determine if WalR T101 phosphorylation was responsible for the stationary phase lysis 
phenotype observed in a ΔprkC background, I patched strains onto LB and let them grow overnight at 
37°C. I left the plate on the bench at ambient temperature and monitored the plates for stationary phase 
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lysis, which is visualized as colonies going from opaque to transparent. I hypothesized that if it is the 
absence of normal regulation of cell wall metabolism or autolysins that mediates this stationary phase 
lysis, then the inability to properly regulate WalR activity could modulate these phenotypes, since it 
regulates many cell wall autolysins. It had previously been shown that a ΔyocH strain also exhibited a 
stationary phase lysis phenotype [238]. This data suggested that a contributing factor to stationary phase 
lysis observed in the ΔprkC background was lack of expression of the cell wall hydrolase, yocH. However, 
experiments have not been performed to determine if overexpression of yocH rescues this stationary 
phase lysis phenotype.  
 
Figure 3.7.2 Stationary Phase Lysis of walR T101A and walR T101S on LB Agar.  
 
 
Figure 3.7.2 Stationary Phase Lysis of walR T101A and walR T101S on LB Agar. Cultures were streaked 
directly from glycerol stocks and grown for one overnight at 37°C. The following morning they were left on 
the bench for 4 days. Pictures were taken with white light on a gel box. On the left hand side are strains 
whose WalRK locus has not been modified (JDB 1772 and JDB1774). On the right panel are the strains 
that include the KanR cassette upstream of the WalRK operon (JDB 3423, JDB 3423, JDB 3425).   
 
 The walR T101A and walR T101S strains had a robust stationary phase lysis on plates in 
comparison to the isogenic ‘wild-type’ strain. For comparison, a strain whose WalRK locus has not been 
modified is included on the left hand side for direct comparison. It should be noted that the walR T101A 
and T101S strain actually lyse out with faster kinetics than that for the ΔprkC. The fact that this effect is 







translational modification, but also for the function of WalR. Further biochemical analysis of WalR T101S 
will be discussed in more detail in later sections.  
 
3.7.3 WalR T101 is Required for YocH Induction 
 Since the walR T101A and walR T101S strain seemed to mirror the ΔprkC stationary phase lysis 
phenotype, I asked whether this threonine modification was required for the high levels of yocH 
expression that is observed in a ΔprpC background. I took advantage of PyocH-GFP transcriptional 
reporter. In contrast to the reporter that was used for the transposon screen, this does not require any 
substrate for visualization. Furthermore, it contains a much small promoter region consisting of 300bp 
upstream of the yocH start codon. This PyocH promoter had previously been shown to be a substrate for 
WalR by Howell et al [108]. I transformed the allelic replacement strains into a ΔprpC amyE:: PyocH -GFP 
background and asked whether the reporter was still expressed.  
 
Figure 3.7.3 PyocH Reporter Expression Relies on WalR T101 Phosphorylation 
 
 
Figure 3.7.3 PyocH Reporter Expression Relies on WalR T101 Phosphorylation. Above is the PyocH -GFP 
transcriptional reporter in a ΔprpC::tet background that has been transformed with genomic DNA of the 
‘wild-type’ (JDB 3237), T101A (JDB 3235), or T101S (JDB3236) allele of WalR. Patched are multiple 
transformants of the indicated genotypes. A substantial portion of transcriptional activity is lost in the 





 To ensure this phenotype was not a fluke, multiple transformants were patched for the various 
genotypes and visualized for PyocH -GFP reporter expression. The wild type indicated in Figure 3.7.3 is the 
isogenic allelic replacement control strain. This provided convincing in vivo evidence that yocH 
expression is dependent on WalR T101 phosphorylation. When PrkC is unable to phosphorylate WalR at 
T101 I saw a marked decrease in yocH expression levels. This suggested that PrkC phosphorylation of 
WalR was sufficient to regulate yocH expression levels in stationary phase.  
 
3.7.4 WalR T101 Phosphorylation is Important for Biofilm Development 
 In addition to increased levels of yocH expression that can readily be visualized by plate assays, I 
wanted to determine if another ΔprpC phenotype previously observed was dependent on WalR T101 
phosphorylation. Specifically, a ΔprpC laboratory strain had decreased production of biofilms [158] and a 
similar phenotype was reported for S. aureus WalRK mutations [69]. So I asked whether WalR T101 
phosphorylation was required for the pellicle defect I observed in B. subtilis 3610 ΔprpC::tet strain. 
 Instead of using laboratory adapted strains of B. subtilis that weakly form biofilms, I asked 
whether PrkC or PrpC is involved in any of the multicellular behavior observed in the B. subtilis 3610 ‘wild’ 
strain. This strain has been shown to exhibit multicellular behavior such as swarming and pellicle 
formation [127, 133]. Pellicles are biofilms that occur at the air and liquid interface and result in a floating 
biofilm with considerable three-dimensional architecture.  Since this strain is non-transformable, mutant 
strains carrying various alleles were generated by phage transduction of marked alleles from B. subtilis 
PY79 into the undomesticated B. subtilis 3610 strain. I initially determined if there were any obvious 
morphological defects in biofilm formation, pellicle formation, and swarming motility between the wild-type, 
ΔprkC::erm, and ΔprpC::tet in the 3610 strain background. 
I observed subtle differences between the strains in the generation of solid agar biofilms on MSgg 
media  (Figure 3.7.4). For example, there appears to be enhanced pigment production and larger overall 
size in JDB 2666 (ΔprkC) compared to JDB 932(wild-type). There were also distinct three-dimensional 
architecture of the biofilms, however, I was unsure how to go about dissecting these phenotypes. It 
should be noted the generation of these biofilms is distinct from the assay performed by Madec et al [158] 
that relied on PVC microtiter plates and quantification of adherence by crystal violet staining. I tried 
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repeating these assays, but saw very poor adherence of laboratory adapted strains and did not repeat 
these assays with our 3610 mutants, as it was not clear if those biofilms were physiologically relevant. 
Figure 3.7.4 Biofilms on Solid Agar of ΔprkC and ΔprpC 3610 
 
 
Figure 3.7.4. Biofilms on Solid Agar of ΔprkC and ΔprpC. Solid agar biofilms on MSgg media of the wild-




 I also looked at pellicle formation in our eSTK and eSTP mutants. I was surprised to see a 
substantial defect in pellicle formation in the ΔprpC::tet 3610 strain (Figure 3.7.4.1). The pellicles were 
very fragile and there was also no three-dimensional architecture as compared to both the wild-type (JDB 
932) and ΔprkC (JDB 2666) pellicles. Knowing that WalR T101~P was a substrate for PrpC in vitro and in 
vivo, I wished to determine if this pellicle defect was mediated through the WalRK regulon. I moved in the 
allelic replacement strains previously characterized in the laboratory strain trpC2 and moved them into 
JDB 2667 (ΔprpC::tet) by phage transduction. I was then able to suppress the pellicle defect by a single 
amino acid substitution. This is the first evidence in B. subtilis that WalR plays a role in biofilm 
development. All of the previous work done regarding biofilm development and the WalRK regulon has 
been performed in organisms that generate robust biofilms such as S. aureus. In contrast, the WalRK 
regulon has only been studied in laboratory adapted strains of B. subtilis that do not mediate this 





Figure 3.7.4.1 Pellicle Defect in 3610 ΔprpC is Dependent on WalR T101   
 
 
Figure 3.7.4 Pellicle defect in 3610 ΔprpC is Dependent on WalR T101. Pellicles were grown in MSgg at 
room temperature for 3 days. JDB 932 (A), ΔprkC::erm JDB 2666 (B), ΔprpC::tet JDB 2667 (C), kan-
PwalRK-walR T101A ΔprpC::tet JDB 3413 (D), kan-PwalRK-walR  ΔprpC::tet JDB 3415 (E). The pellicle 
defect observed in panels C and D can be suppressed by removing walR T101 (D).  
 
 
In addition to using the allelic replacement strain to gauge the involvement of WalR T101~P in 
pellicle development, I also initially tested this phenotype in the strain in which WalR is under its own 
promoter at the amyE locus and the endogenous copy of walR is deleted with a kanamycin resistance 
cassette. Note this is the strain that had previously been characterized and shown to cause polarity 
defects in the laboratory-adapted strain of B. subtilis. The phenotypic differences between the walR and 
walR T101A alleles are even more robust in this sensitized genetic background, where there are polarity 
effects on the downstream WalRK operon genes. Furthermore, I also utilized a WalR phosphomimetic, 
T101D. This allele sometimes does not behave as would be predicted, but in this situation, it appears that 
the T101D mirrors the T101~P phenotype, as I no longer saw suppression of the ΔprpC::tet pellicle 
phenotype. This suggests that the levels and activity of the WalK and its accessory proteins YycH and 




Figure 3.7.4.2 WalR T101 Phosphorylation is Necessary for ΔprpC Pellicle Defect  
 
 
Figure 3.7.4.2 WalR T101 Phosphorylation is Necessary for ΔprpC Pellicle Defect. Pellicles grown in 
MSgg meda for 4 days at ambient temperature. JDB 932 wt (A), JDB 2666  ΔprkC::erm (B), JDB 2667 
ΔprpC::tet (C), JDB 3152 ΔprpC::tet amyE::PwalR-WalR, walR::kanR (D), JDB 3153  
ΔprpC::tet amyE:: PwalR -walR T101A, walR::kanR (E), JDB 3154 ΔprpC::tet amyE:: PwalR -walR T101D, 
walR::kanR (F).  
 
The identification of walR alleles that do not interfere with its essentiality provides a novel tool to 
investigate the role of WalRK regulon activity under its native regulation. Modification of WalR T101 by 
PrkC has profound impacts on WalRK regulon expression. By utilizing allelic replacement strains I was 
able to demonstrate that WalR T101~P is required for yocH expression, contributes to stationary phase 
lysis, and important for the regulation of pellicle formation in undomesticated B. subtilis.   
 
 
3.7.5 WalR-Flag Strain at Endogenous Locus   
 
 In addition to allelic replacement strains, I wanted to assess the in vivo phosphorylation status of 
WalR. I generated a strain expressing a C-terminal flagged WalR that was generated by single cross over 
at the endogenous locus. The rest of the operon, which includes the essential histidine kinase, WalK, and 
WalK accessory protein YycH and YycI, are under the IPTG inducible Pspac promoter (Figure 3.7.5). 









maintain viability. This suggests that in strains in which the entire WalRK operon is under an IPTG 
inducible promoter, the robust loss in viability commonly observed is due to loss of WalR rather than 
WalK under these conditions. 
 
 
Figure 3.7.5 WalR-Flag Strain Schematic and Flag-IP  
Figure 3.7.5. WalR-Flag Strain Schematic and Flag-IP. Bottom panel: WalR is under its native regulation 
and by using a derivative of pMutin-Flag, I was able to generate a C-terminal Flag WalR with the rest of 
the operon under the IPTG response Pspac promoter. Top panel: anti-Flag-HRP (Sigma) western blot of 
Flag-IP of formaldehyde cross-linked cultures of JDB 3580 (walR-Flag Pspac::WalKHIJ) and JDB 
3582(walR-Flag Pspac::WalKHIJ ΔprpC). E= elution from Flag magnetic beads with 3X flag peptide, E* = 
elution boiled at 95°C for 10 minutes to remove crosslinking, and B= Flag magnetic beads.  
 
 Furthermore, I have established conditions to cross-link WalR in vivo using formaldehyde in order 
to capture its oligomerization state. Formaldehyde cross-linking is reversible after 10 minutes of boiling at 
95°C, which is a nice control for loading. In our current method, I cannot differentiate between monomers 
and dimers; I believe this is because WalR is also crosslinking with WalK and PrkC in vivo, as seen by 
the more robust band after boiling of the elution fraction. This suggests that there are high molecular 
weight species of WalR that are not migrating into the protein gels.  Presently, experiments are underway 
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to develop a merodiploid strain of WalR with two different epitope tags, to allow us to perform co-
immunoprecipitation under native and crosslinking conditions to measure the level of heterodimers. I 
predict that in a ΔprpC background in which WalR activity is the highest, I should observe a higher 
percentage of dimers in vivo.  
 
 
 3.8 Biochemical Approaches to Probe the WalR T101~P Mechanism  
 Now that I was confident that WalR T101~P significantly impacted B. subtilis physiology, I wanted 
to determine the mechanism by which threonine phosphorylation modified the activity of WalR. My 
transcriptional studies suggested that threonine phosphorylation led to WalR activation, as I saw further 
activation of positively regulated WalRK regulon genes and further repression of genes negatively 
regulated by the WalRK regulon. If I look at the schematic of two-component signal transduction there are 
four plausible mechanisms underlying this effect (Figure 3.8). One possibility is that threonine 
phosphorylation increases the rate at which the sensor histidine kinase interacts or phosphorylates the 
response regulator. Secondly, the modification could alter the DNA binding ability of the response 
regulator. Thirdly, the modification could interfere with the phosphatase activity of the sensor histidine 














Figure 3.8 Mechanisms of Regulation of Two-Component Systems 
 
 
Figure 3.8 Mechanisms of Regulation of Two-Component Systems. Schematic of two-component signal 





Previously reported interactions of response regulators and eSTKs have shown that threonine 
phosphorylation can have variable affects on response regulator activity (Section 1.8). In S. pneumoniae 
CovR, threonine phosphorylation directly interfered with phosphorylation at the conserved aspartate 
residue, D53, which led to decreased binding of CovR to its promoters [153].  In contrast, the M. 
tuberculosis DosR had enhanced DNA binding activity when phosphorylated at two threonine residues 
within the DNA binding domain. I therefore decided to analyze the previous crystal structures of WalR to 
see if the position of T101 would provide a hint as to the mechanistic role of T101~P, using the two 




















3.8.1 shows PDB ID: 2ZWM and highlights the location of the WalK phosphosite D53 (orange) and the 
PrkC phosphosite T101 (red). This revealed that T101 was at the dimerization interface of the WalR 
receiver domains and did not directly interact with the conserved D53, WalK phosphosite. Secondly, I 
noticed that T101 lies within a hydrophobic pocket that is generated upon dimerization (B).   
 
Figure 3.8.1 Crystal Structure of WalR Receiver Domains 
 
Figure 3.8.1 Crystal Structure of WalR Receiver Domains. PDB ID: 2ZWM. In panel A, two WalR 
monomers generate a dimer, with T101 oriented towards the dimerization interface (α4-β5-α5). In panel B, 
this same structure with an electrostatic potential map with T101 depicted as stick residues, showing the 
hydrophobic nature of the receiver domain that was generated by Kate Stafford (PhD candidate, Arthur 
Palmer Lab, Department of Biochemistry and Biophysics, Columbia University).   
 
 
All of the current structures of WalR receiver domains are unphosphorylated at the conserved 
aspartate, however response regulators dimerize at high protein concentrations. Luckily the receiver 
domains dimerize at the physiologically relevant α4-β5-α5 interface. The location of T101 at the α4-β5-α5 
interface is interesting for several reasons. First, this interface has been shown to be important for 
interdomain contacts between the receiver domain and the DNA binding domain. In the structure of the 
homologous M. tuberculosis MtrA, the DNA binding domain docking on this receiver domain interface 
inhibited autophosphorylation of the receiver domain by small molecule phosphodonors [21, 84]. Second, 
T101 is one amino acid upstream of a highly conserved KPFS motif between β5-α5 which is at the 




regulator co-crystal structures [246]. Third, the α4-β5-α5 interface is important for phosphorylation-
mediated dimerization of response regulators [48].  
I decided to dissect all possible WalR/ WalK interactions by various methods, but primarily by in 
vitro assays using γP32-ATP. In the following sections, I will describe the assays that were developed to 
investigate the role of T101~P. While at times I saw promising differences, these were not robust. One 
explanation for this could be that T101D is not a reasonable phosphomimetic. While a phosphothreonine 
residue could potentially hydrogen bond with three other residues, an aspartate residue only has the 
capacity to form two hydrogen bonds. Secondly, when I used threonine-phosphorylated WalR, it was 
difficult to determine to what extent the protein sample was phosphorylated.  
 
3.8.1 WalK Phosphorylation Kinetics 
  
 Due to the location of T101 at the interface between the response regulator and histidine kinase, I 
decided to determine the kinetics by which WalK phosphorylated WalR. I initially utilized recombinant 
protein that contained the phosphomimetic amino acid substitution, T101D. I did not autophosphorylate 
the histidine kinase, WalK, prior to addition of the response regulator WalR or WalR T101D. In hindsight, 
this is one way in which I could have reduced variability between the reaction conditions and enhanced 
the kinetics of the WalR transphosphorylation reaction. The first time I performed this experiment I 
observed enhanced phosphorylation by WalK. This provided promising data that perhaps the reason I 
were seeing enhanced activity in vivo was a measure of increased WalK mediated D53~P. In addition to 
using the phosphomimetic T101D, I also performed this experiment in which I phosphorylated WalR at 









Figure 3.8.1.1 WalK Phosphorylation Kinetics of WalR or WalR T101D 
 
 
Figure 3.8.1.1. Kinetics of WalK Phosphorylation of WalR. Master mixes of WalK and WalR were spiked 
with γP32-ATP and samples were removed at indicated time points and kept on ice. Samples were run on 
an SDS-PAGE gel, dried, and exposed to a phosphoscreen. Below is the loading control for the reactions 
stained with Coommassie Brilliant Blue.  
  
  
I phosphorylated WalR in vitro using cold ATP in order to only visualize WalK-mediated 
phosphorylation at D53. After phosphorylation with PrkC, I utilized the small molecule kinase inhibitor 
staurosporine to competitively inhibit PrkC activity. I needed to ensure that I shut down PrkC mediated 
phosphorylation, otherwise I would not be able to discern between phosphorylation at T101 and 
phosphorylation at D53. I then added WalK and γP32-ATP and took various time points. Consistent with 
the first assay with the phosphomimetic mutant, I observed enhanced phosphorylation at D53. To confirm 
what I was observing was not PrkC phosphorylation, I boiled the samples at 95°C for 5 min, and observed 














Figure 3.8.1.2. WalK Phosphorylation Kinetics of WalR or WalR T101~P. On the left hand side is the 
schematic used to perform the experiment. WalR was incubated with or without PrkC and cold ATP 
(yellow dot). This allowed for WalR to be phosphorylated at T101 or to remain unphosphorylated. 
Staurosporine was added to turn off PrkC kinase activity. WalK and γP32-ATP (green dot with asterisk) 
was added and WalR D53~P* phosphorylation was monitored. On the right panel shows that WalR was a 
substrate of the histidine kinase, WalK, and this was enhanced in the WalR sample that was pre-
incubated with PrkC for 30 minutes.  
 
  
While I sometimes observed the kinetics seen in Figures 3.8.1.1 and 3.8.1.2, the other half of the 
time I repeated these experiments I would observe the completely opposite effect. In contrast to the 
enhanced phosphorylation seen above, I observed impaired phosphorylation of WalR T101D or WalR 
T101~P by WalK (Figure 3.8.1.3). However, impaired phosphorylation of WalK-mediated phosphorylation 
did not fit with the in vivo activity observed. While the assays seem to be technically working, depending 
on the protein prep and perhaps the ability in which I obtained efficient in vitro phosphorylation of WalR by 


























Figure 3.8.1.3 Impaired Phosphorylation of WalR T101D by WalK 
 
Figure 3.8.1.3 Impaired Phosphorylation of WalR T101D by WalK. Similar assay conditions as performed 
in Figure 3.8.1.1 except that WalK was pre-incubated with γP32-ATP prior to addition of the response 
regulator WalR or WalR T101D. Time course is indicated by the black arrow which goes from time = 1, 3, 




As I could never observe a consistent WalK phosphorylation kinetics phenotype towards WalR 
T101D or WalR T101~P, I decided to try and perform other assays that might provide some insight into 
the variable results. It should be noted that in addition to the lack of phosphorylation that was occasionally 
observed for WalR T101D, I would also see the same lack of transphosphorylation in WalR T101S 
examples that were run in parallel. This would suggest that any modification at the threonine residue 
would interfere with WalK/ WalR interactions.  
 
3.8.2 Interaction of WalK and WalR by Surface Plasmon Resonance 
To study this further I collaborated with Dr. Phini Katsamba and Dr. Lawrence Shapiro in the 
Department of Biochemistry and Biophysics at Columbia University Medical Center.  The goal of the 
experiment was to determine if we could detect the transient interaction of WalK and WalR by surface 
plasmon resonance. Surface plasmon resonance is a technique that allows for the label-free detection of 
intermolecular interactions. One protein is immobilized on a Biacore chip, and the other protein is flowed 






WalK and WalR interacting by this method, we also wanted to determine if there were any differences 
between WalR, WalR T101D, and WalR T101~P.  
I purified WalR-6xHis proteins to greater than 95% purity by Ni-NTA and then subsequent gel 
filtration on an AKTA (GE Healthcare). I also generated a Biotinylated version of WalK that could be 
coupled to the streptavidin Biacore chip by using Avitag technology.  
Figure 3.8.2 SPR Analysis of WalK and WalR, WalR T101D, and WalR T101~P 
 
 
Figure 3.8.2 SPR Analysis of WalK and WalR, WalR T101D, and WalR T101~P. Streptavidin SA chip with 
approximately 460 RU of biotinylated WalK. Binding was tested by flowing WalR (left), WalR T101D 
(middle) and WalR T101~P (right) proteins over a protein range of 20-0.3125 µM in a PBS buffer 
supplemented with 0.1 mg/mL BSA and 0.005% Tween 20. (SPR experiments performed by Dr. Phini 
Katsamba, Dr Lawrence Shapiro Laboratory, Department of Biochemistry and Biophysics, Columbia 
University Medical Center).  
 
  
Even though histidine kinase and response regulator interactions are thought to be extremely 
transient, this interaction can be observed by SPR. We did not see any interaction between WalK and 
WalR T101D, suggesting that my previous kinase assay results suggesting impaired WalK 
phosphorylation may have been accurate. However, while we did observe binding of the T101~P, the 
technical triplicates did not overlay well. Additionally, we do not know what fraction of this T101~P 
population is actually phosphorylated at T101. It is unclear if we see binding because a large fraction of 
the prep is unphosphorylated or rather because T101~P is structurally distinct from T101D. Secondly, the 
binding curves were biphasic, which makes it impossible to determine kinetic parameters for the 
interaction [219].  
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 In conclusion, this Biacore SPR experiment showed that this method can be used to visualize 
response regulator and histidine kinase interactions. While SPR has previously been used to show DNA 
binding of response regulators, to our knowledge this is the first demonstration of protein-protein 
interaction between a histidine kinase and response regulator by SPR. There was no binding of WalK to 
WalR T101D under these conditions. This lack of interaction would be consistent with the kinase results 
in Figure 3.8.1.3. However, it should be noted that while there are technical triplicates within the 
experiment, we did not repeat this SPR experiment multiple times with different protein preparations. 
While there is always a chance that this WalR T101D prep was aggregated or mis-folded, the gel filtration 
profiles were normal and did not show significant aggregation.  
 
3.8.3 WalK Phosphatase Activity Against WalR and WalR T101D 
  
 The important role of WalK phosphatase activity has recently been appreciated by work with the 
non-essential S. pneumoniae homolog, VicK [98, 284]. If I assume the SPR experiments are correct and 
having a phosphomimetic at T101 prevents interaction between WalR and WalK, perhaps the mechanism 
by which threonine phosphorylation enhances WalR activity is by preventing further interaction with WalK, 
and thus buffering WalR from the phosphatase activity of WalK. In order to examine this possibility I 
developed an in vitro assay to monitor WalK phosphatase activity. 
 Unfortunately, WalR does not autophosphorylate in the presence of small molecule 
phosphodonors, which made these experiments technically more challenging. Given the close homology 
of WalR to M. tuberculosis MtrA, this inability of WalR to autophosphorylate is not entirely surprising, as 
they were only able to observe considerable autophosphorylation if they used a receiver domain only 
construct of MtrA [21]. Therefore, I developed a novel assay to monitor the phosphatase activity of WalK 
and the influence of T101~P (Figure 3.8.3 Panel A). 
 To generate D53~P* labeled WalR, I incubated WalK-Biotin and WalR-6xHis with radioactive 
ATP*. After 30 minutes, I incubated this reaction on ice with Ni-NTA resin to selectively remove WalR 
D53~P* from excess ATP* and WalK. WalR sticks to the column non-specifically and therefore it was 
eluted with imidazole. To remove the imidazole, WalR D53~P* was spun through a desalting column, in 
order to avoid the detrimental effects of imidazole on enzymatic activity. I then incubated WalR D53~P* in 
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the presence of PrkC and cold ATP to get phosphorylation at T101. Fresh WalK was subsequently spiked 
back in to the reaction and time points were taken as indicated to determine the rate of WalK-mediated 
phosphatase activity.  
 




Figure 3.8.3 Assay for Detecting Influence of T101~P on WalK Phosphatase Activity. Panel A: Schematic 
used to monitor WalK phosphatase activity. WalR was phosphorylated with WalK using γP32-ATP 
depicted as a yellow dot with an asterisk (1), WalR D53~P* was removed from WalK by using a Ni-NTA 
agarose (2), WalR D53~P* was phosphorylated with PrkC using cold ATP (3), WalR D53~P* or WalR 
D53~P* T101~P was incubated with fresh WalK (4), D53~P* was monitored by taking aliquots at 1, 5, 10, 
20, and 30 minutes (5). Panel B: Primary data monitoring only D53~P* and whether or not unlabeled 
T101~P plays a role in WalK phosphatase activity over a time course as indicated by the black triangle. 
Panel C: Quantification of the phosphatase assay from Panel B where data is % of signal as compared to 
































































 However, I only observed subtle differences in WalK phosphatase activity if WalR had been 
phosphorylated at T101.  It should be noted that this experiment was repeated several times, and there 
was no significant difference between the D53~P and the D53~P T101~P sample. Based off our genetic 
data and SPR interaction data, I would have predicted that T101~P would prevent further interaction with 
WalK and actually inhibit WalK phosphatase activity against WalR D53~P. These results suggest that 
mechanism of WalR T101~P is not through inhibition of WalK phosphatase activity.  
 
3.8.4 Intrinsic Stability of D53 Phosphorylation in the Presence of T101 Phosphorylation 
 Since I did not observe any significant changes in the phosphatase assay, I speculated that the 
T101 phosphorylation exerted its effects independently of WalK. One prediction is that it could stabilize 
the intrinsic stability of D53~P and thus elongate the WalK-mediated activation of WalR. To examine this 
possibility, I performed a similar experiment as done above to measure WalK phosphatase activity, with 
the main difference being that instead of spiking WalK back into the reaction, I just incubated WalR at 
37°C to facilitate the intrinsic dephosphorylation rate. It has previously been reported for a cognate 
response regulator, VicR in S. pneumoniae, that VicR has an intrinsic stability of 22 hours at room 
temperature as determined by HPLC analysis [98]. While they are homologs, VicR is quite distinct from 
the B. subtilis and S. aureus WalR, as is most evident by its ability to autophosphorylate with the small 
molecule phosphodonor, acetyl phosphate.  
 I determined the intrinsic rate of WalR D53 dephosphorylation in the absence of WalK and asked 
whether I could modulate the kinetics if WalR was phosphorylated at T101. A representative gel showing 
the rate of WalR D53~P intrinsic dephosphorylation can be seen in Figure 3.8.4. However, 
phosphorylation at T101 did not alter the rate of dephosphorylation (Figure 3.8.4 lower panel). Therefore, 
that mechanism of T101~P activation of WalR is not by stabilizing the intrinsic stability of D53~P. 
However, this experiment is limited by the fact that I am only monitoring D53 and perhaps the 
dimerization status is distinct from what is seen by monitoring radiolabelled phosphoaspartyl residues 




Figure 3.8.4 Influence of T101 Phosphorylation on the Intrinsic D53 Phosphorylation Rate 
 
Figure 3.8.4 Influence of T101 Phosphorylation on the Intrinsic D53 Phosphorylation Rate. Top panel is 
autoradiograph monitoring loss of D53~P in a proof of principle experiment. Bottom panel is quantification 
of signal as normalized to the t=0 time point. After normalization, there is no difference between WalR 
D53~P or WalR D53~P T101~P stability.   
 
 
3.8.5 Measuring WalR DNA Binding by Electrophoretic Mobility Shift Assay 
 
 My experiments up until this point have either been inconclusive or did not show a significant 
difference between single phosphorylated WalR D53~P, versus double phosphorylated WalR D53~P 
T101~P. While I have developed assays to measure differences in kinetics of WalK kinase activity and 
WalK phosphatase activity, I have not looked at WalR DNA binding. Considering that T101 is in the 
receiver domain, it is difficult to imagine a scenario when DNA binding would be significantly altered upon 
T101~P. However, DNA binding is a good read-out of WalR protein function. Initially I took 
unphosphorylated WalR or the WalR T101D phosphomimetic, and asked if there was a difference in the 
intrinsic DNA binding of the proteins in the absence of WalK phosphorylation at D53. I performed 





























Electrophoretic Mobility Shift Assays using a 5’ biotinylated 300 base pair promoter of yocH that had 
previously been used by Howell et al [108]. 
 
Figure 3.8.5 Intrinsic WalR DNA Binding to YocH Promoter 
 
 
Figure 3.8.5 Intrinsic WalR DNA Binding to YocH Promoter. WalR or WalR T101D was incubated with the 
5’ Biotin-PyocH in EMSA reaction conditions. Protein concentrations were: 0.5, 1, 2, 4, 8, and 16µM. 
 
  
This experiment suggests that the overall binding affinity of WalR for the PyocH promoter is the 
same for WalR and WalR T101D. However, there is a subtle trend in the fourth lane (8µM) in WalR 
T101D, which looks like a smear, which suggests that there might be differential binding affinity. Only in 
an artificial case that uses high protein concentrations that induce dimer formation, are response 
regulators able to bind promoter DNA. This data suggests that there is a higher proportion of dimer 
formation in the WalR T101D protein preps. In preparation for the SPR experiments (Section 3.8.2) we 
performed Analytical Ultracentrifuge Centrifugation experiments to determine the fraction of monomers 
and dimers for WalR and WalR T101D. Dr. Goran Ahlsen performed these experiments in collaboration 
with Dr. Lawrence Shapiro in the Department of Biochemistry and Biophysics at the Columbia University 
Medical Center. He determined that WalR and WalR T101D were both weak dimer formers in solution, 
however, not statistically different.  
 Thus, threonine phosphorylated WalR could have a distinct conformation from wild-type WalR. I 









mediated phosphorylation in the presence or absence of WalR T101 phosphorylation. As a negative 
control for the PrkC phosphorylation I utilized WalR T101S. I initially performed the PrkC phosphorylation 
at 37°C for 2 hours, to ensure that a substantial fraction of the WalR sample was phosphorylated. I chose 
this order, as the phosphothreonine modification is more stable than the phosphoaspartyl modification. I 
then incubated either WalR + PrkC, or WalR T101S + PrkC with WalK and asked whether I could observe 
a difference in DNA binding to the yocH promoter.  
 
Figure 3.8.5.1 WalR DNA Binding to yocH Promoter 
 
 
Figure 3.8.5.1 WalR DNA Binding to yocH Promoter. Top panel, WalK has not been added to the 
reactions. I am measuring intrinsic WalR binding at these concentrations. In the bottom panel, which is 
from the same experiment both WalK-mediated D53 phosphorylation and/or PrkC mediated T101 
phosphorylation occur simultaneously. It should be noted that these EMSAs are within the same 
experiment and the degree of migration in the bottom panel would mask the subtle differences seen in the 
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 The top panel of Figure 3.8.5.1 is WalR binding to the PyocH promoter in the indicated 
concentrations. To ensure that WalK or PrkC did not influence this migration, I added the maximum PrkC 
or WalK concentration used to ensure that was no non-specific migration of the Biotin-PyocH promoter. It 
appears that the PrkC + WalR T101S and WalR only samples have nearly identical migration profiles as 
would be predicted, as the WalR T101S protein is no longer a substrate for PrkC phosphorylation. I 
observed enhanced migration of the WalR + PrkC at 2.5 µM, which replicates the subtle trend observed in 
the WalR T101D EMSA performed in Figure 3.8.5.  
 In the bottom panel I added WalK for 30 minutes to ensure I got efficient D53 phosphorylation. In 
this scenario at the higher concentrations singly phosphorylated WalR at D53 and doubly phosphorylated 
at D53 and T101 was able to shift the Biotin- PyocH promoter to the same extent. However, at lower 
concentrations of WalR, I observed enhanced binding to PyocH. Interestingly I do not see the same degree 
of migration between the WalR and PrkC/WalR T101S samples, which theoretically should be the same. 
In contrast, I saw less migration, suggesting that WalR T101S is deficient in WalK phosphorylation or 
dimerization. In summary, these DNA binding assays provided the first glimpse of evidence that doubly 
phosphorylated WalR might have a higher intrinsic ability to bind to YocH promoter DNA, which would 
explain the enhanced activity of WalR in vivo in a ΔprpC background.  
 
3.8.6 Monitoring WalR Dimerization by Reverse Phase HPLC  
 I monitored the dimerization status of WalR using reverse phase HPLC as has been 
characterized previously for VicR [98]. I collaborated with Paul O’Brien, PhD candidate in the Department 
of Biochemistry and Biophysics in Dr. Arthur Palmer’s Lab at the Columbia University Medical Center. He 
established conditions that allowed for WalR to bind to the Jupiter C4 column (Phenomenox). Once he 
was able to establish running conditions to separate WalR from WalK and PrkC I produced samples and 
ran them on a Walters HPLC machine that was kindly provided by Dr. Virginia Cornish at the Department 
of Chemistry at Columbia University and managed by Charoan Jing.  
 However, I did not visualize differences in elution times when WalR or WalR T101S was 
incubated with PrkC. This suggests that the threonine phosphorylation does not cause a large enough 
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conformational change that can be measured by reverse phase HPLC. Different elution times are the 
result of conformational changes in the protein that allows for differential binding to the C4 column, and 
therefore different elution times. I was able to visualize a difference between WalR and WalR that had 
been incubated with WalK. I saw the peak shift to an earlier elution time, which is consistent to what was 
seen by VicR in S. pneumoniae [98]. 
 
Figure 3.8.6 HPLC Elution Profiles of WalR Incubated with PrkC and WalK 
 
Figure 3.8.6 HPLC Elution Profiles of WalR Incubated with PrkC and WalK. Control experiments with 
WalR, WalR T101S, PrkC, and WalK only were performed and are not shown above. Elution peaks are 
labeled with the respective protein name. WalR when it is incubated with PrkC and WalK shifts to the left 
(top panel). In contrast, when WalR T101S is incubated with PrkC and WalK, only a portion of the 




























While I was able to observe a complete shift of the elution profile in WalR samples that had been 
incubated with WalK, I always observed a biphasic elution profile for WalR T101S, suggesting that a 
substantial fraction of the protein preparation did not dimerize. Table 3.8.6 shows the elution times seen 
for WalR or WalR T101S under all the reaction conditions tested.  
 
Table 3.8.6 WalR Elution Times on Reverse Phase HPLC 
 
Conditions  WalR   WalR T101S  
unphosphorylated  42.3 42.3 
+ PrkC  42.3 42.3 
+ WalK 42.13 42.15 & 42.3  
+ PrkC + WalK  42.13 42.15 & 42.3 
 
Table 3.8.6. WalR Elution Times from Reverse Phase HPLC profiles. WalR only migrated upon 
incubation with WalK, independent of the presence of PrkC. In contrast, the WalR T101S only a fraction 
of the population shifted in the presence of WalK.  
 
 
 I was able to come up with several important conclusions based off these preliminary HPLC 
experiments. I observed no difference between elution profiles in the presence of PrkC, suggesting that 
T101 phosphorylation does not alter the elution times. WalR T101S appears to be either deficient in its 
ability to get phosphorylated by WalK or in its ability to undergo phosphoaspartyl-mediated dimerization. 
Another caveat is that WalK was not removed from these reactions and samples were put on ice to slow 
down the reaction conditions. It is possible that WalK phosphatase activity is more robust towards WalR 
T101S in contrast to WalR or WalR T101~P. However, I have not seen any evidence for this in our in vitro 
assays that probe phosphatase activity of WalK. Therefore, these data suggest that in addition to its 
inability to be phosphorylated by PrkC, WalR T101S, is also impaired in its interaction with WalK. This 
could provide a rationale for why WalR and WalR T101S+ PrkC did not behave identically in the EMSA 
profiles in the presence of WalK (Figure 3.8.5.1). Therefore I need to keep in mind that there are some 
pleiotropic effects when using the walR T101S allele in vivo.  
 It would be interesting to determine if WalR T101A behaves similarly to WalR T101S in the HPLC 
analysis, and if there was an impaired interaction with WalK. The threonine residue is found in many 
response regulators and is immediately adjacent to Lys102, which has been shown to form a salt bridge 
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with the D53 phosphoaspartyl in the S.pneumoniae VicR homolog structure [29]. Therefore, while Thr101 
appears to be in a distinct part of the protein, T101~P could have impacts on the conformational changes 
that occur at the α4-β5-α5 receiver domain dimerization interface. Now that I have developed the tool to 
study WalK mediated WalR dimerization by reverse phase HPLC, it gives us the opportunity to assess 
whether the dimer is more stable in WalR T101~P D53~P in comparison to WalR D53~P alone. In future 
experiments, I would like to perform a kinetic experiment after removing WalK, and see if WalR D53~P is 
different from WalR D53~P T101~P in its intrinsic dimer stability. 
 
3.8.7. Native PAGE Analysis of WalR  
 While I did not observe any change in elution profiles in WalR that has been phosphorylated with 
PrkC by HPLC analysis, I wanted try an alternative method. I therefore adapted a Native PAGE protocol 
that had previously been used by Casino et al [44] to demonstrate differences in elution profiles for 
response regulator receiver domains upon phosphorylation. I used full length WalR and determined if 
there was a difference in elution if phosphorylated with PrkC. I performed an in vitro kinase with non-
radioactive ATP and performed Native PAGE electrophoresis (Figure 3.8.7).  
Figure 3.8.7 WalR T101~P Migrates Differentially Than WalR  
Figure 3.8.7 WalR T101~P Migrates Differently than WalR. In vitro kinase assays were performed with 
WalR or WalR T101S with PrkC. This is a 12% Native-PAGE gel stained with CBB. Indicated by the arrow 
is PrkC which appears to migrate as a doublet. Only when WalR is incubated with PrkC do we see 














 While I was able to see enhanced DNA binding to the PyocH promoter, this is the only other piece 
of data that suggests that threonine phosphorylation significantly alters WalR. Unfortunately with Native 
PAGE electrophoresis it is difficult to determine if the change in mobility is due to a difference in charge or 
a difference in size. So, the only conclusion I can make is WalR T101~P differentially migrates by Native 
PAGE. Interestingly, this effect is in the opposite direction than seen for WalR dimerization. I have also 
generated conditions in which I can see WalK phosphorylation of WalR results in a clean shift by Native 
PAGE. It should be noted that depending on the buffer conditions, such as in PrkC-like conditions, WalR 
has a higher propensity to dimerize in the absence of WalK. Furthermore, at high protein concentrations 
WalR will dimerize independently of phosphorylation at D53 [197].  
 I have also generated and worked out purification conditions for the WalR receiver domain only in 
order to facilitate the biochemical characterization of WalR. While I would not be able to measure DNA 
binding, this construct does allow for easier visualization of WalR D53~P by native PAGE. This would 
facilitate some of the earlier biochemical experiments in which I required WalK to phosphorylate WalR at 
D53.  
Figure 3.8.7.1 Purification of WalR-REC Domain Construct  
 
 
Figure 3.8.7.1 Purification of WalR-REC Domain Construct. I generated a N-terminal 6his-SUMO-WalR 
REC domain construct that expressed robustly in E. coli BL21 (JDE 2394). After purification by Ni-NTA 
resin and dialysis overnight, I incubated this with ULP1 protease (ULP1 dig.), which specifically cleaves 
SUMO tags. I was able to effectively remove WalR REC domain, as it no longer has the 6xHis-tag and 





























 I purified very clean WalR REC domain constructs and examined if I could autophosphorylate 
WalR by a small molecule phosphodonor. It had previously been reported by a group generating the 
crystal structure of B. subtilis WalR REC domain that it was able to autophosphorylate with the small 
molecule phosphodonor, carbamoyl phosphate [305]. In parallel to performing WalR REC 
autophosphorylation with carabamoyl phosphate, I performed an in vitro kinase assay with WalR REC 
domain and WalK and also incubated WalR with carbamoyl phosphate.  
 
 
Figure 3.8.7.2 WalR Autophosphorylation with Carbamoyl Phosphate 
 
 
Figure 3.8.7.2 WalR Autophosphorylation with Carbamoyl Phosphate. WalR REC domain only was 
incubated with carbamoyl phosphate or WalK and ran on a 15% Native PAGE gel at 100V. As a control, 
WalR REC domain is robustly phosphorylated by WalK, while only a small fraction of the protein 






















While I was unable to see robust autophosphorylation with carbamoyl phosphate under these 
conditions, this is not a commonly used small molecule phosphodonor. In discussions with Dr. Robert 
Bourret at UNC Chapel Hill, I learned that the most robust and efficient small molecule phosphodonors 
are acetyl phosphate and phosphoramidate. Therefore, it would be worth repeating these experiments at 
different temperatures and with other small molecule phosphodonors. Once I establish conditions that 
permit robust WalR REC autophosphorylation it would be worth testing if phosphorylation at Thr101 
influences the kinetics or the ability to autophosphorylate in the presence of small molecule 
phosphodonors.  
 I have developed several assays in the lab to assay WalR or WalR REC domain dimerization. 
These two techniques, reverse phase HPLC and native gel electrophoresis, each provide important 
glimpses into the conformational changes that occur in the presence or absence of threonine 
phosphorylation. The ability to use a small molecule phosphodonor, would allow us to readily 
phosphorylate at D53 during or before phosphorylation at threonine 101. Phosphoaspartyl modifications 
are considered labile, and for many of the previous experiments, for technical ease, I would initially 
phosphorylate at T101.  This is evident from the intrinsic stability of D53~P and I know that within half an 
hour, I lose half of WalR D53~P, making it technically difficult to obtain a protein prep that is 
phosphorylated at both residues. Furthermore, I do not know the temporal timing or WalK or PrkC 




 The aim of this project was understand PrkC-dependent yocH expression. I initially took an 
unbiased genetic approach to investigate if any novel factors could be modulating yocH expression. 
Simultaneously, I performed a directed approach in which I investigated whether PrkC directly interacts 
with the WalRK two-component system. I showed that that WalR is a substrate of the eukaryotic-like 
Ser/Thr kinase and phosphatase PrkC and PrpC in B. subtilis using in vitro kinase assays.  In vivo, I 
showed that PrkC and PrpC interact with the WalRK two-component system. In a genetic situation when 
PrkC is not regulated by its cognate partner phosphatase, I observed enhanced activation of the 
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positively regulated WalRK regulon genes and well as increased repression of negatively regulated 
WalRK regulon genes (Figure 3.9). I have also shown in vivo that phosphorylation at T101 contributes to 
stationary phase lysis, is required for PrkC-dependent yocH expression, and is important for pellicle 
formation.  Taken together, this evidence suggests that phosphorylation at T101 enhances the activity of 
WalR in vivo. 
To understand the mechanistic details of WalR T101 phosphorylation, I developed in vitro assays 
to probe the influence of threonine phosphorylation on the interaction between WalR and WalK.  I 
observed a difference in DNA binding affinity in doubly phosphorylated WalR compared to WalR only 
phosphorylated at D53. However, the mechanism by which WalR D53~P T101~P mediates enhanced 
DNA binding remains elusive. One hypothesis that has not been thoroughly tested is the dimerization 
status of WalR D53~P versus WalR D53~P T101~P.  One way I can address this in vitro is by performing 
reverse phase HPLC or native PAGE electrophoresis during a kinetic experiment of dimer formation or 
dissolution.  
Another approach is to perform co-immunoprecipitation experiments in vivo using a merodiploid 
strain of WalR that has both C-terminal WalR Flag and Strep-tag II. If the enhanced activity of WalR is 
due to dimer stability, then I would be able to observe an increased level of heterodimers in a ΔprpC 
background. I have performed preliminary experiments showing that I can perform efficient in vivo 
crosslinking.  I would also like to try these experiments under native conditions. These experiments would 











Figure 3.9 Threonine Phosphorylation Regulates the WalRK Two-Component System 
 
 
Figure 3.9 Threonine Phosphorylation Regulates the WalRK Two-Component System. This is a simplified 
model, as both PrkC and WalK should be depicted as dimers. However, WalR is activated at a conserved 
aspartate residue D53, by WalK, and at T101, by PrkC. Phosphorylation seems to work synergistically to 














Chapter 4. Conservation of T101 Phosphorylation in B. subtilis and S. aureus  
4.1 Introduction  
Since I observed robust phosphorylation of B. subtilis WalR at T101, I was curious if this could be 
a generalizable mechanism of response regulator regulation. First, T101 is conserved in approximately a 
quarter of the 34 B. subtilis two-component systems[78] so I wanted to ask if these response regulators 
were targets of PrkC in vitro. Secondly, I wanted to know if the regulation of WalR I observed in B. subtilis 
was conserved in other low-G+C% Gram-positive bacteria. I chose to work in S. aureus as the literature 
has previously reported down-regulation of WalR target genes in a ΔpknB genetic background [66].  
 
4.2 Thr101 Phosphorylation of B. subtilis Response Regulators 
 I performed a ClustalW analysis (MacVector) of all of the B. subtilis response regulators, focusing 
on the α4-β5-α5 interface in the receiver domain, which contains T101 in B. subtilis WalR. Approximately 
one quarter (23.5%) of B. subtilis response regulators contain T101 at the same position as WalR (Figure 
4.2.). I then proceeded to purify recombinant proteins corresponding to all these response regulators and 
asked if I could observe transphosphorylation by PrkC in vitro. I incubated the various response 
regulators in the same kinase assay conditions used to assay WalR transphosphorylation. I was able to 
observe transphosphorylation in 5 out of the 8 response regulators tested (Figure 4.2.1). In addition to 
testing the wild-type proteins I repeated this assay with T101A amino acid substitutions, and in all cases 
except YvcP, I lost phosphorylation. It should be noted that these phosphorylation events were quite 
weak in comparison to that seen for WalR. Therefore in vivo analysis would need to be performed in 














Figure 4.2 Response Regulator Alignment. Alignment of B. subtilis response regulator amino acid 
sequences. Highlighted in blue are threonine residues that are conserved with WalR T101. The darker 
the gray color the more highly conserved the amino acid at that position is. WalR T101 is one amino acid 
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Figure 4.2.1 PrkC Phosphorylation of B. subtilis Response Regulators 
 
Figure 4.2.1 PrkC Phosphorylation of B. subtilis Response Regulators. Kinase reaction performed by 
incubating PrkCKD (2µM) with 2µM of the following response regulators (RR): PhoP, CssR, YvrH, YvcP, 
YkoG, YclJ, YrkP, and LytT. All RR contain the conserved T101 residue, except for CssR, which contains 
a S101. Reactions were performed for 30 min at 37°C using 4µCi γP32-ATP. The phosphorylation event(s) 
seen for YvcP do not occur at T101.  
 
 
4.3 Preliminary Characterization of PrkC and PhoPR Two-Component System  
I further investigated regulation of PhoP by PrkC since WalRK and PhoPR two-component 
systems cross talk in vivo. The histidine kinase, PhoR, phosphorylates and activates WalR under 
phosphate limiting conditions, however the efficacy of which it phosphorylates WalR in vitro is markedly 
reduced in comparison to WalK-mediated phosphorylation [109]. The close structural similarities between 
these two-component systems is revealed by two amino acid substitutions that can be introduced into the 
α1 helix of the histidine kinase DHp1 domain and the α1 helix of the response regulator receiver domain 
to change the specificity of phosphotransfer [120]. Therefore, it would be interesting to see if PhoPR 
regulon was differentially expressed under phosphate limitation conditions depending on the presence of 
































Figure 4.2.2 Relative Expression of PhoPR Regulon Genes  
 
Figure 4.2.2 Relative Expression of PhoPR Regulon Genes. Preliminary experiments were performed in 
LPDM conditions to determine if PrkC and PrpC influence PhoPR regulon genes. This was only repeated 
once, which is why no error bars are present. PhoPR positively regulates regulon genes tuaA, phoA, and 
pstS are negatively regulates tagA. 
 
 I performed preliminary experiments under low phosphate defined conditions, as used by Howell 
et al [109] to show cross-talk between the WalRK and PhoPR two-component system. In hindsight this 
might not have been the best condition to assay the contribution of PrkC and PrpC to the PhoPR regulon. 
There is no evidence to suggest that PrkC is active under conditions of phosphate limitation, which may 
account for the lack of a difference between the various genotypes indicated. I did not pursue this very 
aggressively, however, I think it would warrant further investigation due to the in vivo parallels between 
the PhoPR and WalRK two-component systems. In hindsight, it would be worth testing the expression of 
regulon genes in vegetative growth or stationary phase to determine if PhoPR regulon genes were 
differentially expressed.  
 
4.4 WalR T101 Phosphorylation is Conserved in S. aureus in vitro 
 I also wanted to see if the specific regulation of the PASTA domain containing eSTK PrkC and 
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alignment (MacVector) of WalR homologs in clinically relevant Gram-positive pathogens and noticed that 
T101 was present in all those investigated (Figure 4.4).  
Figure 4.4 Sequence Alignment of WalR Homologs 
 
Figure 4.4 Sequence alignment of WalR Homologs. I performed a ClustalW (MacVector) alignment of S. 




I noticed that there was a high degree of conservation in this region with the mostly highly 
divergent WalR homolog being that of E. faecalis. However, all of the homologs contained the conserved 
T101 residue. In addition to the high conservation of WalR T101, all of the bacteria queried also had a 
conserved eSTK that contained the highly conserved intracellular domain and extracellular PASTA 
domains of varying repeats. In addition to the high conservation between WalR and the eSTKs, previous 
literature has suggested that WalR might be modified by eSTK in other gram-positive bacteria [3]. All of 
the homologs have been previously been implicated in cell wall metabolism and regulation of cell wall 
(Section 1.5). Deletion of the S. aureus eSTK homolog, PknB, results in down-regulation of known WalRK 
regulon genes in S. aureus 8325 [66]. In addition, a similar down-regulation of VicRK (WalRK homolog) 
target genes in S. pneumoniae was also observed in an Stk1 deletion strain [229]. This data suggests 
that threonine phosphorylation of these WalR homologs might also mediate these effects as I have 
demonstrated for B. subtilis.  
I initially took a biochemical approach to investigate whether S. aureus WalR was a substrate of S. 
aureus PknB. I purified full-length PknB, as had been previously done [55] and observed robust 
phosphorylation of WalR by PknB (Figure 4.4.1). I then asked whether the position of this phosphorylation 
event was conserved to T101. PknB was unable to phosphorylate WalR T101S or T101A (Figure 4.4.1), 
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suggesting that a similar biochemical mechanism is occurring in S. aureus. Furthermore, PknB was as 
specific to threonine residues, as was previously seen for PrkC. 
Figure 4.4.1 S. aureus PknB Phosphorylates S. aureus WalR in vitro 
Figure 4.4.1 S. aureus PknB Phosphorylates S. aureus WalR in vitro. In vitro kinase of S. aureus PknB 
(JDE 1870) incubated with S. aureus WalR (JDE 1859), WalR T101A (JDE 1901), or WalR T101S (JDE 
2342). Robust phosphorylation is only observed with wild-type WalR.  
 
 
The results with the S. aureus proteins prompted me to test the homologs in E. faecalis, IreK and 
WalR. However, I did not observe phosphorylation by IreK under the conditions used perhaps because 
the E. faecalis WalR protein is more divergent from B. subtilis than the S. aureus homolog. Furthermore, 
there has been limited characterization of the WalRK regulon in E. faecalis [100] and no microarray 
performed with E. faecalis IreK to indicate that there is any functional overlap of these signaling 
paradigms in vivo. In personal communication with Dr. Malcolm Winkler at Indiana University, his lab did 
not observe robust phosphorylation of WalR by Stk1. However, I am unaware of the conditions or 
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4.5  Characterization of WalR and PknB in S. aureus   
 Since S. aureus PknB phosphorylated WalR, I wondered whether S. aureus ΔpknB had a 
stationary phase lysis phenotype like that observed in a B. subtilis ΔprkC strain. B. subtilis is 
hypersensitive to cold temperatures, and therefore plates are kept on the bench, which is how it became 
apparent that the ΔprkC had robust stationary phase lysis on plates. Leaving plates on the bench is not a 
normal practice in S. aureus labs, therefore I asked whether if I grew up the wild-type or ΔpknB strain on 
TSA overnight at 37°C and allowed them to sit an ambient temperature, if I would observe stationary 
phase lysis. It should be noted that due to the slower growing time of S. aureus, all strains continue to 
grow for the first day or two, however, after 1 week, one can see robust stationary phase lysis in the 
ΔpknB strain and enhanced growth in Δstp1 strain (Figure 4.5). 
Figure 4.5 Opposing Stationary Phase Phenotype of S. aureus PknB and Stp1 
Figure 4.5 Opposing Stationary Phase Phenotype of S. aureus PknB and Stp1. Strains were provided by 
Dr. Stefanie Donat at University Wuerzberg. I streaked out strains directly from glycerol stocks onto TSA 
agar. I allowed strains to grow overnight at 37°C and allowed them to incubate at ambient temperature for 
7 days. ΔpknB (left) shows enhanced stationary phase lysis, and suppressors start growing up out of the 
lysed culture. In contrast, Δstp1 does not lyse out and appears to be growing, as can be observed by 






4.6 S. aureus WalR T101S Allelic Replacement Strain Characterization 
Since S. aureus PknB and Stp1 had opposing phenotypes in stationary phase similar to what was 
observed with B. subtilis PrkC and PrpC, I investigated the contribution of WalR T101 to this phenomenon. 
I generated a WalR T101S marker-less allelic replacement strain using the pIMAY system developed by 
Monk et al [178]. While this system is a marked improvement in S. aureus genetic manipulation, it does 
require at least 3 to 4 days of counter-selection. Unfortunately, I did not observe stationary phase lysis 
with my WalR T101S strain, which suggests that this lysis is independent of WalR T101 phosphorylation. 
Alternatively, suppressor mutations might have arisen during the derivation of these strains. I did not 
perform whole genome sequencing on these strains to confirm that the only amino acid substitution was 
in walR. Consistent with this possibility, I was able to readily obtain genotypic suppressor mutations in the 
ΔpknB background.  
I proceeded to investigate whether other previously reported PknB/ Stp1 phenotypes were 
dependent on WalR phosphorylation.  For example, hyperhemolysis was observed in ΔpknB background 
while hypohemolysis was observed in Δstp1 background [39, 57]. It was also shown that overexpression 
of a constitutively active WalR D55E allele in S. aureus led to up-regulation of α, β, and δ-hemolysin 
encoding genes. When I initially performed these experiments, I had not seen the work from Delaune et al 
[57], showing that WalR was able to up-regulate hemolysin genes. I would predict based off the positive 
regulation of hemolysin genes in a WalR overexpression strain, that I would see diminished hemolysis 
activity in a ΔpknB strain. However, this is in contrast to what has been previously observed in the 
literature.  
I therefore asked whether the hemolysis phenotypes of these allelic replacement strains differed 
on Sheep Blood Agar plates. After streaking out the strains, I let the plates incubate overnight at 37°C 
and then stored the plates at 4°C to make the clearance more prominent. I observed hemolysis in the 
wild-type 8325 strain. I observed hyperhemolysis in the ΔpknB strain and hypohemolysis in the Δstp1 
strain, which is in conformation with the previous literature [39]. To my surprise, I did not observe any 
hemolysis for the walR T101S transformants. This suggests that WalRK activity is defective in these 
strains. However, this phenotype seems to be independent of PrkC-mediated phosphorylation, as I would 
predict that walR T101S would mirror the ΔpknB strain. It should also be noted that when allelic 
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replacement strains were generated in a clinical isolate of S. aureus, the presence or absence of WalR 
T101 had no impact on the hemolysis activity, suggesting there are many signaling pathways that can 
regulate hemolysin expression.  
Figure 4.6 Hemolysis on Sheep Blood Agar 
 
 
Figure 4.6 Hemolysis on Sheep Blood Agar. Strain Δstp1::erm (JDB 3401), ΔpknB::erm (JDB 3400), wild-
type (JDB 3399), walR T101S transformant #1 (JDB 3567) and walR T101S transformant #2 (JDB 3568) 
were incubated on TSA supplemented with 1% Sheep Blood Agar. Plates were grown at 37°C and then 
incubated at 4°C for one day.  
 
4.6.1 WalR T101S and Vancomycin-Intermediate Staphylococcus aureus   
 I became aware of a study performed by Dr. Ann-Catrine Uhlemann in the Department of 
Medicine at Columbia University Medical Center that observed WalR SNPs in Vancomycin Intermediate 
Staphylococcus aureus (VISA) [99]. The resistance to vancomycin in hVISA and VISA populations is due 
to increased cell wall thickness, altered penicillin-binding protein profiles, and decreased cell wall 
autolysis. Modulation of the WalRK regulon would significantly impact cell wall architecture and cell wall 





studies of VISA isolates that have identified other SNPs within either the sensor histidine kinase WalK, 
and WalR, the response regulator [40, 119, 241].  
 Dr. Uhlemann’s group identified two clinical isolates of VISA that contained amino acid 
substitutions in walR at T101, walR T101A and walR T101S. These are the exact amino acid 
substitutions I would have generated to ablate PknB phosphorylation of WalR. However, because they 
were in a clinical background and whole genome sequencing was not performed, I could not verify there 
were not additional mutations in these backgrounds that contributed to this VISA phenotype. Thus, to 
determine the role of WalR T101 in the VISA phenotype, I reverted the S101 to T101 in S. aureus clinical 
isolate 8007. Unfortunately, I was unable to generate a revertant of the clinical isolate C506. Clinical 
isolates are notoriously difficult to transform, and I was unable to transform the allelic replacement vector 
into clinical isolate C506.  
I collaborated with Dr. Anne-Catrin Uhlemann and her technician Madeleine Sowash who 
performed the MIC characterization of our strains. They used both E-test and subpopulation analysis to 
characterize the vancomycin susceptibility of our laboratory strains in addition to the clinical isolate and its 
walR S101T revertant (Table 4.6.1).  
Table 4.6.1 Vancomycin Susceptibility of Laboratory and Clinical WalR Strains 
JDB # Genotype Exp 1 Exp 2 
3399  Laboratory 8325  hVISA  VSSA 
3400 ΔpknB::erm  hVISA  VSSA 
3401 Δstp1::erm VISA hVISA  
3567 8325 WalR T101S VISA hVISA 
3568 8325 WalR T101S VISA hVISA 
        
3426 Clinical 8007 VISA VISA 
3570 8007 WalR S101T hVISA VSSA 
3571 8007 WalR S101T hVISA  VSSA 
Table 4.6.1 Vancomycin Susceptibility of Laboratory and Clinical WalR Strains. The annotations are 
VSSA=vancomycin sensitive S. aureus, hVISA= hetero-VISA, while the majority of the population is 
sensitive, a 1 in 105 to 106 organisms are resistant, VISA= vancomycin intermediate S. aureus 
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 Within the laboratory strains of S. aureus there was no categorical difference between the 
isogenic parental strain and the ΔpknB::erm strain. In contrast, the Δstp1::erm strain exhibited enhanced 
resistance to vancomycin, which is consistent with a previous report identifying stp1 as a novel mutation 
in VISA [41]. One hypothesis for this decreased susceptibility could be increased WalR activation in the 
Δstp1 background. I did notice that our walR T101S laboratory strain was more resistant than the parental 
control and I did not observe this phenotype in a ΔpknB strain. However, it might be due to pleiotropic 
effects of the walR T101S allele that I uncovered through HPLC analysis of B. subtilis WalR T101S, which 
suggested that this mutant protein had a defect in WalK-mediated phosphorylation dimerization. I see the 
inverse relationship in analysis of clinical isolate 8007. walR S101T was now more sensitive to 
vancomycin. This suggests that threonine 101 is an important residue for the biological function of WalR 
and for the VISA isolate. Thus, the SNP identified in the survey of clinical isolates [99], is physiologically 
relevant for the VISA phenotype.  
4.7 Discussion 
 In this chapter, I describe experiments aimed at addressing whether phosphorylation at T101 is a 
conserved mechanism of response regulator regulation. I initially used biochemical approaches to 
determine if PrkC could phosphorylate other B. subtilis response regulators that contained this conserved 
T101. I noticed through bioinformatics analysis that approximately one quarter of B. subtilis response 
regulators contained a T101 at that position. Of those, 5/8 were phosphorylated by PrkC in vitro, although 
less robustly than that observed for WalR. One response regulator that I observed to be phosphorylated 
in vitro by PrkC is the response regulator PhoP.  Since the PhoPR and WalRK two-component systems 
interact, including the ability of the PhoR sensor histidine kinase to phosphorylate WalR in vitro and in 
vivo, the relatively weak phosphorylation observed in vitro by PrkC may be physiologically significant.  
 I also addressed if the specific regulation of WalR by PrkC and PrpC was conserved in other 
clinically relevant gram-positive pathogens. I was able to observe specific in vitro phosphorylation of 
WalR T101 by S. aureus PknB. WalRK target genes are downregulated in a ΔpknB background [66], 
suggesting that this modification may have physiological consequences. My observation of stationary 
phase lysis in a ΔpknB background is consistent with a deregulation of cell wall metabolism and 
autolysins. To address the in vivo relevance of this modification, I generated allelic replacement strains in 
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both laboratory and clinical isolates of S. aureus. I observed that the walR T101S allele in S. aureus has 
PknB-independent phenotypes. First, I noticed ablation of hemolysis in the walR T101S transformants.  
This phenotype suggests diminished WalR activity, as it was previously shown that constitutive 
expression of walR D55E in S. aureus enhanced expression of hemolysin genes [57]. Second, I observed 
that phosphorylation of T101 can modulate sensitivity to vancomycin since both clinical and laboratory 
strains exhibited decreased sensitivity to vancomycin in the presence of the walR T101S allele. These 
data suggest that in S. aureus, the WalR T101S allele does more than just disable the PknB-dependent 
phosphorylation site at T101, but rather changes the ability of WalR to interact with its cognate histidine 


















Chapter 5. Threonine Phosphorylation Regulates VanB-type Vancomycin Resistance in 
Enterococcus faecalis 
5.1 Introduction  
Vancomycin resistance enterococci (VRE) pose a significant threat to patients in hospital settings. 
The resistance module is carried on a Tn1549 conjugative transposon that contains both regulatory and 
resistance operons. The ability of VanB-type VRE to disseminate so widely is due to the inducible nature 
of its resistance [82]. A two-component system (TCS) consisting of the sensor histidine kinase (VanSB) 
and response regulator (VanRB) is required for expression of the glycopeptide resistance genes. In 
response to vancomycin, VanRB activates transcription of genes encoding the two-component system and 
genes that in concert make the bacteria no longer susceptible to vancomycin treatment [51] including 
enzymes that synthesize modified peptidoglycan precursors ending in D-Ala D-Lac, lowering their affinity 
to vancomycin, as well as enzymes that remove precursors terminating in D-Ala [14].  
How VanRSB  senses vancomycin still remains unclear. Vancomycin could be a direct ligand for 
VanSB, or alternatively, VanSB detects the presence of vancomcyin indirectly through interaction with cell 
wall intermediates that accumulate or degrade upon vancomycin treatment [107]. A third possible 
mechanism is input from another sensory system that senses cell wall fragments since vancomycin 
treatment leads to the release of cell wall fragments into the milieu [34]. A signaling system in 
Enterococcus faecalis that responds to cell wall fragments is the eukaryotic-like serine/threonine kinase 
(eSTK), IreK [139]. IreK is a member of a highly conserved family of eSTKs in Gram-positive bacteria, 
which contains a conserved intracellular Hank’s type serine/threonine kinase domain and extracellular 
PASTA domains that bind peptidoglycan [206]. It is co-transcribed with its cognate eSTP, IreP, which has 
been shown to regulate IreK function in vitro and in vivo [141].   
I therefore determined if eukaryotic-like Ser/Thr kinase signaling partners, IreK and IreP, 
regulated the VanB-type VanRS two-component system. I performed these experiments in collaboration 
with Dr. Patrice Courvalin and Dr. Florence Depardieu at the Pasteur Institute Antibacterial Agents Unit. 
They were kind enough to provide us with strains and perform phenotypic characterization of engineered 
strains. We took both a biochemical and in vivo approach to try and dissect the role of IreK in VanB-type 




5.2 Threonine Phosphorylation of Sensor Histidine Kinase, VanS, by IreK in vitro  
 When this project initially began, I was influenced by my observation that WalR T101 is 
phosphorylated by the eSTKs PrkC in B. subtilis and PknB in S. aureus. I noticed that VanRB, the 
response regulator, had the conserved threonine residue and therefore hypothesized that the T101~P 
mechanism could also be present in E. faecalis. However, in addition to obtaining the protein expression 
vectors for VanRB (pAT818) from Dr. Courvalin, I also obtained the sensor histidine kinase protein 
expression construct that had the cytoplasmic domain of VanSB (pAT816) [58]. I generated a kinase 
domain only construct of IreKKD from both E. faecalis JH-2 and E. faecium BM4484. I wanted to ensure 
that this mechanism was not specific to only one Enterococci species. I performed an in vitro kinase 
assay with IreKKD, VanSB and VanRB.  
 




Figure 5.2 IreK Phosphorylates the Sensor Histidine Kinase, VanSB. In vitro kinase assay of E. faecalis 
IreKKD (4 µM) was incubated with 4 µM of two-different VanRB -6his constructs or VanSKD. Samples were 
boiled at 95°C to ensure I was not observing phosphohistidine autophosphorylation. Gels were visualized 







While IreKKD did not transphosphorylate VanRB, I did observe robust transphosphorylation of 
VanSKD. I submitted our in vitro phosphorylated VanSKD sample for mass spectrometry identification of the 
phosphosites by Dr. Mary Ann Gawinowicz at the Columbia University Medical Center Protein Core 
Facility. She identified multiple phosphopeptides that showed phosphorylation at T223. She also identified 
one phosphopeptide that was shown to be either S243 or T244. I therefore performed site-directed 
mutagenesis on the VanSKD plasmid (pAT816) and mutated the threonine or serine residue(s) to either 
alanine or aspartate residues.  
I performed an additional in vitro kinase assays to ask which amino acids were phosphorylated 
under stringent in vitro conditions (Figure 5.2.1). To verify that I was only observing signal from 
phosphothreonine or phosphoserine modifications, I incubated in parallel the histidine kinase alone. From 
my previous experiments with WalK and PrkC I knew that histidine kinases are minimally active under 
‘eSTK-like’ kinase reaction conditions. I also ensured that I was getting efficient phosphohistidine residue 
removal by boiling the reactions at 95°C.  
Generation of single amino acid substitutions at S243 and T242 had no effect on the 
transphosphorylation signal of IreKKD to VanSKD. So, IreKKD specifically phosphorylated VanSKD at T223. 
A reason that the apparently non-specific S243/T242 residues were observed in the mass spectrometry 
analysis was the extended incubation period I used to ensure that I had enough of a phosphorylated 
sample to be identified. This phenomenon of non-specific phosphorylation under extended incubation 
conditions is well documented. This has been showed most elegantly in the histidine kinase and response 
regulator field, where it was shown that non-cognate response regulators could be substrates but only 
under extended incubation conditions [147]. 
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Figure 5.2.1 IreKKD Phosphorylates VanSKD at T223 
 
Figure 5.2.1 IreKKD Phosphorylates VanSKD at T223. In vitro kinase assay was performed with either 2µM 
E. faecalis or E. faecium IreKKD with 2µM of various VanSKD mutant proteins to verify the site of 
phosphorylation. Reactions were incubated in the presence of 4µCi γP32-ATP in the presence of 1mM 
cold ATP. All samples were boiled at 95°C for 5 min. Reactions were run on an SDS-PAGE gel and gels 
were visualized by autoradiograph.  
 
   
5.2 VanSKD T223~P Is a Substrate of IreP, a Eukaryotic-like Ser/Thr Phosphatase 
 From my previous experiments, it became clear that IreK, the E. faecalis eSTK, was able to 
phosphorylate VanS in vitro even under very stringent conditions. I was able to identify and confirm 
through mutagenesis studies that this residue was T223. In order for this modification to be 
physiologically relevant, it needs to be reversible in nature. Due to the stability of phosphothreonine 
residues, I wanted to ensure that the cognate, eSTP, IreP was able to target VanSKD in vitro. Therefore, I 
generated a construct with the entire IreP coding sequence and a C-terminal 6xHis tag for protein 
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 I performed an in vitro kinase assay in which IreK phosphorylated VanSKD using γP32-ATP. I then 
split this reaction in half and either stopped the reaction or spiked the reaction with IreP for 1 hour at 37°C 
(Figure 5.2). After incubation with the phosphatase, I observed significant dephosphorylation of both IreK 
and VanS. I also observed differential migration of IreK upon dephosphorylation by IreP, which I have 
previously observed for PrkC and PrpC. Furthermore, this differential migration of IreK upon 
dephosphorylation has also been observed by Kristich et al [141]. This provided convincing evidence that 
VanSKD can be reversibly modified by the partner eSTK and eSTP, IreK and IreP, in vitro.  
Figure 5.2 IreP Dephosphorylates VanS T223~P in vitro  
 
Figure 5.2 IreP dephosphorylates VanSKD T223~P in vitro. An in vitro kinase assay was performed with 
1µM Irek and 3µM VanSKD for 30 minutes at 37°C using γP32-ATP. After 30 minutes, the reaction was 
split and 2µM IreP was added and allowed to incubate for 1 hour at 37°C. Samples were run an SDS-
PAGE gel, dried, and visualized by autoradiography.   
 
5.3 Staurosporine Inhibition of IreK in vitro  
 Due to the complications of performing genetics in E. faecalis, I wanted to perform a chemical 
approach to assess the role of IreK in VanB-type vancomycin resistance. However, before performing the 
in vivo experiments, I wanted to assess whether the small molecule eukaryotic kinase inhibitor 
staurosporine was effective against E. faecalis IreK. As reviewed in Section 1.5.1, staurosporine is 











presence of a bulky amino acid group within the ATP-binding active site of the eukaryotic-like Ser/Thr 
kinase domain [223]. I performed a ClustalW alignment (MacVector) of the eSTK kinase domains and 
identified the amino acid E. faecalis IreK had at that position (Figure 5.3).  
 
Figure 5.3 Amino Acid Alignment of eSTK Domains from Gram-Positive eSTKs. 
 
 
Figure 5.3.  Amino acid alignment of eSTK domains from various Gram-positive bacteria. S. aureus PknB 
(Sa PknB), B. subtilis PrkC (Bs PrkC), E. faecalis IreK (Ef IreK), M. tuberculosis PknB (Mtb Pknb).  Only 
bacteria that contain threonine at this site are sensitive to staurosporine. This analysis was done with the 
ClustalW plug-in within MacVector Assembler.  
 
  
I noticed in the sequence alignment that M. tuberculosis PknB and S. aureus PknB, which are 
known to be less sensitive to staurosporine treatment, both had bulky amino acids within the ATP-binding 
site of the Ser/Thr kinase domain. To my delight, E. faecalis had a threonine residue. The homologous 
residue in eukaryotic PKA was shown to be important for the interaction with staurosporine as seen in the 
co-crystal of eukaryotic PKA and staurosporine [211]. I confirmed that IreK was sensitive to staurosporine 
by performing an in vitro kinase assay with IreKKD with γP32-ATP and observed inhibition of 
autophosphorylation (Figure 5.3.1). In parallel I performed this assay with the B. subtilis PrkCKD that was 
previously shown to be sensitive to staurosporine in vivo [237]. Furthermore, I also included a B. subtilis 
PrkCKD that had a bulky amino acid in the active site T151M, which was previously shown in vivo to 
complement PrkC and prevent staurosporine inhibition (unpublished data by Dr. Ishita Shah, Dworkin 
Laboratory). The inhibition of E. faecalis IreKKD by staurosporine was comparable to the level of inhibition 
seen with B. subtilis PrkC, and particularly at 13.3 µM and 2.6µM the E. faecalis IreKKD acts similarly to 















Figure 5.3.1 Staurosporine Inhibits IreK in vitro. Top panel: 2 µM B. subtilis PrkCKD, E. faecalis IreKKD, B. 
subtilis PrkCKD T151M was incubated with indicated concentrations of staurosporine. Amount of 
staurosporine is indicated above the lanes. DMSO was used as a negative control. Reactions were 
performed in the presence of .5µCi γP32-ATP (~11nM). Staurosporine was added prior to addition of 
radioactive ATP and reactions were allowed to incubate for 30 minutes at 37°C. SDS-PAGE gels were 
run, dried, and exposed to a phosphoscreen for autoradiography. Bottom panel: Inhibition of eSTKs by 
staurosporine by quantifying bands using ImageJ software and normalizing to the DMSO only control. 



































































































































Figure 5.3.2 IreK T152F and IreK T152M are Insensitive to Staurosporine in vitro  
 
Figure 5.3.2 IreK T152F and IreK T152M are Insensitive to Staurosporine in vitro. An in vitro 
staurosporine sensitivity assay was performed as done for Figure 5.3.1. IreKKD were significantly less 
sensitive to staurosporine upon introduction of a bulky amino acid within the ATP-binding site.  
 
  
I wanted to determine if I could engineer bulky amino acids into the IreKKD active site and thereby 
change the staurosporine sensitivity. I generated two variations, one that mimics S. aureus PknB, T152F, 
and the other that mimics the M. tuberculosis PknB, T152M. I performed the same experiment as shown 
in Figure 3.5.1 and observed that introduction of the bulky amino acid groups (T152F and T152M) into the 
ATP binding pocket, greatly diminished the sensitivity of IreKKD to staurosporine. This trend was 
comparable to what I had previously observed for B. subtilis T151M. Thus, by mutating a single amino 
acid residue, I was able to modulate the staurosporine sensitivity of the kinase, an insight that I will use in 
later experiments aimed at investigating the kinase in vivo.  
I wanted to confirm that staurosporine was only active against eukaryotic-like Ser/Thr kinase 
domains and not an inhibitor of all kinases. I therefore performed in vitro staurosporine sensitivity assays 
with a panel of sensor histidine kinases. I had previously used these constructs and knew they were 
capable of autophosphorylation. In the case of WalK, I knew that it was not sensitive to staurosporine 
treatment, as I had used this compound in some of the assays described in Section 3.8. However, I had 































using 2 µM histidine kinase and 0.5µCi γP32-ATP. The major difference between this reaction compared 
to the one performed with the eSTKs is that the incubations were performed at room temperature rather 
than at 37°C. In the two-component field, histidine kinases are autophoshorylated in the presence of ATP 
at room temperature and the reactions are also performed at room temperature. Therefore, I felt it would 
be more appropriate to perform this assay at room temperature.  I chose to test E. faecalis VanS, B. 
subtilis WalK, and B. subtilis CssS, a close homolog of VanS (Figure 5.3.3).  
 
Figure 5.3.3 Specificity of Staurosporine for eSTKs 
Figure 5.3.3 Specificity of Staurosporine for eSTKs. In vitro staurosporine sensitivity assay with 2µM 
Sensor histidine kinase, B. subtilis CssS (JDE), B. subtilis WalK (JDE1601), and E. faecalis VanS (JDE 
1985) and 0.5µCi γP32-ATP were incubated for 30 minutes at room temperature. SDS-PAGE gel was run, 
dried, and exposed to a phosphoscreen for autoradiography.  
 
 I observed no significant inhibition by staurosporine of the B. subtilis histidine kinases WalK and 
CssS. I did observe inhibition of VanS autophosphorylation; however, the levels in which I observed 
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suggests that while I was able to inhibit VanS activity in vitro with high concentrations of staurosporine, 
this would most likely not inhibit VanS activity. Therefore, when performing the in vivo staurosporine 
inhibition of VanB-type VRE cultures, I made sure to use a low level of staurosporine to ensure I did not 
obtain off-target effects, and specifically inhibit IreK.  
In summary, these in vitro staurosporine sensitivity assays using recombinant protein 
demonstrated that IreK is acutely sensitive to staurosporine treatment at levels comparable to the 
inhibition observed in B. subtilis PrkC. To ensure this kinase inhibition was specific to eSTKs, I tested a 
panel of sensor histidine kinases to determine their sensitivity. To my surprise, I did observe some 
inhibition of VanS in vitro, however, the levels of inhibition were comparable to the levels of inhibition I 
have previously observed with the B. subtilis PrkC T151M allele, that I know from unpublished in vivo 
experiments is insensitive. Therefore, I concluded that staurosporine could be used to specifically inhibit 
IreK in vivo.  
 
5.4 Staurosporine Inhibits the VanRS Regulon in vivo 
 Since I observed comparable levels of staurosporine inhibition of IreK as with B. subtilis PrkC in 
vitro, I took a chemical approach to dissect the contribution of IreK in vivo. The genetics of E. faecalis are 
not trivial, as will be discussed in further depth in Section 5.5, so I wanted to get an indication that IreK 
was important for VanB-type vancomycin resistance. The hypothesis was that if IreK was able to sense 
cell wall fragments that are released during vancomycin treatment, that IreK would sense these fragments 
and phosphorylate VanS, leading to its robust activation. In a situation when cultures are treated with 
staurosporine and IreK activity is inhibited, I would predict reduced induction of the VanRS regulon upon 
vancomycin treatment.  
 To monitor VanRS activity, I performed qPCR to assay expression of two VanRS regulon genes, 
vanY and vanB. Upon vancomycin treatment, these genes become rapidly induced in order to modify E. 
faecalis peptidoglycan and remove substrates for vancomycin. I treated cultures with vancomycin and 
staurosporine or DMSO, the empty vehicle control. I observed reproducible and robust inhibition of 
VanRS regulon genes in the presence of staurosporine (Fig. 5.4). This inhibition was present whether I 
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pre-treated cultures with staurosporine for 10 minutes or whether I added staurosporine simultaneously 
as vancomycin.  
Figure 5.4 Staurosporine Inhibits VanRS Regulon Induction in vivo  
 
 
Figure 5.4 Staurosporine Inhibits VanRS Regulon Induction in vivo. Simultaneous treatment of E. faecalis 
JH2-2 TN1549 (JDB 3368) cultures with 2 µg/ml vancomycin and 10µM staurosporine for 10 min at 37°C. 
Samples harvested by addition of Qiagen Bacterioprotect RNA Reagent. RNA, cDNA and qPCR analysis 
was performed as described in Materials and Methods. Data was normalized to the vancomycin and 
DMSO control cultures.  
 
 Staurosporine inhibition of VanRS regulon genes was promising data that suggested that the 
IreK-mediated phosphorylation of VanS contributes to induction of the VanRS regulon in vivo. To further 
verify that the staurosporine inhibition of VanRS regulon induction was specific to IreK activity, I 
performed some genetic experiments in E. faecalis.  
 
5.5 Genetic Attempts to Reveal IreK’s Contribution to VanB-type Vancomycin Resistance 
 The observation that staurosporine inhibited induction of the VanRS regulon in vivo prompted us 
to further investigate this phenomenon and to perform genetics in the significantly less tractable organism 
E. faecalis. These efforts were performed in collaboration with Dr. Patrice Courvalin and Dr. Florence 




































5.5.1 Deletion of ireK in JH2-2::Tn1549  
 
My previous studies of staurosporine inhibition used E. faecalis JH2-2::Tn1549 which was 
previously characterized to have high levels of vancomycin resistance [82]. We therefore sought to 
generate a ΔireK strain in this genetic background. We tried two different strategies. Dr. Depardieu 
originally attempted using the pGhost9 system [160] that the Courvalin Laboratory had previously used to 
generate deletions in E. faecalis. The schematic for the deletion is depicted in Figure 5.5.1. Sequences 
immediately upstream and downstream of the gene of interest are amplified and inserted into the 
temperature-sensitive pGhost9 plasmid. After transformation into E. faecalis the plasmid is propagated at 
the permissive temperature (28°) with antibiotic selection.  It is shifted to the non-permissive temperature 
(42°C) in the presence of antibiotic selection to stimulate single crossover events to occur. After selecting 
for single crossover events, the cultures are further shifted back to the permissive temperature in absence 
of selection and screened for double crossover events. Unfortunately they were never able to retrieve 
single or double crossover events.  
 
Figure 5.5.1 pGhost9 Deletion Strategy of IreK 
 
Figure 5.5.1 pGhost9 Deletion Strategy of IreK. Schematic showing the primers and possible single 
crossover events that could occur upon plasmid integration. Single crossover events can be screened by 
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 Another strategy to obtain an ΔireK deletion in this genetic background was to use a derivative of 
pCJK47 [140]. In contrast to the pGhost9 strategy used above, I used 1kb flanks upstream and 
downstream of ireK to enhance our chances of obtaining a single crossover event. There are several 
other unique features of pCJK47. First, it requires RepA in trans for propagation of the plasmid, which 
means after conjugation from an E. faecalis strain that constitutively expresses repA under a P23 
Lactococcus lactis promoter, the plasmid is unable to propagate. Second, the plasmid contains a lacZ 
marker, which allows the investigator to monitor the presence or absence of the plasmid, as E. faecalis is 
notorious for generating suppressors to various antibiotics. Third, the plasmid contained a counter 
selection marker, pheS, which in the presence of 4-Chloro-DL-phenylalanine is toxic and stimulates 
excision of the plasmid and a double crossover event. .  
 I was able to obtain single cross-over events of pLG373 into JH2-2::Tn1549, however, when I 
counter selected with Chloro-DL-phenylalanine, all of the colonies screened had repaired with the wild-
type copy of ireK. In addition to screening transformants by colony PCR, I also took advantage of the 
phenotype that the OG1RF ΔireK strain was hypersensitive to cephalosporins. Therefore I patched over 
200 colonies onto BHI and replica patched it onto BHI with 1µg/ml cefotaxime and asked whether 
colonies were able to survive on BHI but unable to survive on BHI + cefotaxime. I saw no sensitivity to 
cefotaxime for any of the transformants.  
After multiple attempts using two different strategies by both Dr. Florence Depardieu and myself, I 
came to the conclusion that ireK was essential in this genetic background. However, I cannot say this with 
absolute certainty, as I have not used this strategy to delete ireK in a strain background, such as OG1RF, 
in which deletion if possible [139]. It would also be worth seeing if we could obtain this deletion in E. 
faecalis JH2-2 that doesn’t harbor the VanB-type transposon and this would address whether the 
essentiality was linked to the presence of the transposon, or rather due to strain differences between 
JH2-2 and OG1RF.  
 
5.5.2 Conjugation of TN1549 into OG1RF ΔireK  
 Since neither the Courvalin lab nor I was able to delete ireK in a genetic background that was well 
characterized for its VanB-type vancomycin resistance, we took the inverse approach. Dr. Christopher 
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Kristich at the Medical College of Wisconsin kindly provided his OG1RF and OG1RFΔireK allele to Drs. 
Courvalin and Depardieu [139]. They were able to obtain a single transfer event of Tn1549 from 
Clostridium symbosium into OG1RFΔireK.  This was performed by their long-time collaborator Dr. Thierry 
Lambert at the Pasteur institute, who has previously transferred this exact transposon element into other 
E. faecalis genetic backgrounds [148]. Unfortunately, they were never able to obtain transfer of Tn1549 
into OG1RF even after parallel attempts by both Dr. Lambert and Dr. Depardieu.  
 Even though we were unable to obtain the isogenic parent strain OG1RF::Tn1549, we were 
curious if there was inducible vancomycin resistance in the OG1RFΔireK::Tn1549 strain. Dr. Depardieu 
performed disk assays of OG1RF, OG1RFΔireK, and OG1RFΔireK::Tn1549 (Figure 5.5.2) against 
teicoplanin, vancomycin, and other antibiotics. We noticed that there was an approximately two-fold 
increased sensitivity to vancomycin in the OG1RFΔireK strain compared to its isogenic parental control. 
After addition of Tn1549 into OG1RFΔireK the vancomycin resistance increased approximately 10-fold. 
While significant, this was in stark contrast to when Tn1549 was introduced into JH2-2. The vancomycin 
MIC went from 1µg/ml to 256µg/ml, which is a greater than 200-fold induction in vancomycin resistance. 
We considered this result to be quite promising, unfortunately we did not have an isogenic 
OG1RF::Tn1549 strain to directly compare the OG1RFΔireK::Tn1549. Another thing that we became 
aware of is that the enhanced cephalosporin sensitivity originally reported for OG1RFΔireK [141], was 
diminished after generation of the OG1RFΔireK::Tn1549 which suggests that the conjugation event 
introduced some suppressor mutations into the strain, or perhaps basal expression of the VanRS regulon 
in this background, was sufficient to modify E. faecalis peptidoglycan and altered the sensitivity of the 










Figure 5.5.2 Preliminary Characterization of Vancomcyin Resistance in OG1RFΔireK::TN1549 
Figure 5.5.2 Preliminary Characterization of Vancomcyin Resistance in OG1RFΔireK::Tn1549. Assay was 
performed by Dr. Florence Depardieu. Cultures were incubated with E-test strips of vancomycin (left) and 
teicoplanin (right). On the right side are antibiotic disk assays. All strains seem sensitive to erythromycin 
(top red) and teicoplanin (black). There were differences in vancomycin resistance, as reported on the far 
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5.5.3 Complementation of IreK in OG1RFΔireK::TN1549 
To bypass the limitation of being unable to obtain the isogenic parental OG1RF::Tn1549, I 
decided to complement IreK in the OG1RFΔireK::Tn1549. While I initially decided to use the pAT29 
vector system [267], I had issues with obtaining spectinomycin resistant suppressors. Therefore I used an 
approach developed by Dr. Danielle Garsin’s group at the University of Texas Medical School at Houston 
that allowed for ectopic integration of DNA at a chromosomal locus in E. faecalis [56]. This approach was 
a modification of the pCJK47 vector system previously described and developed by Dr. Christopher 
Kristich [140]. The major adaptation was the integration vector contained homology regions to the ef2238 
and ef2229 locus in the E. faecalis genome in order to target the integration. By integration at an ectopic 
chromosomal locus there are no polarity effects and only a single copy is present in the genome. The 
most attractive feature about this system was that after successful double crossover, antibiotic selection 
is no longer required. This was a major benefit since I wanted to minimize complicating effects by having 
to use additional antibiotics in assessing vancomycin sensitivity. 
 The native regulation of IreK and IreP remains unknown.  Therefore I put IreK under a constitutive 
Lactococcus lactis P23 promoter that had previously been shown to be constitutively active in E. faecalis 
[273].  Placing IreK under the control of the P23 promoter was able to complement cephalosporin 
sensitivity in a previous vector-based approach [141]. I was able to generate complementation strains 
using this approach. In addition to the wild-type IreK allele, I also engineered strains that would express 
IreK T152F or IreK T152M. Before asking if these strains were able to restore full vancomycin resistance, 
as this role is unknown, I first asked if it could restore sensitivity to cephalosporins. I incubated strains on 
either BHI or BHI with 1µg/ml cefotaxime since I knew that the OG1RFΔireK::TN1549 was unable to grow 
in the presence of this level of cefotaxime, unlike the wild-type OG1RF which had no problems growing. I 
observed complementation of IreK in all of the strains, including the staurosporine insensitive alleles and 





 Table 5.5.3 MIC Characterization of IreK Complementation Strains  
         
Table 5.5.3 MIC Characterization of IreK Complementation Strains. The parent strain is 
OG1RFΔireK::Tn1549  (JDB 3539). All of the genotypes above contain Tn1549 in the OG1RF 
background. For complemented strains, the P23-ireK construct is at the ef2228/ef2229 ectopic locus.  
JDB 3664 is the same genotype as JDB 3539, however it also went through the complementation 
protocol and repaired with the native locus.  
 
 Dr. Florence Depardieu conducted E-test analysis as well disk assays of vancomycin, teicoplanin, 
ceftriaxone, and erythromycin. While teicoplanin is also a glycopeptide antibiotic, it does not induce the 
VanB-type VanRS two-component system. All of the strains should be equally sensitive to erythromycin, 
as after the double-crossover event there is no erythromycin cassette. As I was able to obtain multiple 
transformants for P23-ireK T152F, I included them as an internal control for biological replicates. While 
there seems to be a modest increase in vancomycin resistance, it is extremely subtle, so these data 
suggest that IreK does not contribute to VanB-type vancomycin resistance. However, if one compares the 
levels of ceftriaxone sensitivity in these strains, it can be observed that JDB 3669 and JDB 3670, which 
are theoretically the same genotype, behave quite differently. This could be due to the extended period of 
time needed to generate these complementation strains and suggests the possible emergence of 
suppressor(s).  
 Thus, in conclusion the P23-ireK complementation strains do not appear to enhance the level of 
VanB-type vancomycin resistance. While we have tried several genetic approaches to dissect the role of 
IreK threonine phosphorylation of VanS, the genetic data is incomplete. I have major concerns that 
suppressor mutations exist in strain JDB 3539 for a number of reasons. First, this was the only 
transconjugant obtained from the in vivo transfer of Tn1549 from C. symbiosum to E. faecalis 
OG1RFΔireK. The low efficiency in which we were able to obtain OG1RFΔireK and the fact that we were 
MIC (µg/ml)* Antibiotic resistance (diameter in mm) 
Strain Genotype Vm Te Cro Vm Te Cro Em 
3539 !ireK 16-24 0.094 4 14 18 23 19 
3663 !ireK + P23-ireK 32 0.125 8 10 17 18 19 
3664 !ireK 24 0.094 4 14 18 22 19 
3669 !ireK + P23-ireK T152F 16 0.25 4-8 11 17 21 22 
3670 !ireK + P23-ireK T152F 32 0.125 24 11 17 15 20 
3671 !ireK + P23-ireK T152M 32 0.094 6 10 17 20 20 
* Vm= vancomycin, Te= teicoplanin, Cro=ceftriaxone, Em= erythromycin 
!"!#$%&'&($)*'+),(-%./00+
,12 '2.3)%.12+14+5)2,16/,%2+
7.3)%2+ 8'21./&'+ 91.+:2$;,'$+ 56+<=>?6@+
ABBA+ C!"#$%&%'()*!"#$+ DEB+F?#+GED+ HH+F?#+I+
ABBJ+ C!"#$+ DE<+F?#+GED+ HB+F?#+A+
  
134 
never able to obtain OG1RF::Tn1549 suggests that there are probably significant alterations in the 
genome of this strain.  Second, I was never able to obtain a ΔireK allele in a well-characterized VanB-
type vancomycin resistance strain.  
 In the future there are several approaches that we can take to try and dissect the interaction 
between IreK and the VanRS two-component system. One strategy is to transform a plasmid that 
contains IreK and overexpress it in JH2-2::Tn1549. If our hypothesis is correct, we could potentially see 
VanRS regulon expression in the absence of vancomycin, or see faster or larger induction in the 
presence of vancomycin. A second approach would be to move the VanRS operon coding sequence into 
OG1RF and OG1RFΔireK at the ectopic ef2228ef2229 locus. While it would be technically challenging to 
move the entire VanRS regulon, it might be possible to move just the VanRS structural genes along with 
an engineered luciferase reporter downstream of PYB to measure induction. This would be independent of 
vancomycin resistance, but would allow us to assess the question if IreK works synergistically with the 
VanRS two-component system to induce the VanRS regulon.  
 
5.6 Biochemical Approaches to Dissect IreK Stimulation of VanS Activity 
 In also wished to determine the mechanism of action for IreK activation of VanS. The in vivo 
staurosporine experiment demonstrated that inhibition of IreK leads to inhibition of the VanRS regulon 
genes. Therefore, my hypothesis is that IreK-mediated T223~P activates VanS activity. I came up with 
three mechanisms by which VanS T223 phosphorylation could activate its activity: increased 
autophosphorylation, enhanced VanS to VanR phosphotransfer, and diminished VanS phosphatase 
activity.  
 Previously, phosphorylation of DegS S76 by either of the B. subtilis eSTKs YabT and YbdM led to 
enhanced autophosphorylation and enhanced phosphotransfer to a response regulator [121]. Since they 
successfully used a phosphomimetic mutant, S76D, to perform biochemical experiments, I also used a 




5.6.1 Autophosphorylation Kinetics of VanS  
 Since stimulation of the autophosphorylation of the sensor histidine kinase would enhance 
VanRS regulon induction in vivo, I performed kinetic experiments in which I measured the rate of 
autophosphorylation of VanS or VanS T223D after addition of γP32-ATP (Figure 5.6.1).  
 
Figure 5.6.1 Autophosphorylation Kinetics of VanS and VanS T223D 
 
 
Figure 5.6.1 Autophosphorylation Kinetics of VanS and VanS T223D. I performed in vitro kinase assays 
using VanS or VanS T223D at room temperature by using a 100 µl reaction volume, and pulling out 10 
microliters at the indicated times.  
  
  
 However, I did not observe any substantial difference in the autophosphorylation kinetics of VanS 
or VanS T223D under these reaction conditions, suggesting that this is most likely not the mechanism of 
how T223~P mediates its activating effects. I then decided to use in vitro phosphorylated VanS T223~P, 
as while sometimes phosphomimetics are effective, they do not always reflect the phosphorylated version 
of the protein. Therefore, I developed a strategy, similar to what I performed previously to dissect WalR 
T101~P, in which VanS was autophosphorylated by IreK using cold ATP and desalted. After desalting, 
VanS was allowed to autophosphorylate in the presence of γP32-ATP (Figure 5.6.2). To confirm that I was 
getting sufficient inhibition of IreK under these conditions, for the last time point, I took the sample and 
boiled it at 95°C for 5 min, which should selectively remove phosphohistidine modifications. I wanted to 




ensure complete inhibition of IreK otherwise I am unfairly contributing transphosphorylation signal to the 
VanS autophosphorylation signal. 
Figure 5.6.1.1 Autophosphorylation of VanS or VanS T223~P 
 
Figure 5.6.1.1 Autophosphorylation of VanS or VanS T223~P.  Left hand panel: Schematic of the 
procedure that was used to generate VanS T223~P, and still be able to differentiate between 
phosphohistidine versus phosphothreonine incorporation of VanS. Initially VanS or VanS T223A are 
phosphorylated with IreK with cold ATP (1). After the IreK kinase reaction, the reaction is put through a 
desalting column to remove excess cold ATP. IreK is inhibited with staurosporine and γP32-ATP is added 
to the reaction (2). VanS autophosphorylation is measured by incorporation of γP32-ATP (3). To confirm 
that I was only observing autophosphorylation, I boiled the last time point. Right hand panel: 
Representative kinase assay gel showing the kinetics of autophosphorylation, in minutes. The asterisk 
indicates that samples were boiled at 95°C for 5 min to differentiate between phosphohistidine and 
phosphothreonine. 
 
 However, there was not a significant difference in the kinetics of VanS autophosphorylation 
between VanS/IreK and VanS T223A/IreK. Also, staurosporine was insufficient to completely inhibit IreK 
activity, as one can see the presence of an upper band. Furthermore, I am also detecting 
phosphothreonine incorporation of VanS, if one compares the 30 minute time point that was loaded 
directly versus the sample that was boiled for 5 minutes. There is a significant amount of signal that did 
not get removed with boiling, suggesting that it might be phosphothreonine residues. To avoid these 
complications, I developed a VanS derivative vector that has a N-terminal 6xHis-SUMO tag that can be 

















incorporation of labeled phosphothreonine into the gel, which should help facilitate analysis (Figure 
5.6.1.2).  
 
Figure 5.6.1.2 Generation of Untagged VanS 
 
5.6.1.2 Generation of tag-less VanS. To facilitate further biochemical experiments, I generated a pSMT3 
derivative VanS construct that allows for efficient ULP1 digestion of VanS and the removal of VanS from 
SUMO. Undig= undigested protein purification. + ULP1 10 min= 10 min of 1:1000 ULP1 treatment at 
room temperature, +ULP1 2hrs 4C= digestion of SUMO-VanS for 2 hours at 4C. FT= Flow through after 
running over 6his-column. W=wash.  
 
 Figure 5.6.1.2 is a representative gel testing 6xHis-SUMO-VanS and its ability to be cleaved by 
the SUMO –specific protease ULP1.  I was able to observe robust cleavage of the SUMO tag after 10 
minutes at room temperature and complete digestion after 2 hours at 4°C. After cleavage, I incubated 
these proteins with Ni-NTA resin to selectively remove the 6his-SUMO tag from VanS. Theoretically, only 
VanS should be in the flow through, as it should not bind the resin. While VanS is present in the flow 
through, there was also a significant amount of 6his-SUMO present. This suggests that I did not incubate 
the digested protein sample with enough resin, or that I need to ensure thereis no imidazole, as 6xHis -






























































bind the resin when doing the WalR REC purifications, suggesting I need to optimize the separation of 
VanS from SUMO. However, this provides us with a nice launching point to improve the 
autophosphorylation experiments.  
 
5.6.2 VanS Transphosphorylation of VanR 
 
 Another parameter that could be altered by T223~P is the ability of VanS to phosphotransfer to 
VanR. While I was able to obtain robust autophosphorylation of VanS, I did not observe robust 
phosphotransfer to the cognate response regulator, VanR, under conditions I had previously used for 
WalK and WalR. I noticed that in vitro VanS protein preparations were notoriously inactive [295] and even 
though VanS to VanR phosphotransfer was observed in the original publication, the kinetics are much 
slower than what is typically observed for histidine kinase and cognate response regulator 
transphosphorylation.  
 I was eventually able to obtain VanS to VanR phosphotransfer, however only when using a 1:5 
ratio of histidine kinase to response regulator (Figure 5.6.2). In order to separate kinase activity from 
phosphatase activity of VanS on VanR, I compared the loss of signal from VanS, and this was 
comparable between VanS and VanS T223D indicating that the phosphomimetic was not acting 
differently.  I have not performed this experiment with T223~P VanS, although this should be done to 
eliminate this mechanism completely. However, it appears unlikely that the mechanism underlying 











Figure 5.6.2 Response Regulator Phosphorylation by VanS and VanS T223D 
 
 
 Figure 5.6.2 Response Regulator Phosphorylation by VanS and VanS T223D. VanS or VanS T223D 
were allowed to autophosphorylate for 1 hour in the presence of γP32-ATP. After 1 hour, the reactions 
were desalted, and VanS was added to a reaction mixture containing VanR, the response regulator. 
Aliquots were pulled at indicated time points. Samples were run on an SDS-PAGE gel, dried, and 
visualized by autoradiography.  
 
5.6.3 Phosphatase Activity of VanS 
  A third possible mechanism of activation of VanS is the inhibition of VanS phosphatase activity 
towards VanR. VanS phosphatase activity is physiologically relevant as constitutive expression of VanRS 
regulon gene is observed in a ΔvanS strain [114]. This was attributed to VanR’s ability to use small 
molecule phosphodonors in vivo, as deletion of the acetyl phosphate synthesis genes, removed the 
constitutive expression of VanRS regulon genes [114]. While it can be argued that the VanRS two-
component is sufficiently divergent in S. coelicolor, genetic mutations have been identified in VanS from 
the VanB-type vancomycin resistance that inhibit phosphatase activity. A six amino acid deletion within 
the ATP-binding motif was shown to result in constitutive expression of the VanRS regulon, which was 
shown in vitro to be attributable to lack of phosphatase activity [58]. Furthermore, single point mutations 
within JH2-2::Tn1549 VanS were implicated in constitutive expression [82] suggesting that modification 
within this region can lead to constitutive expression of VanB-type vancomycin resistance genes.  







 To test this mechanism I took advantage of the fact that VanR, unlike WalR, can be 
phosphorylated by small molecular phosphodonors. Therefore, I synthesized radiolabelled acetyl 
phosphate using a protocol kindly provided by Dr. John Kirby from the University of Iowa where 
commercially available acetate kinase is incubated with fresh potassium acetate and γP32-ATP. If freshly 
made potassium acetate is not used, this protocol does not work. I then tried several published protocols 
to determine which one most robustly labeled VanR (Figure 5.6.3). I did not remove acetate kinase from 
the reaction mixture as it had been previously shown not to interfere with downstream reactions [213]. I 
also tried a protocol that was previously used to label M. xanthus CrdA with radiolabelled acetyl 
phosphate [289]. In addition, I made some modifications to the previously published protocols. However, 
adding the concentrated response regulator to the acetyl phosphate reaction turned out to provide the 
most robust autophosphorylation.  
Figure 5.6.3 Autophosphorylation of VanS by Acetyl Phosphate 
 
 
Figure 5.6.3 Autophosphorylation of VanS by acetyl phosphate (AcP). Acetyl phosphate was generated 
by incubating fresh potassium acetate, γP32-ATP, and E. coli acetate kinase (Sigma) for 1 hour at RT. 
This mix was added to generate A) 10 µl of AcP* in a 25 microliter reaction volume, B) 10 µl of AcP* 
incubated with 10µl of 5µM VanR [289], C) 2.5µl 100 µM VanR with 7.5µl AcP* [213]. VanR was allowed 
to autophosphorylate for 1 hour at room temperature.  
 
 Once I obtained robustly labeled VanR D53~P, I determined if T223D or T223~P had a defect in 














no residual γP32-ATP that could be incorporated by VanS or IreK by running VanR through a desalting 
column, to remove unbound γP32-ATP. I then incubated VanR D53~P* with VanS, VanS T223D, or 
VanS/IreK or VanS T223/IreK. The VanS/IreK reactions were performed with cold ATP and therefore 
should not contribute to the signal I was monitoring by autoradiography. My experimental strategy 
mirrored experiments previously done that showed a phosphatase defect resulting from a six amino acid 
deletion in VanS [58]. While these experiments need to be repeated and optimized, preliminary 
experiments suggest that T223~P results in decreased phosphatase activity. Thus, inhibition of VanS 
phosphatase activity, could explain the enhanced induction that is observed in vivo in early time points 
after vancomycin treatment. 
 
In preliminary experiments, I observed robust dephosphorylation of VanR D53~P* by both VanS 
and VanS T223D. This dephosphorylation activity was much more robust than the kinase activity 
observed with these proteins. After quantification of the bands by ImageJ, it became apparent that at 
early time points, there was slower phosphatase activity in VanS T223D in comparison to VanS (Fig. 
5.6.3.1). While at this point the phenotypic differences are fairly subtle, this is promising preliminary data 
that suggests T223 phosphorylation may impair VanS phosphatase activity. I performed a second trial 
this time adding 1 µM VanS or VanS T223D, rather than the 4 µM used in the pilot experiment. This 
significantly helped in slowing down the kinetics of phosphatase activity. I was also able to observe 
slower phosphatase activity of VanS T223D compared to VanS at early time points. This provides 
promising preliminary data that the phosphatase activity is impaired upon VanS T223~P, and this is the 

















Figure 5.6.3.1 Phosphatase Activity of VanS and VanS T223D. In vitro phosphatase assay of VanS and 
VanR. Radiolabelled VanR D53~P was incubated with 4 µM VanS or VanS T223D and aliquots were 
taken as the specified time point. The bands were measured using ImageJ and phosphorylation activity 
was measured as signal compared to t=0 time point.  
 
   
 

























I also performed this phosphatase assay in parallel with VanS that had been phosphorylated by 
IreK in vitro using cold ATP. While I did see a similar trend, it was not as striking as with the 
phosphomimetic. One obvious reason for the discrepancy is that perhaps I had inefficient IreK 
phosphorylation of VanS. It is technically difficult to determine what percentage of the protein population 
has been phosphorylated, unless there is differential migration.  I have not run these samples via gel 
filtration, native gel, or HPLC to determine if the structure or hydrophobic nature of the protein is distinct. I 
performed IreK phosphorylation of VanS in parallel with either wild-type VanS or VanS T223A, which is 
unable to be phosphorylated, as demonstrated in previous experiments (Figure 5.2.1). However, I did not 
run these particular samples in the presence of radioactive γP32-ATP, so I cannot know if I achieved 
robust transphosphorylation of IreK to VanS. One way to circumvent this limitation would be to use the 
untagged VanS protein constructs and after IreK phosphorylation to perform phosphoprotein enrichment. 
This would give me enhanced confidence that the sample I am working with is primarily phosphorylated.  
 
5.7 Threonine Phosphorylation of a Sensor Histidine Kinase is Conserved in B. subtilis   
 
During investigation of VanS as a substrate of the E. faecalis eSTK, IreK, I noticed a high degree 
of homology between VanS and CssS, a sensor histidine kinase involved in cell membrane integrity in B. 
subtilis [192]. Both have the same modular intracellular domain architecture with a BLAST score of 5e-16. 
Since PrkC and its homologs in other bacteria play important roles in cell wall maintenance and cell 
membrane integrity, I wondered if in addition to its regulation of the WalRK two-component system, if 
PrkC could also be interacting with the CssRS two-component system. However, in previous kinase 
assays with PrkC and the response regulator CssR, no transphosphorylation was observed (Figure 4.2.1). 
I therefore investigated whether the histidine kinase CssS is a target of PrkC.  
I modeled the CssS expression construct off a published construct that comprises the entire 
cytoplasmic domain of CssS [192] and I was able to successfully purify CssS. In an in vitro kinase assay, 










Figure 5.7 PrkC Phosphorylates the Sensor Histidine Kinase, CssS, in vitro. In vitro kinase assay of 1µM 
PrkC (JDE 1582) and the cytoplasmic domain of CssS (pLG352) The third lane includes CssS in the 
absence of PrkC, and under these conditions there is no noticeable autophosphorylation after boiling. 
WalR was included as a positive control for the PrkC protein prep.  
 
 
Since I was able to visualize transphosphorylation of CssS by PrkC, I performed cold versions of 
these reactions and submitted them for mass spectrometry analysis by Dr. Mary Ann Gawinowicz of the 
Columbia Protein Core Facility. She identified several threonine residues as being phosphorylated. Her 
identification of phosphopeptides identified by Mascot can be found in Table 5.7. I’ve included this data 






























Sequence Residue (approx) 
[NNDSLL]     
[LLQQM]     
LVQKDETERTLLQNISHDLK ?   
TLLQNISHDLK ?   
GYTQSIK Thr-263 0.15 
GYTQSIKDGIFPK Thr -263   
GDLENTVDVIECEALK Thr-279 0.018 
 
Table 5.7 Phosphopeptide Analysis of CssS by Mass Spectrometry. This data was generated by Dr. Mary 
Ann Gawinowicz at the Columbia Protein Core Facility.  Below are peptides that Mascot identified as 
having phosphorylation sites. The first two peptides were incorrectly identified. The two with ? are actually 
the site of the conserved His residue in the HisKA domain, which would be hard to verify as the samples 
were previously boiled to remove phosphohistidines. She identified Thr 263 as the prominent site of 
phosphorylation and a secondary site, Thr279. The fraction of phosphorylated peptide over the number of 
all peptides is listed in the far right hand column.  
 
 Her identification of Thr 263 and possibly Thr 279 as being sites of phosphorylation lie within the 
HisKA domain. It is 11 amino acids C-terminal from the conserved His residue and within the dimerization 
domain. At this point I cannot say for certain if this modification is physiologically relevant. However, given 
the high amounts of cold ATP used in the reaction conditions, CssS is likely a real substrate. For example, 
I did not observe phosphorylation of WalK, which also contains the conserved HisKA domain. However, 
the role for this modification remains unclear. It would be necessary to see if the CssRS regulon genes 
were differentially expressed in a ΔprkC and ΔprpC background. It could be imagined that in a scenario of 
cell wall stress, which is thought to active PrkC, cell wall maintenance would want to be coordinated with 
cell membrane integrity. Future studies should focus on whether these signaling paradigms converge in 
vivo.   Unlike, WalRK, the CssRS two-component is not essential and would therefore facilitate genetic 





5.8 Discussion  
 In this chapter, I have discussed experiments aimed at analyzing how threonine phosphorylation 
regulates the VanRS two-component system in VanB-type vancomycin resistance. I observed robust 
transphosphorylation of VanS by IreK at T223 and that the cognate eSTP, IreP, can dephosphorylate 
VanS T223~P in vitro. I also characterized the staurosporine sensitivity of the eSTK, IreK, and also 
through amino acid sequence alignments, showed that IreK is sensitive to staurosporine. I also 
constructed T152F and T152M alleles of IreK, while functional in vivo, are insensitive to staurosporine 
treatment.  
 I then used staurosporine in vivo with E. faecalis JH2-2::Tn1549 to determine if IreK inhibition 
resulted in reduced expression of the VanRS regulon. I observed marked inhibition of VanRS regulon 
genes vanY and vanB when pre-treating or simultaneously treating staurosporine with low levels of 
vancomycin. This led me to hypothesize that IreK could be acting as another sensory input to activate the 
VanRS two-component system. These results suggested that the mechanism of action of T223~P was to 
further stimulate VanS activity. 
 I initiated genetic experiments to try and dissect the role of IreK in VanB-type vancomycin 
resistance. Unfortunately, neither my collaborators at the Pasteur nor I were unable to generate a ΔireK 
deletion in JH2-2::Tn1549. As an alternative, we obtained OG1RF and OG1RFΔireK from Dr. Christopher 
Kristich and attempted to move in Tn1549 through transfer from C. symbiosum in vivo. Unfortunately, we 
were only able to obtain one OG1RFΔireK::Tn1549 transconjugant. I also introduced ireK under a 
constitutive P23 promoter at the ectopic locus ef2228ef2229 in this strain. While these strains were no 
longer hypersensitive to cefotaxime, there was no dramatic difference seen between 
OG1RFΔireK::Tn1549 (JDB 3663) and OG1RFΔireK::Tn1549 P23-ireK (JDB 3664). While this data 
suggests that IreK does not contribute to VanB-type vancomycin resistance, I am nervous about the 
presence of suppressors in these strains, as we obtained them at such low frequencies.  
 While my efforts to definitively show the involvement of IreK in VanB-type vancomycin resistance 
were non-conclusive, there are alternative strategies. Foucault et al have previously been able to 
introduce point mutations into the Tn1549 transposon in vivo [82]. Therefore I could introduce a T223A 
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and T223D allele into VanS. The vanS T223A allele would remove the IreK phosphorylation site and 
therefore mimic a ΔireK strain. The vanS T223D allele would mimic a ΔireP strain in which constitutive 
phosphorylation of VanS T223~P would be predicted. Alternatively, I could transform a plasmid I obtained 
from Dr. Christopher Kristich that expresses IreK under a constitutive promoter (pCJK160) [141]. This 
would permit overexpression of IreK in JH2-2::Tn1549. The prediction would be that one would see 
enhanced VanRS regulon expression in the absence of vancomycin.  A final approach would be to move 
VanRS and a VanRS transcriptional reporter into OG1RF and OG1RFΔireK that would allow us to 
address the contribution of IreK phosphorylation on induction of the VanRS regulon, even if I could not 
measure vancomycin resistance. 
 To date, my experiments have been directed at investigating the role of IreK in VanB-type 
vancomycin resistance; however, it would be interesting to investigate the involvement of IreK in VanA-
type vancomycin resistance. VanA-type resistance is also inducible and could therefore obtain input from 
an additional sensory input signal. Furthermore, it has been reported in the literature that VanA strains 
are able to induce their regulon with other cell wall acting antibiotics, such as bacitracin and D-cycloserine, 
which would ultimately lead to the accumulation of Lipid II [6]. Preliminary data from our lab by Dr. 
Elizabeth Libby suggests that the B. subtilis IreK homolog, PrkC, preferentially localizes to the septum, 
and is delocalized specifically by cell wall antibiotics. Therefore it would be interesting to investigate the 
contribution of IreK in VanA-type induction of VanRS regulon genes to other cell wall acting antibiotics.   
 In addition to using genetic strategies to investigate the contribution of IreK to induction of the 
VanRS regulon, I also performed biochemical assays to investigate the underlying molecular mechanism. 
I tested three hypotheses that would contribute to VanS activation: (1) enhanced VanS 
autophosphorylation, (2) enhanced VanS to VanR phosphotransfer, and (3) inhibition of VanS 
phosphatase activity. I did not observe any substantial differences in VanS autophosphorylation or VanS 
to VanR phosphotransfer. However, preliminary data suggests that VanS T223 phosphorylation might 
inhibit VanS phosphatase activity. I am currently in the process of repeating and optimizing these assays, 
however, genetic mutations within the region have previously been identified to interfere with 
phosphatase activity. Clinical isolates that contain these mutations are constitutively active, suggesting 
that this mechanism has physiological consequences in vivo [82].  
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 In addition to our analysis of VanS and IreK, I wondered if threonine phosphorylation of a sensor 
histidine kinase could also be observed in B. subtilis. I hypothesized that cell wall metabolism and cell 
membrane integrity would need to be coordinated in order to prevent unnecessary cell wall lysis or 
damage. These processes would need to be coordinated by a sensory input system. In B. subtilis the only 
eSTK with a defined sensory input domain is PrkC. I therefore asked if PrkC could interact with the 
CssRS two-component system involved in cell membrane integrity [192]. I purified the histidine kinase 
CssS, which interestingly contains a high degree of homology with VanS. I observed that PrkC could 
phosphorylate CssS on two threonine residues within the HisKA domain by mass spectrometry analysis. 
At this point I can only speculate what this modification could be doing. PrkC appears to have a high 
specificity in vitro, as the lab has tested many other targets. Therefore, this suggests that the 
phosphorylation event may be occurring in vivo. Further experiments to characterize the physiological 
significance of this interaction are warranted. The CssRS regulon is very well defined and stimulated 
under specific conditions. Therefore CssRS reporter strains should be assessed in a ΔprkC and a ΔprpC 
background. If I see a difference under these conditions, it is worth pursuing the construction of allelic 















Chapter 6. Biochemical Characterization of Gram-Negative eSTKs 
 
6.1 Introduction  
In addition to understanding the role of eSTKs in regulating cell wall metabolism in Gram-positive 
bacteria, I also wanted to understand Gram-negative eSTks. While Gram-positive eSTKs/eSTPs have 
received considerable attention over the past decade, the same cannot be said for their Gram-negative 
counterparts. Part of this can be attributed to the divergence in primary sequence of Gram-negative 
eSTKs from Hank’s type eukaryotic Ser/Thr kinase domains [240]. Many of the Ser/Thr kinases 
characterized do not share homology with Hank’s type eukaryotic Ser/Thr kinases [101]. For example, the 
most well characterized Escherichia coli eSTK, HipA, is a member of the PI/3-4 kinase superfamily. The 
kinase activity of HipA is necessary for the formation of persisters and is actually toxic when 
overexpressed [50], although the targets remain unclear. The homology to eukaryotic kinases was not 
fully appreciated until the crystal structure of HipA was generated [234]. Proteins with homology to E. coli 
HipA can be found in many Gram-negative genomes, suggesting that this kinase domain plays an 
important role in bacterial physiology. I therefore sought to purify Caulobacter crescentus HipA homologs 
and develop conditions to test for substrates in vitro.  
 Our lab was approached by Dr. Michael Rust at the University of Chicago who works on the 
cyanobacterium Synechococcus elongatus PCC 7942. S. elongatus is a Gram-negative cyanobacterium 
photoautotroph [83]. In addition to being able to use photosynthesis to drive metabolism, S. elongatus 
also has a circadian clock that is composed of the KaiA, KaiB, and KaiC oscillator proteins [292]. It had 
previously been shown that a bacteriophytochrome histidine kinase, CikA, is an important regulator of 
circadian rhythm [233]. Furthermore, CikA has also been implicated to be important for cell division [175]. 
In a yeast two-hybrid assay, CikA was identified as an interaction partner for the eukaryotic-like Ser/Thr 
kinase, PrkE (Synpcc7942_0600). Therefore, since I have experience working with eSTKs and histidine 
kinases, I decided to determine expression conditions for PrkE in addition to determining if any of the 
circadian rhythm proteins, including CikA, were substrates.  
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6.2 Caulobacter crescentus HipA Homologs 
  
I initially became interested in Caulobacter crescentus when I was pursuing whether response 
regulator phosphorylation at T101 was conserved in Gram-negative bacteria. Unlike B. subtilis, there are 
no Hank’s type eSTKs in C. crescentus. However, there are HipA homologs, as mentioned in the 
introduction to this chapter. Another reason I was interested in studying C. crescentus eSTKs is the key 
roles that histidine kinases play in its complex life cycle where it develops from a swarmer cell to a stalked 
cell that divides into a swarmer and stalked cell [245]. The asymmetric cell division, strict cell cycle control, 
and bacterial morphogenesis make C. crescentus an interesting and very well-studied model organism. 
 
6.2.1 Bioinformatics Analysis of C. crescentus HipA Homologs 
I initially identified three HipA homologs in C. crescentus by BLASTing the C. crescentus genome 
with E. coli HipA. The two that have the highest amount of homology are CC_2770 (435 amino acids) and 
CC_2735 (444 amino acids) and a smaller protein CC_2386 (198 amino acids). Holly Wolcott, PhD 
candidate in the Department of Biochemistry and Biophysics at Columbia University Medical Center 
performed an amino acid alignment using ESPript2.2 using the E. coli HipA structure against the three C. 
crescentus HipA-like proteins  (Figure 6.2.1). These proteins contain all the conserved catalytic residues 
that have been shown in E. coli to be important for catalytic activity [50, 234]. Furthermore, there is even 
higher sequence conservation if you exclude the smaller HipA-like protein, CC23856. Based off this 
structural alignment, I thought it was quite likely that all three HipA-like proteins in C. crescentus had 
kinase activity. I have not been able to find any primary research articles discussing these HipA-like 







Figure 6.2.1 Amino Acid Alignment of CC2735 and CC2730 with HipA Structural Data 
 
Figure 6.2.1 Amino Acid Alignment of CC2735 and CC2730 with HipA Structural Data. This alignment 
was performed by Holly Wolcott using ESPript2.2. The closest structure if the E. coli HipA structure (PDB 
ID: 2WIU) from Schumacher et al[234]. HipA1 is C. crescentus CC_2770 (Pubmed Accession Number: 
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While there have been no publications in the literature regarding the functional characterization or 
biological significance of these HipA-like proteins, there is transcriptional data available from McGrath et 
al [172] which performed an unbiased analysis of C. crescentus transcription start sites throughout the 
cell cycle (Figure 6.2.1.1).  
Figure 6.2.1.1 Cell Cycle Expression of HipA-like Proteins 
Figure 6.2.1.1 Cell Cycle Expression of HipA-like Proteins. Plot of data from McGrath et al [172] 
Supplementary Table 8. Plotting HipA-like Ser/Thr kinases against the minutes of the cell cycle.  
 
While the smaller HipA-like protein, CC2386 has very basal expression throughout the cell cycle; 
the larger HipA proteins have variable expression, suggesting that expression of these proteins is 
important for successful cell cycle progression. Now that I had gleamed everything I could from the 
literature, I proceeded to generate protein expression constructs of the three HipA-like proteins to 
determine if they were also kinases.  
 
6.2.2 Protein Expression of HipA Homologs 
   
 I used a pBad24 vector based approach for expression of the HipA homologs, as the E. coli HipA 
structure was generated using a pBad33 derivative [234]. I obtained C. crescentus NA1000 from Dr. 




























construction. I induced them with 0.2% arabinose and let them express for 3 hours at 37 °C (Figure 6.2.2). 
Furthermore, after a failed attempt at performing a Ni-NTA native purification, I determined that my 
recombinant proteins were primarily in the pellet fraction. After performing several Triton X-100 washes, it 
became apparent that our protein constructs were in inclusion bodies (Figure 6.2.2). 
 




Figure 6.2.2 Expression of HipA Homologs in E. coli. Left panel: Coomassie Brilliant Blue staining of 12% 
SDS-PAGE gel with uninduced (-) and induced (+) E. coli lysates containing the HipA homologs: CC2386 
(JDE 2145), CC2735 (JDE 2147), and CC2770 (JDE 2146). Right panel: Representative gel showing that 
that recombinant protein is only found in the inclusion bodies. The protein is present in the whole lysates, 
and remains absent even during the membrane washes with Triton X-100, and only reappears upon 








































































 While I was able to establish conditions in which I could obtain robust expression, all proteins 
ended up in the inclusion bodies. One reason proteins end up in inclusion bodies is they are toxic to E. 
coli. This led us believe that the HipA homologs are similar enough to E. coli HipA to cause toxicity issues. 
To generate the HipA structure, they used a catalytically dead variant of HipA [234]. However, I was 
unable to use this trick, as I wanted to assess their kinase activity. I therefore proceeded to purify the 
kinases from the inclusion bodies based off protocols provided by Holly Wolcott, PhD Candidate in Dr. 
Lawrence Shapiro’s Lab at Columbia University Medical Center. This denaturing protocol required 
solubilization of the inclusion bodies into guanidine hydrochloride. However, going from inclusion bodies 
to folded proteins is not a trivial process. Therefore, I tested a panel of renaturing buffers to determine if I 
could obtain folded protein.  
Figure 6.2.2.1 Renaturing HipA Homologs 
 
 
Figure 6.2.2.1 Renaturing HipA Homologs. Overnight renaturation of HipA homologs in renaturing buffers 
after solubilization in Guanidine HCl. To the left are the various amounts of Guanidine HCl and L-Arginine 
that were added to help facilitate folding. All the buffers contained the same base components of 55mM 
Tris, 21mM NaCl, 88mM KCl, 1mM MgCl2, 1mM DTT. To the right are protein gels showing which base 
refolding buffers resulted in soluble protein. All of the fractions were spun at 15,000g at 4°C to remove 
any precipitated protein prior to performing TCA precipitation and running samples on SDS-PAGE.  
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 The renaturing was done in the presence of denaturants in order to facilitate productive folding 
and prevent aggregation.  While CC2386 did not seem to prefer any renaturing buffer, CC2735 seemed 
to only fold in the presence of denaturants. In order to confirm I was not observing precipitated proteins, I 
spun each fraction at 15,000g for 15 min at 4°C to pellet any unfolded proteins or aggregates. Solubilized 
proteins will remain in solution. However, since the renaturing was performed with low concentrations of 
proteins, I performed TCA protein precipitation of the fractions to visualize them by SDS-PAGE.  Since I 
was able to obtain renatured protein after the first step, I dialyzed some of the promising fractions into 
eSTK dialysis buffer in order to remove guanidine HCl and L-arganine.  The following morning after 
dialysis into eSTK dialysis buffer, I performed a similar centrifugation step to remove precipitated proteins. 
In addition, I added solubilized inclusion bodies directly to the dialysis buffer, to see if I could bypass the 
base refolding buffers. 
 
6.2.3 Kinase Activity of C. crescentus HipA Homologs 
 
 I wanted to determine if the renatured proteins had refolded properly and were catalytically active. 
It is not uncommon that proteins do not fold properly after a denaturing purification, however, since I did 
still have some soluble protein I was hopeful that I retained catalytic activity. I incubated them in the 
presence of γP32-ATP to allow for autophosphorylation and ran the gel and visualized the results by 
autoradiography. 
Figure 6.2.3 Kinase Activity of C. crescentus HipA Homologs 
Figure 6.2.3 Kinase Activity of C. crescentus HipA Homologs. Fractions from the indicated refolding 
buffers were dialyzed into eSTK dialysis buffer overnight and added to an in vitro kinase assay to 
determine the activity of C. crescentus homologs. FT indicates it was dialyzed directly from the 
Guanidine-HCl solubilized inclusion body.  















 I was not able to see any activity by CC2386. However, I was able to see robust activity of 
CC2770 in all three fractions that had been refolded in the base refolding buffers. I saw intermediate 
activity with CC2735 from Fraction 8, but it was not very robust. Therefore, future optimization of the 
refolding conditions needs to be done for both CC2386 and CC2735. While the vast majority of the 
protein was in the inclusion bodies, I could obtain a small fraction of the HipA proteins that were not within 
the inclusion bodies if the reactions were scaled up. I therefore decided to put these proteins into our 
kinase assays and to determine if I could use these protein preparations for future kinase assays. I was 
able to observe autophosphorylation of both CC2735 and CC2770. However, like with the denaturing 
purification, I was unable to observe in vitro kinase activity of CC2386. Therefore, it remains unclear 
whether CC2386 has kinase activity. In addition to testing the kinase activity of the HipA homologs, I also 
tested if they phosphorylated the essential response regulators CtrA, involved in cell cycle progression, 
and CenR [8], involved in cell envelope biogenesis [245]. Both of these response regulators contain a 
threonine at the homologous position of WalR T101, however, neither CC2770 nor CC2735 
transphosphorylated CtrA or CenR.  
 
6.3 Synechococcus elongatus PCC 7942 PrkE and Circadian Rhythm Proteins 
6.3.1 Introduction  
In collaboration with Dr. Michael Rust at the University of Chicago and his postdoctoral fellow Dr. 
Gopal Pattanayak, I investigated the eukaryotic-like Ser/Thr kinase PrkE and its possible role in the 
regulation of circadian rhythm. This work was based off the identification of an interaction with CikA, a 
histidine kinase, through a yeast two-hybrid approach [157].  In addition, a null mutation in prkE resulted 
in unpredictable magnitude and direction phase shifting, and unpredictable phase resetting [157] of the 
circadian clock. Epistatic genetic experiments suggested that PrkE was upstream of CikA. However, this 
interaction was not further characterized and it is unknown whether this is a direct protein-protein 




6.3.2 Expression and Purification of Eukaryotic-like Kinase PrkE 
PrkE (PCC 7942_0600) is predicted to have a eukaryotic-like Ser/Thr kinase domain. In addition 
to a conserved eukaryotic-like kinase domain, it contains an uncharacterized C-terminal domain that is 
only annotated as having three regions of low complexity with the SMART algorithm. I initially tried 
generating N-terminal 6xHis construct of both the full length and only the cytoplasmic domain; however, I 
was not able to detect expression of either construct. Therefore, I used the pSMT3 vector, which contains 
an N-terminal 6XHis-SUMO tag that is thought to stabilize and help aid in solubility of recombinant 
proteins. I initially tested the full-length ORF of PrkE in frame with 6XHis-SUMO. I texted expression at 
room temperature, 30°C and 37°C. and observed that the SUMO-PrkE construct expressed most robustly 
at 30°C (Figure 6.3.2).  
I also purified PrkE using Ni-NTA resin using the same protocol as done previously for 6xHis 
tagged proteins. During the purification, I noticed that a vast fraction of the SUMO-PrkE protein was in the 
pellet. This means that it is either in inclusion bodies or in the membrane fraction. Considering that I did 
not remove the predicted low complexity domains within the sensory input domain, it is not entirely 
surprising that the majority can be found within the pellet. However, I was able to obtain a small fraction 
that was soluble. While the majority of the protein prep is running around the predicted size of 69 kDa, 
there are some degradation products. I believe that the SUMO tag is being cleaved from this fraction, as 
there is a substantial band running at ~17 kDa, which is where the SUMO domain normally migrates 
(Figure 6.3.2).   
While the low yield meant that I needed to scale up my cultures, I was able to purify enough 
protein for an in vitro PrkE kinase reaction. I observed that PrkE was able to autophosphorylate robustly 
(Figure 6.3.2.1). I then obtained recombinant proteins of S. elongatus KaiA, KaiB, KaiC, and CikA from 








Figure 6.3.2 Expression and Purification of Full-length PrkE 
Figure 6.3.2 Expression and Purification of Full-length PrkE. Left Panel: I was able to induce SUMO-PrkE 
at all temperatures tested, however 30°C provided the most robust expression. Right panel is a 
representative purification gel that shows a majority of PrkE is in the pellet, however, I was able to elute 
SUMO-PrkE from the Ni-NTA resin.  
 
Figure 6.3.2.1 Autophosphorylation of SUMO-PrkE 
 
Figure 6.3.2.1. Autophosphorylation of 6xHis-SUMO-PrkE. Increasing concentrations of full-length 
SUMO-PrkE were incubated in the eSTK kinase buffer with 2 µCi γP32-ATP and 200 µM cold ATP for 30 
minutes at 37°C. 




































6.3.3 PrkE and Proteins Involved in S. elongatus Circadian Rhythm  
 
 In addition to asking whether CikA was a direct target of PrkE, our collaborators were also 
wondering if PrkE was able to directly phosphorylate any of the proteins that comprise the circadian clock, 
KaiA, KaiB, and KaiC. They also provided protein for KaiC mutants that contain amino acid substitutions 
in the threonine phosphorylation sites within KaiC that are important for maintaining the cyclic nature of 
the KaiABC oscillator with either alanine (KaiC AA) or glutamate (KaiC EE) residues [124]. I performed an 
in vitro kinase assay using full-length PrkE and the proteins they provided. 
 
Figure 6.3.3 PrkE Phosphorylates the Histidine Kinase CikA 
 
Figure 6.3.3 PrkE Phosphorylates the Histidine Kinase CikA. In vitro kinase assay with 1 µM SUMO-PrkE 
and 2µM of indicated substrates for 30 minutes at 37°C in the presence of 2µCi γP32-ATP. Samples were 
boiled at 95°C prior to loading to select for phosphothreonine, phosphoserine, and phosphotyrosine 
residues. I only observed phosphorylation of CikA by PrkE, as indicated with an asterisk.  
 










 PrkE was able to robustly phosphorylate CikA, consistent with the yeast two-hybrid data (Figure 
6.3.3). In contrast,  transphosphorylation of the KaiA, KaiB, and KaiC oscillator proteins was not 
observed. After noticing such robust CikA phosphorylation, I performed an in vitro kinase assay using 
cold ATP and submitted it to the Columbia Protein Core Facility for identificaiton of the phosphosites. The 
results from the mass spectrometry analysis are indicated in Table 6.3.3. 
 
  




Phosphorylated P/P + nonP 
 Sequence Residue (approx) Comment 
LAPSSNCSLASQR Ser-5 or Ser-9 0.014 
Evidence for Ser-5 and Ser-9; may 
be a mixture of both. 
FQQGETLLIDSVGFYK Thr-270 0.065 Confirmed 
VLERTQELIDALALAQAANAAK Thr-367 0.087 





Cannot determine if it's Thr-467 or 
Thr-469; may be a mixture of both 
FQQLDTSIR Thr-564 0.022 Confirmed 
FQQLDTSIRR Thr-564 0.34 Confirmed 
 
Table 6.3.3 Mass Spectrometry Analysis of CikA Phosphorylation by PrkE. Data provided by Dr. Mary 
Ann Gawinowicz at the Columbia Protein Core Facility.  The sequence on the left is the phosphopeptide 
identified. The phosphorylated residue is the residue she determined to be phosphorylated based off the 
spectra. If it is unclear, this is clearly indicated. In addition, the fraction of phosphorylated peptides over 
the total number of peptides provides an indication of the efficiency of phosphorylation.  
 
 Due to the large size of CikA, when preparing samples for submission to the Protein Core Facility 
I incubated them for 2 hours in the presence of excess cold ATP. I wanted to ensure that a large enough 
fraction of the protein sample was phosphorylated in order to obtain identification of the phosphorylated 
residue(s). My interpretation of the mass spectrometry data is that Thr 564 is the primary site of 
phosphorylation with Thr 476 /Thr 469 being possible sites of phosphorylation. Given the low abundance 
of the remaining phosphopeptides, they are likely not physiologically relevant. Since Thr 564 is within the 
histidine kinase ATPase domain, it could enhance the ability of CikA to bind ATP or catalyze the 
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autophosphorylation of the conserved histidine residue. However, these experiments are still underway 
and confirmation of Thr 564 by site directed mutation has not been performed. 
 
6.4 Discussion  
 I established conditions for the expression and purification of PrkE and established that PrkE 
phosphorylates CikA in vitro. We also identified several candidate phosphorylation sites on CikA that 
should be confirmed by amino acid substitutions. I did not observe direct phosphorylation of the circadian 
oscillator proteins KaiA, KaiB, or KaiC. The data suggests that PrkE might phosphorylate CikA in order to 
regulate circadian rhythms. This has been hinted at through epistasis analysis showing that a ΔprkEΔcikA 
strain has the same phenotype as a ΔcikA strain. The genetic data suggest that the phenotype of the 
ΔprkE strain is mediated by an absence of threonine phosphorylation of the histidine kinase, CikA. Thus 
my data provides further evidence that the eukaryotic-like Ser/Thr kinase, PrkE, converges with the CikA 
histidine kinase to regulate circadian rhythms in the cyanobacterium S. elongatus.  
 Further experiments are warranted to explore this interaction. I would initially make a kinase dead 
mutant of PrkE and determine if it replicates a ΔprkE strain, as this would prove that the phenotypes are 
dependent on the kinase activity of PrkE. Once confirmation of the phosphorylation sites of CikA by PrkE 
are confirmed in vitro, it would be interesting to make allelic replacement strains of CikA in S. elongatus 
and see if the allelic strains replicate a ΔprkE phenotype. In addition to confirming the physiological 
relevance of the phosphorylation modifications of CikA, it would be interesting to determine the biology of 
the eSTK, PrkE. What activates this eSTK, and how is it regulated? Which of the candidate eSTPs in the 








Chapter 7. General Conclusions and Future Directions 
 
7.1 PrkC/PrpC Converge with the WalRK TCS To Regulate Cell Wall Metabolism 
 
 In my initial efforts to understand PrkC-dependent yocH expression, I established that PrkC 
phosphorylates WalR, the essential response regulator, at T101. I demonstrated through a PyocH-GFP 
transcriptional reporter that PrkC-dependent yocH expression is dependent on phosphorylation of T101. I 
further showed that this is not specific to yocH, but that PrkC/PrpC regulate the entire WalRK two-
component system regulon. This phenotype is most apparent in stationary phase cultures, when WalK 
activity is thought to be the most minimal. This modification is also critical for the pellicle defect I observed 
in a ΔprpC strain. These phenotypes are consistent with a model where WalR T101~P synergistically 
activates the WalRK two-component system.  
 To understand the mechanistic implications of this T101 phosphorylation, I developed and 
performed in vitro biochemical experiments to determine which step in two-component system regulation 
was being altered. Since I observed both increased activation of positively regulated genes and increased 
repression of negatively regulated genes, I hypothesized that T101 phosphorylation was enhancing the 
binding of WalR to DNA and my experiments suggest that there is enhanced DNA binding of WalR 
D53~P T101~P to the Biotin-PyocH promoter by Electrophoretic Mobility Shift Assay. 
 T101 may be critical for dimerization, as it lies at the conserved α4-β5-α5 receiver domain 
dimerization interface [16]. Furthermore, this region has also been shown to be an important contact point 
between sensor histidine kinases and their cognate response regulators in co-crystals of T. maritima 
HK853/RR468 [44] and B. subtilis Spo0F/Spo0B [302]. Based off insights from the structures, I tested 
whether WalR and WalK could interact. While this interaction can be detected by the technique Surface 
Plasmon Resonance (SPR), the contribution of WalR T101~P was inconclusive. I developed both in vitro 
kinase assays and in vitro phosphatase assays of WalR/WalK to assay the influence of T101 
phosphorylation.  
I also sought to understand how the conformation of WalR was affected by T101~P. I observed 
that WalR that had been phosphorylated by PrkC had a distinct migration pattern by Native PAGE 
electrophoresis, suggesting that this modification alters the charge or size of the protein. This is also 
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reflected in the enhanced ability of WalR T101~P versus WalR to bind Biotin- PyocH promoter DNA in 
EMSAs. I adapted a tool commonly used by the response regulator field to assess response regulator 
D53~P, reverse phase HPLC, but I was unable to observe different elution profiles in WalR D53~P versus 
D53~P T101~P. However, this assay was performed under steady state conditions so I may have missed 
physiologically relevant changes. 
In the future, I would like to understand how T101~P mediates enhanced WalR activity in vivo. 
My current hypothesis is that T101~P stabilizes the active WalR dimer. To test this, I would like to take 
both in vivo and in vitro approaches. First, I would like to determine if WalR dimers are more stable in the 
presence of T101~P. I would propose phosphorylating WalR at D53 and determining if T101~P is able to 
stabilize these dimers over time. I can assess dimer stability by either reverse phase HPLC or by native 
PAGE electrophoresis. I would not be able to use the WalR T101S as a negative control, as it has some 
pleiotropic effects. However, the lab has a catalytically dead PrkC protein that could be used as a 
negative control for threonine phosphorylation. The prediction from these experiments would be that 
WalR dimers are more stable and last for a longer period of time if T101 has been phosphorylated. 
Second, to address the presence of active dimers in vivo, I am developing strains that are 
merodipoid for WalR. I have a strain with a C-terminal tagged WalR-Flag strain at its endogenous locus 
(discussed in Section 3.7.5) and I am in the process of constructing a C-terminal tagged WalR-strep tag II 
at the amyE locus under either its endogenous promoter or an inducible promoter. I will perform co-
immunoprecipitation experiments under native conditions to determine if I can obtain a higher percentage 
of heterodimers in the ΔprpC background as compared to wild-type. I will use the ΔprpCprkC strain to 
ensure that the ΔprpC effect I am observing is PrkC-mediated. Alternatively, I have developed methods 
based off Fukushima et al [86], to perform in vivo formaldehyde cross-linking to capture transient 
interactions, as dimers are thought to be relatively labile.  
 
7.2 T101 Phosphorylation as a General Mechanism of Regulation 
 While the exact mechanism of T101 phosphorylation remains elusive, I wanted to know if this 
modification was a more general mechanism of response regulator regulation by eSTKs. I performed a 
ClustalW alignment of B. subtilis response regulators and 23.5% of them contain a threonine at the same 
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position as WalR T101. I performed in vitro kinase assays with all threonine containing response 
regulators, as a control I also included CssR, which contains a serine at that position. 5/8 out of the 
response regulators tested were phosphorylated by PrkC in vitro. I generated mutant proteins with T101A 
substitutions to ask if the phosphorylation events observed were specific to T101 and only one response 
regulator, YvcP, was phosphorylated at a different amino acid(s).  
 However, the phosphorylation events I observed in vitro were typically much weaker than 
observed with PrkC and WalR. Therefore, it remains unclear if these modifications have any physiological 
relevance. One of the hits I obtained was PhoP, the response regulator involved in phosphate limitation 
and part of the PhoPR two-component system that cross-talks with the WalRK two-component system in 
vitro and in vivo [31, 109, 120]. I established qPCR conditions to test PhoPR regulon genes, and 
performed very preliminary experiments under low phosphate conditions that did not reveal an effect. 
However, I am unsure if PrkC is active under these conditions. Therefore, I think it would be interesting to 
more systematically dissect if PrkC and PrpC can interact with the PhoPR two-component system.  
 I also wanted to test conservation of WalR T101 phosphorylation by eSTKs in other low G+C% 
Gram-positive pathogens. I generated recombinant proteins of S. aureus PknB and S. aureus WalR, 
WalR T101A, and WalR T101S and observed PknB-dependent phosphorylation of WalR, specifically at 
T101. I obtained S. aureus ΔpknB and Δstp1 strains from Dr. Stefanie Donat, and observed that these 
strains also had opposing stationary phase phenotypes, similar to what was observed for ΔprkC and 
ΔprpC in B. subtilis. WalRK regulon genes are downregulated in a ΔpknB strain [66], suggesting this 
modification might be conserved and also contribute to stationary phase lysis. However, I did not observe 
stationary phase lysis in my unmarked walR T101S allelic replacement strains but I hypothesize that this 
may result from the manner in which the strains were constructed, which would facilitate the accumulation 
of suppressors. For example, both wt and ΔpknB strains will eventually lyse on plates, however, no lysis 
was ever visualized for the allelic replacement strains.  
 The importance of WalR T101 was recently reflected in a survey of Vancomycin Intermediate S. 
aureus (VISA) that showed amino acid substitutions of walR T101A and walR T101S [99]. The 
identification of these mutations suggested that T101 is in an important residue in WalR biology. I was 
able to restore a more vancomycin sensitive phenotype by restoring walR S101T in clinical isolate 8007. I 
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was further able to enhance vancomycin resistance when testing walR T101S in laboratory strains. These 
finding suggest that position T101 is a very important for regulation of WalR activity in vivo. At this point I 
do not know if these are PrkC-dependent or independent effects. Unlike B. subtilis, in which the walR 
T101S strain mirrors the ΔprkC strain, it is not the case for S. aureus. However, generation of strains in S. 
aureus is not as efficient as for B. subtilis and requires a lot of selective pressure, especially when 
modifying an essential locus. Therefore, it remains unclear if I have obtained suppressor mutations in our 
S. aureus strains.  
 In the future it would be interesting to determine if WalR T101~P occurs in S. aureus in vivo. The 
walR T101S allele seems to have some pleiotropic effects; however, I believe this is due to the 
accumulation of suppressors. I could generate an allelic replacement strain similar to the one generated 
in B. subtilis, thus minimizing the amount of suppressors in the final strain by moving the marked strain by 
phage transduction. Additionally, I should confirm down-regulation of WalRK regulon genes by qRT-PCR 
that had previously been identified in a ΔpknB microarray [66]. To confirm that this phosphorylation event 
occurs in vivo, I could perform immunoprecipitation of WalR and determine by mass spectrometry if 
threonine 101 is phosphorylated. This would confirm that T101~P is physiologically relevant in S. aureus.  
 
7.3 Threonine Phosphorylation Regulates the VanB-type Sensor Histidine Kinase, VanS 
 The E. faecalis eSTK, IreK, is a homolog of PrkC and PknB and contains the conserved 
intracellular eukaryotic-like Ser/Thr kinase domain and four extracellular PASTA domains that bind 
peptidoglycan fragments [237, 249]. Thus, I predicted that cell wall fragments released during 
vancomycin treatment activate IreK and its activation is critical for full induction of the VanRS two-
component system.  
 I found that IreK was able to specifically phosphorylate VanS at T223. This modification was 
found to be reversible as VanS T223~P is a substrate for the eSTP, IreP, in vitro. This is the first 
demonstration of IreP activity on a physiologically relevant substrate, besides IreK. I additionally showed 
that IreK was sensitive to staurosporine in vitro, and I could obtain single amino acid substitutions in the 
ATP binding site that result in reduced staurosporine sensitivity.  My plan was to use these alleles in vivo 
to demonstrate the specificity of staurosporine inhibition of the VanRS two-component system.  
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 In order to determine if IreK was involved in VanB-type vancomycin resistance, I took a qRT-PCR 
approach to monitor induction of the VanRS regulon genes, vanY and vanB. I observed that pre-treating 
cultures with staurosporine or simultaneously treating cultures with staurosporine, in addition to 
vancomycin, led to drastic inhibition of the VanRS regulon genes. Therefore, I propose a model in which 
IreK detects cell wall fragments released by vancomycin and activates the VanS histidine kinase through 
phosphorylation at T223.  
 To test this hypothesis in vivo, efforts to generate strains in E. faecalis that did not contain IreK 
were initiated. Dr. Florence Depardieu and I tried independent approaches to delete IreK from JH2-
2::Tn1549 but to no avail. In an alternative approach, Dr. Depardieu was able to transfer Tn1549 from C. 
symbiosum to OG1RFΔireK. She was never able to obtain transfer to the isogenic parental strain OG1RF. 
However, the vancomycin MIC of OG1RFΔireK::Tn1549 (JDB 3539) was much lower level than that of 
JH2-2::Tn1549, providing preliminary data that IreK may play an important role in VanB-type vancomycin 
resistance. Working with existing strains, I complemented E. faecalis OG1RFΔireK::TN1549 using the L. 
lactis P23 constitutive promoter driving IreK expression at an ectopic chromosomal locus. While I could 
restore normal cefotaxime sensitivity, I was unable to observe a substantial difference between the 
OG1RFΔireK::TN1549 versus OG1RFΔireK::TN1549 P23-ireK strains.  
 To date our current genetic attempts do not support our hypothesis, however, the low efficiency in 
which we were able to obtain OG1RFΔireK::Tn1549 and our inability to generate a ΔireK strain in JH2-
2::Tn1549 suggests to us that suppressors are present. I would like to test several alternative strategies 
in the future. First, is to generate allelic replacement strains of VanS T223A or T223D in JH2-2::Tn1549. 
Foucault et al, recently generated point mutations within Tn1549 using the pGhost9 vector system [82]. 
This suggests that I should be able to genetically manipulate the VanRS regulon. I would predict that a 
VanS T223A would behave like a ΔireK strain and have inhibited induction of the VanRS regulon. While 
in the past I have had variable success with phosphomimetics in vivo, it would be worth determining if a 
VanS T223D has faster kinetics or constitutive expression of the VanRS regulon genes. In addition, I 
could transform a plasmid, which has IreK under a constitutive promoter, and determine if IreK 
overexpression in JH2-2::Tn1549 leads to enhanced VanRS regulon activity in the absence of 
vancomycin. In addition, I could also generate a reporter strain in which only the VanRS structural genes 
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are moved, along with a transcriptional reporter for vanRS activity, similar to the bioluminescence also 
used in Foucault et al [82]. By taking only the structural genes instead of the entire transposon, I could 
more easily transfer these genes into a clean strain and assess transcriptional read-out.  
 Beyond genetic characterization of IreK phosphorylation of VanS, I also want to explore the 
mechanistic implication of VanS T223 phosphorylation. Thus far, I have been unable to observe 
differences in the autophosphorylation kinetics of VanS or VanS to VanR phosphotransfer kinetics. 
However, I do have preliminary data suggesting that T223 phosphorylation may reduce VanS 
phosphatase activity and thereby increase activation of the VanRS-dependent genes. Constitutive 
expression of VanS activity has previously been reported for a clinical isolate in which a six amino acid 
deletion was in the ATP binding pocket and also single amino acid substitutions within Tn1549 during in 
vitro selection with another glycopeptide, teicoplanin [60, 82]. Therefore I would like to further optimize the 
reaction conditions to further explore the idea that T223 phosphorylation leads to impaired phosphatase 
activity of VanS.  
 These experiments have shown that VanB-type vancomycin resistance is sensitive to the small 
molecule kinase inhibitor, staurosporine, in vivo. Staurosporine could be used in conjunction with 
vancomycin to sensitize E. faecalis VRE strains to vancomycin treatment in clinical settings. To further 
assess whether this phenomenon is specific to VanB-type vancomycin resistance, I am also interested in 
testing the in vivo inhibition of VanA-type vancomycin resistance by staurosporine. It is inducible like 
VanB-type, but also is able to respond to teicoplanin, and to a lesser degree to other cell wall acting-
antibiotics. Therefore, it would be interesting to address if IreK can interact in this other type of clinically 
relevant VRE.  
 Finally, I was able to show in vitro that CssS, the sensor histidine kinase that regulates cell 
membrane integrity in B. subtilis, is also a substrate of threonine phosphorylation by the eSTK PrkC. This 
suggests that regulation of two-component systems on the level of the sensor histidine kinase is a 
common regulatory mechanism. However, this is currently only speculative, as I would need to perform 





7.4 Biochemical Approaches to Study Uncharacterized Eukaryotic-like Ser/Thr Kinases and Two-
Component Systems Interactions 
   
 While I primarily studied how threonine phosphorylation regulated two-component systems 
involved in cell wall metabolism, I also took a biochemical approach to study Gram-negative eSTKs. Due 
to the complex of life cycle and highly regulated cell cycle control in C. crescentus, I wanted to study 
eukaryotic-like Ser/Thr kinases in this organism. eSTKs play important roles in developmentally regulated 
bacteria, such as Myxococcus xanthus. However, unlike the Gram-positive bacteria I studied in Chapters 
3, 4, and 6, C. crescentus does not contain Hank’s type eSTKs, but it does contain three HipA-like 
homologs. HipA eukaryotic-like Ser/Thr kinases are a member of the phosphatidylinositol 3/4 kinase 
superfamily. Structure-guided alignment of E. coli HipA with three C. crescentus HipA homologs indicates 
that they all have the conserved active site residue.  
The majority of the proteins for each of the over-expressed kinases was in inclusion bodies. I 
proceeded to perform denaturing purification and solubilized inclusion bodies, primarily containing our 
protein of interest and tested a panel of renaturing buffers to help facilitate refolding of these proteins. 
While a native purification resulted in a very poor yield, as the majority still ended up in the inclusion 
bodies, scaled up protocols yield sufficient amounts of C. crescentus HipA homologs for kinase assays. I 
observed autophosphorylation activity for CC2735 and CC2770, however I was never able to observe 
kinase activity of CC2386 using native or denaturing conditions. Therefore, it remains unclear if CC2386 
is a catalytically active kinase.  
In the future it would be important to address the role of these eSTKs in vivo especially since the 
transcriptional data from McGrath et al [172] shows that there may be temporal expression of these 
eSTKs. It would be interesting to see if there were any permutations in C. crescentus cell cycle 
progression in the absence of eSTKs. Furthermore, a phosphoproteomics approach could be used in wild 
type, Δcc2770, Δcc2386, and Δcc2735 genetic backgrounds to determine substrates of these eSTKs in 
vivo. It would be interesting to determine why overexpression of these kinases appears to be toxic in E. 
coli. Could the larger homologs, CC2770 and CC2735 substitute for HipA? It would also be interesting to 
know if their toxicity in E. coli is due to the kinase activity. This could easily addressed by an amino acid 
substitution in the kinase active site, similar to the D309Q substitution in E. coli HipA [50].  
  
169 
Another Gram-negative eSTK I studied was PrkE from Synechococcus elongatus PCC 7942. 
This work was done in collaboration with Dr. Michael Rust and Dr. Gopal Pattanayak. PrkE interacted with 
CikA, a bacteriophytochrome histidine kinase, in a yeast two-hybrid screen [157] and a ΔprkE strain 
exhibited irregularities in circadian rhythm phase setting that appeared to be upstream of CikA. I therefore 
generated a SUMO-PrkE construct that expressed robustly at 30°C and I obtained sufficient soluble full 
length PrkE for in vitro kinase assays. I found that PrkE phosphorylated CikA on at least one threonine 
residue within the histidine kinase ATPase domain. Future experiments are underway to study the role of 
the threonine modification in S. elongatus by Dr. Rust and Pattanayak. Experiments that I think are critical 
for dissecting this phosphorylation of CikA include confirmation of the threonine phosphorylation site(s) 
identified by mass spectrometry analysis by amino acid substitutions. After confirmation of these sites of 
modification, it would be interesting to determine if mutations of these residues in vivo would mirror a 
ΔprkE phenotype. It was also be important to verify the phenotype observed in a ΔprkE background is not 
due to protein-protein interactions independent of kinase activity. I would engineer an amino acid 
substitution in the kinase active site in order to ablate this activity. This could be tested in vitro prior to 
introducing this strain into S. elongatus. In conclusion, my work with the eSTK, PrkE, and the histidine 
kinase CikA provide promising preliminary data that the convergence of eukaryotic-like Ser/Thr signaling 
and two-component systems is important for regulation of circadian rhythm in the cyanobacterium S. 
elongatus. 
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Appendix A. Strains Used in This Study 
 




Strain Genotype Source 
B. subtilis PY79 Derivative Strains 
3 PY79 Lab Stock 
2341 ∆prkC (∆33-611)::erm Lab Stock 
2482 ∆prpC::tet (18-224)  Lab Stock 
2978 sacA:: PyocH(Howell)-GFP cm This work 
3002 amyE: PwalR- walR-Flag cm This work 
3095 amyE: PwalR-walR-Flag cm, walR::kan This work 
3106 amyE: PwalR-walR T101D-Flag cm, walR::kan This work 
3107 amyE: PwalR- walR T101A-Flag cm This work 
3110 amyE: PwalR- walR T101A-Flag cm walR::kan This work 
3113 amyE: PwalR- walR T101D-Flag cm walR::kan This work 
3187 walR-Flag Pspac::WalK erm This work 
3221 purA-kanR-walR T101A This work 
3224 purA-kanR-walR  T101S This work 
3226 purA-kanR-walR  This work 
3228 purA-kanR-walR T101A ∆prpC::tet This work 
3230 purA-kanR-walR  T101S ∆prpC::tet This work 
3232 purA-kanR-walR   ∆prpC::tet This work 
3235 purA-kanR-walR  T101A ∆prpC::tet sacA: PyocH-GFP cm This work 
3236 purA-kanR-walR  T101S ∆prpC::tet sacA: PyocH-GFP cm This work 
3237 purA-kanR-walR   ∆prpC::tet sacA: PyocH-GFP cm This work 
      
Strain Genotype Source 
B. subtilis trpC2 (PB2) Derivative Strains 
1772 wild type [88] 
1773 prpC∆1 [88] 
1774 prkc∆1 [88] 
1786 ΔprpC amyE::PyocH-lacZ cmR This work 
1787 ΔprkC amyE::PyocH-lacZ cmR This work 
3423 purA-kanR-walR  T101A This work 
3424 purA-kanR-walR  T101S This work 
3425 purA-kanR-walR  This work 
3580 walR-Flag Pspac::WalK erm This work 
3582 walR-Flag Pspac::WalK erm prpc∆1 This work 
3584 walR-Flag Pspac::WalK erm prkC∆1 This work 
   
   Strain Genotype Source 
B. subtilis 3610 Derivative Strains 
932 wild B. subtilis strain 3610 Lab Stock 
2666 ∆prkC::erm This work 
2667 ∆prpC::tet This work 
3146 amyE: PwalR-walR-Flag cm, walR::kan This work 
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3147 amyE: PwalR- walR T101A-Flag cm walR::kan This work 
3148 amyE: PwalR- walR T101D-Flag cm walR::kan This work 
3152 amyE: PwalR-walR-Flag cm, walR::kan ∆prpC::tet This work 
3153 amyE: PwalR- walR T101A-Flag cm walR::kan ∆prpC::tet This work 
3154 amyE: PwalR- walR T101D-Flag cm walR::kan ∆prpC::tet This work 
3410 purA-kanR-walR T101A This work 
3411 purA-kanR-walR T101S This work 
3412 purA-kanR-walR  This work 
3413 purA-kanR-walR T101A ∆prpC::tet This work 
3415 purA-kanR-walR  ∆prpC::tet This work 
   Strain Genotype Source 
E. coli  Protein Expression Strains 
890 BL21 (DE3) Lab Stock 
1601 pLG43 amp pAF461 cm - WalK 6his This work 
1591 pLG44 amp- WalR -6his This work 
1706 pLG89 amp - WalR T101D-6his This work 
1582 pSFP37 amp - 6his- PrkC KD This work 
1708 pLG98 amp - WalR T101A -6his This work 
1713 pLG103 amp- WalR T101S - 6his This work 
1604 pLG59 amp - PrkCKD-6his and WalR-6his This work 
1779 pLG140 amp pLG143 kan pBirA cm - WalK-Biotin This work 
1715 pSFP65 amp - PrpC-strep tag II This work 
1903 pLG202 amp PrpC D36N-strep tag II This work 
2394 pLG350 kan - 6his-SUMO-WalR REC This work 
2395 pLG351 kan - 6his-SUMO-WalR  This work 
 
Details of Construction 
 
JDB 2978: JDB 3 transformed with pLG55. Selected for cmR and confirmed by TSS sucrose plates and 
PCR. 
 
JDB 3002: JDB 3 transformed with pLG7.  Selected for cmR. Confirmed by starch plates.  
 
JDB 3095: JDB 3002 transformed with linearized pLG91 and selected for KanR.  
 
JDB 3106: JDB 3 transformed with pLG129 and selected for cmR.  
 
JDB 3107: JDB 3 transformed with pLG130 and selected for cmR. 
 
JDB 3110: JDB 3107 transformed with linearized plasmid pLG91 and selected for kanR.  
 
JDB 3113: JDB 3106 transformed with linearized plasmid pLG91 and selected for kanR.  
 
JDB 3187: JDB 3 transformed with pLG170 and selected for ermR on 100 µM IPTG.  
 
JDB 3221: JDB 3 transformed with overnight ligation of pLG225 (Xba1/Sal1) insert and pLG232 (Sal1/ 
Kpn1) insert. Selected for kanR.  
 
JDB 3224: JDB 3 transformed with overnight ligation of pLG225 (Xba1/Sal1) insert and pLG233 (Sal1/ 
Kpn1) insert. Selected for kanR. Confirmed by sequencing.  
 
JDB 3226: JDB 3 transformed with overnight ligation of pLG225 (Xba1/Sal1) insert and pLG231 (Sal1/ 




JDB 3228: JDB 3221 transformed with JDB 2482 genomic DNA and selected for tetR. 
 
JDB 3230: JDB 3224 transformed with JDB 2482 genomic DNA and selected for tetR. 
 
JDB 3232: JDB 3226 transformed with JDB 2482 genomic DNA and selected for tetR. 
 
JDB 3235: JDB 3228 transformed with JDB 2978 genomic DNA and selected for cmR.  
 
JDB 3236: JDB 3230 transformed with JDB 2978 genomic DNA and selected for cmR.  
 
JDB 3237: JDB 3232 transformed with JDB 2978 genomic DNA and selected for cmR.  
 
JDB 1786: JDB 1773 transformed with JDE 1683 (pDG1661-yocH) and selected for cmR. 
 
JDB 1787: JDB 1774 transformed with JDE 1683 (pDG1661-yocH) and selected for cmR. 
 
JDB 3423: JDB 1772 transformed with JDB 3410 genomic DNA and selected for kanR. 
 
JDB 3424: JDB 1772 transformed with JDB 3411 genomic DNA and selected for kanR. 
 
JDB 3425: JDB 1772 transformed with JDB 3412 genomic DNA and selected for kanR. 
 
JDB 3580: JDB 1772 transformed with JDB 3187 genomic DNA and selected for ermR.  
 
JDB 3582: JDB 1773 transformed with JDB 3187 genomic DNA and selected for ermR. 
 
JDB 3584: JDB 1774 transformed with JDB 3187 genomic DNA and selected for ermR. 
 
JDB 2666: JDB 932 transduced with SPP1 phage made from JDB 2341. Selected for ermR.  
 
JDB 2667: JDB 932 transduced with SPP1 phage made from JDB 2482. Selected for tetR.  
 
JDB 3146: JDB 932 transduced with SPP1 phage made from JDB 3095, first selected for cmR and then 
re-transduced with JDB 3095 for kanR.  
 
JDB 3147: JDB 932 transduced with SPP1 phage made from JDB 3110, first selected for cmR and then 
re-transduced with JDB 3110 for kanR. 
 
JDB 3148: JDB 932 transduced with SPP1 phage made from JDB 3113, first selected for cmR and then 
re-transduced with JDB 3113 for kanR. 
 
JDB 3152: JDB 3146 transduced with SPP1 phage made from JDB 2482. Selected for tetR.  
 
JDB 3153: JDB 3147 transduced with SPP1 phage made from JDB 2482. Selected for tetR.  
 
JDB 3154: JDB 3148 transduced with SPP1 phage made from JDB 2482. Selected for tetR. 
 
JDB 3410: JDB 932 transduced with SPP1 phage made from JDB 3221. Selected for kanR.  
 
JDB 3411: JDB 932 transduced with SPP1 phage made from JDB 3224. Selected for kanR.  
 
JDB 3412: JDB 932 transduced with SPP1 phage made from JDB 3226. Selected for kanR. 
 










Strains Used in Chapter 4 
 
Strain Genotype Source 
S. aureus Strains 
3399  8325 
 3400  8325 ∆pknB::erm [66] 
3401  8325 ∆stp1::erm [152] 
3426  Clinical isolate 8007 [99] 
3567  8325 walR T101S This work 
3568  8325 walR T101S This work 
3570  Clinical isolate 8007 walR S101T This work 
3571  Clinical isolate 8007 walR S101T This work 
   Strain Genotype Source 
E. coli Protein Expression Strains 
1854 pLG145 amp - YclJ-6his This work 
1855 pLG146 amp- YkoG-6his This work 
1856 pLG147 amp- YkrP-6his This work 
1857 pLG148 amp- YvcP-6his This work 
1858 pLG149 amp- CssR-6his This work 
1870 pLG151 amp- 6his- S. aureus PknB  This work 
1859 pLG152 kan- S. aureus WalR-6his This work 
1862 pLG158 amp- PhoP-6his This work 
1948 pLG178 amp- YvrH-6his This work 
1871 pLG185 amp- YkrP T100A - 6his This work 
1872 pLG186 amp- YclJ T99A-6his This work 
1873 pLG187 amp- YvcP T100A-6his This work 
1874 pLG188 amp- YkoG T103A- 6his This work 
1879 pLG189 amp- PhoP T102A-6his This work 
1876 pLG190 amp- YvrH T103A-6his This work 
1905 pLG199 amp- LytT-6his This work 
1906 pLG200 amp- LytT T101A- 6his This work 
1901 pLG201 kan- S. aureus WalR T101A-6his This work 
2342 pLG310 kan- S.aureus WalR T101S -6his This work 









Details of Construction 
 
Strains were constructed according to methods in Section 2.26. 
 
JDB 3567: JDB 3399 transformed with pLG334 (pIMAY-derivative vector) and selected for as described 
in Monk et al[178]. To facilitate screening we digested with AatII and then submitted for sequencing. 
Transformant #1. 
 
JDB 3568: JDB 3399 transformed with pLG334 (pIMAY-derivative vector) and selected for as described 
in Monk et al [178]. To facilitate screening we digested with AatII and then submitted for sequencing. 
Transformant #2.  
 
JDB 3570: JDB 3426 transformed with pLG335 (pIMAY-derivative vector) and selected for as described 
in Monk et al [178]. To facilitate screening we digested with AatII and then submitted for sequencing.  
 
JDB 3571: JDB 3426 transformed with pLG335 (pIMAY-derivative vector) and selected for as described 
in Monk et al [178]. To facilitate screening we digested with AatII and then submitted for sequencing.  
 
 
Strains Used in Chapter 5 
 
Strain Genotype Source 
E. faecalis Strains 
JDB Genotype Source 
3367  JH2-2 [82] 
3368  JH2-2 TN1549 (vanB) [82] 
3535 OG1RF [139] 
3537 OG1RF ∆ireK [139] 
3539 OG1RF ∆ireK ::TN1549 This work 
3641 CK111 [140] 
3698 CK111 + pLG364 This work 
3699 CK111 + pLG371 This work 
3700 CK111 + pLG372 This work 
3701 CK111 + pLG373 
 3663 OG1RF ∆ireK ::TN1549 P23-ireK This work 
3664 OG1RF ∆ireK ::TN1549 This work 
3669 OG1RF ∆ireK ::TN1549  P23-ireK T152F This work 
3670 OG1RF ∆ireK ::TN1549 P23-ireK T152F This work 
3671 OG1RF ∆ireK ::TN1549 P23-ireK T152M This work 
   Strain Genotype Source 
E. coli Protein Expression Strains 
2003 pLG226 amp - E. faecalis 6his-IreKKD This work 
2474 pLG227 amp - E. faecalis VanR-6his This work 
2004 pLG234 amp - E. faecium 6his- IreKKD This work 
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1986 pAT816 amp pAF461 cm - VanSKD-6his This work 
1985 pAT818 amp pAF461 - VanR-6his This work 
2280 pLG244 amp pAF461 - VanSKD T223A -6his This work 
2057 pLG246 amp - VanSKD S243A -6his This work 
2058 pLG247 amp - VanSKD T242D - 6his This work 
2064 pLG258 amp - VanSKD T223D T242D-6his This work 
2346 pLG323 amp - E. faecalis 6his- IreKKD T152F This work 
2348 pLG324 amp - E. faecalis 6his- IreKKD T152M This work 
2391 pLG346 kan- 6his-SUMO- VanSKD T223A This work 
2392 pLG347 kan- 6his-SUMO- VanSKD T223S This work 
2393 pLG349 kan- 6his-SUMO- VanSKD This work 
2450 pLG370 amp- E. faecalis IreP-6his This work 
2475 pLG352 amp - 6his-CssSKD This work 
 
 
Details of Construction  
 
Strains were generated using the method in Section 2.30.  
 
JDB 3698: JDB 3641 was electroporated with pLG364 and selected on BHI 10µg/ml erm and 200µg/ml X-
gal.  
 
JDB 3699: JDB 3641 was electroporated with pLG371 and selected on BHI 10µg/ml erm and 200µg/ml X-
gal.  
 
JDB3700: JDB 3641 was electroporated with pLG372 and selected on BHI 10µg/ml erm and 200µg/ml X-
gal.  
 





Strains Used in Chapter 6 
 
 
Strain Genotype Source 
E. coli Protein Expression Strains 
2145 pLG278 amp -CC2386 This work 
2146 pLG285 amp - CC2770 This work 
2147 pLG286 amp - CC2735 This work 
2441 pLG365 kan - 6his-PrkE This work 
      
   






Appendix B. Plasmids Used in This Study 
 
For SOE PCR products that were used in the generation of plasmids, the underlined primers are the 
outside primers used to SOE. 
 
Plasmids Used in Chapter 3 
 
For E. coli Replication 
Plasmid Purpose Content Source Vector 
pAF461 T7-GroLS 
GroLS from E. coli 
MG1655 




6his B. subtilis WalR T101S 
Mutagenesis of pLG43 w/ 
LG225/LG242 pETDUET 
pLG140 T7-WalK-Avitag 
B. subtilis WalK 
cytoplasmic domain PY79, LG279/LG129 pETDUET 
pLG143 T7-GroLS 
GroLS from E. coli 
MG1655 Sucbcloned from pAF461 pRSFDUET 
pLG202 
T7-PrpC (D36N) - 
streptag II B. subtilis PrpC D36N 
Mutagenesis of pSFP65 w/ 




B. subtilis WalR REC (1-
120) PY79, LG690/LG691 pSMT3 
pLG351 T7-6his-SUMO-WalR B. subtilis WalR PY79, LG690/LG692 pSMT3 
pLG43 T7-WalR-6his B. subtilis WalR PY79, LG130/LG150 pETDUET 
pLG44 T7-'WalK-6his 
Cytoplasmic domain of 




B. subtilis PrkC and B. 
subtilis PrkC Subcloned from pSFP37 pETDUET 
pLG89 
T7-WalR (T101D) -
6his B. subtilis WalR T101D 




6his B. subtilis WalR T101A 




pSFP37 T7-6his-PrkC KD 
Cytoplasmic domain of 
B. subtilis PrkC PY79, SFP59/SFP60 pETDUET 
pSFP65 T7-PrpC-streptagII B. subtilis PrpC PY79, SFP61/SFP62 pET11a 
For B. subtilis Strain Construction 
Plasmid Purpose Content Source Vector 
JDE683 PyocH-lacZ reporter yocH promoter (800bp) trpC2, oIMS55/oIMS56  pDG1661 
pLG7 
Tagged WalR under 
PwalR B. subtilis WalR-Flag PY79, LG66/LG67 pG1662 
pLG55 PyocH-GFP reporter 
yocH promoter fused to 
GFP 
PY79, LG140/LG139 + 
LG141/LG144 pSac-CM 
pLG129 
Tagged WalR T101A 
under PwalR 
B. subtilis WalR T101A-
Flag 
Mutagenesis of pLG7 w 
LG189/LG190 pG1662 
pLG130 
Tagged WalR T101D 
under PwalR 
B. subtilis WalR T101D-
Flag 








1kb upstream of WalRK 




WalRK promoter and 




WalRK promoter and 
WalR T101A 





WalRK promoter and 
WalR T101S 





Plasmids Used in Chapter 4 
 
 
For E. coli Replication 
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Plasmid Purpose Content Source Vector 
pLG145 T7-YclJ-6his B. subtilis YclJ PY79, LG298/LG299 pETDuet 
pLG146 T7-YkoG-6his B. subtilis YkoG PY79, LG300/LG301 pETDuet 
pLG147 T7-YrkP-6his B. subtilis YrkP PY79, LG302/LG303 pETDuet 
pLG148 T7-YvcP-6his B. subtilis YvcP PY79, LG304/LG305 pETDuet 
pLG149 T7-CssR-6his B. subtilis CssR PY79, LG306/LG307 pETDuet 
pLG151 T7-6his-PknB S. aureus PknB Newman, LG312/LG313 pET15b 
pLG152 T7-WalR-6his S. aureus WalR Newman, LG314/LG315 pET28b 
pLG158 T7-PhoP-6his B. subtilis PhoP PY79, LG318/LG319 pETDUET 
pLG178 T7-YvrH-6his B. subtilis YvrH PY79, LG338/LG339 pETDUET 
pLG185 
T7-YrkP T100A-
6his B. subtilis YrkP T100A 
Mutagenesis of pLG147 
w/ LG347/LG348 pETDUET 
pLG186 T7-YclJ T99A-6his B. subtilis YclJ T99A 
Mutagenesis of pLG145 
w/ LG341/LG342 pETDUET 
pLG187 
T7-YvcP T100A-
6his B. subtilis YvcP T100A 
Mutagenesis of pLG148 
w/ LG349/LG350 pETDUET 
pLG188 
T7-YkoG T103A-
6his B. subtilis YkoG T103A 
Mutagenesis of pLG146 
w/ LG345/LG346 pETDUET 
pLG189 
T7-PhoP T102A-
6his B. subtilis PhoP T102A 
Mutagenesis of pLG158 
w/ LG353/LG354 pETDUET 
pLG190 
T7-YvrH T103A -
6his B. subtilis YvrH T103A 
Mutagenesis of pLG178 
w/ LG351/LG352 pETDUET 
pLG199 T7-LytT-6his B. subtilis LytT PY79, LG321/LG322 pET11a 
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pLG200 T7-LytT T101A-6his B. subtilis LytT T101A 
Mutagenesis of pLG199 
w/ LG343/LG344 pET11a 
pLG201 
T7-WalR T101A-
6his S. aureus WalR T101A 
Mutagenesis of pLG152 
with LG357/LG358 pET28b 
pLG310 
T7-WalR T101S-
6his S. aureus WalR T101S 
Mutagenesis of pLG152 
with LG581/LG582 pET28b 
pLG312 T7-6his-Stp1 S. aureus Stp1 Newman, LG629/LG630 pET15b 
For S. aureus Replication 
Plasmid Purpose Content Source Vector 
pLG329 WalR (8325 AatII) 




pLG330 WalR (8007 AatII) 




pLG334 8325 AatII T101S 
S. aurues WalR T101S 
with AatII RE site 
LG666/LG580 + 
LG667/LG579 of pLG329 pIMAY 
pLG335 8007 AatII S101T 
S. aurues WalR S101T 
with AatII RE site 
LG640/LG667 + 




Plasmids Used in Chapter 5 
 
For E. coli Replication 
Plasmid Purpose Content Source Vector 
pLG226 T7-6his- IreKKD E. faecalis IreKKD JH2-2, LG455/LG456 pETDuet 
pLG227 T7-WalR-6his E. faecalis WalR JH2-2, LG457/LG458 pETDuet 
pLG234 T7-6his- IreKKD E. faecium  IreKKD 
E. faecium BM4484, 
LG459/ LG461 pETDuet 
pAT816 T7-6his-VanSKD VanB-type VanSKD   pET16/28 
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pAT818 T7-VanR-6his VanB-type VanR   pET16/28 
pLG244 T7-6his- VanSKD T223A VanB-type VanSKD T223A 
Mutagenesis of pAT816 w/ 
LG466/LG467 pET16/28 
pLG245 T7-6his- VanSKD T223S VanB-type VanSKD T223S 
Mutagenesis of pAT816 w/ 
LG464/LG465 pET16/28 
pLG246 T7-6his- VanSKD S243A VanB-type VanSKD S243A 
Mutagenesis of pAT816 w/ 
LG476/LG477 pET16/28 
pLG247 T7-6his- VanSKD T242D VanB-type VanSKD T242D 
Mutagenesis of pAT816 w/ 
LG474/LG475 pET16/28 
pLG258 
T7-6his- VanSKD T223D 
T242D 
VanB-type VanSKD T223D 
T242D 
Mutagenesis of pLG247 w/ 
LG468/LG469 pET16/28 
pLG323 T7-6his- IreKKD T152F E. faecalis IreKKD T152F 
Mutagenesis of pLG226 w/ 
LG644/LG645 pETDUET 
pLG325 T7-6his- IreKKD T152M E. faecalis IreKKD T152FM 




T223A VanB-type VanSKD T223A 




T223S VanB-type VanSKD T223S 
LG693/LG694 off of 
pLG245 pSMT3 
pLG349 T7-6his-SUMO- VanSKD VanB-type VanSKD 
LG693/LG694 off of 
pAT816 pSMT3 
pLG370 T7-IreP-6his E. faecalis IreP JH2-2, LG766/LG767 pETDUET 
For E. faecalis Strain Construction 
Plasmid Purpose Content Source Vector 
pLG358 L. lactis P23  
Lactococcus lactis P23 
promoter 
L. lactis MG1363, 
LG658/LG719 pSD15 
pLG359 P23-ireK 
E. faecalis IreK under P23 
promoter OG1RF, LG720/LG661 pSD15 
pLG364 P23-IreK Complentation 
E. faecalis IreK under P23 
promoter 
Subcloned from pLG359 






E. faecalis IreK T152M 
under P23 promoter 





E. faecalis IreK T152F 
under P23 promoter 
Mutagenesis of pLG364 w/ 
LG644/LG645 pRV1 
pLG373 IreK deletion construct 
1kb upstream and 
















































Appendix C. Oligos Used In This Study 
 



































































































































pIMAY FWD: GGTACCCAGCTTTTGTTCCCTTTAGTGAGG 
pIMAY REV: GAGCTCCAATTCGCCCTATAGTGAGTCG 
SFP59 TATCCATGGCTCATCATCATCATCATCATGCTctaatcggcaagcggatcagc 
SFP60 TATCTGCAGTTATCAttttcttttgccgttcttc 
SFP61 CTCCAAGCGCCGCACTGATCTTCACCC 
SFP62 CATATGTTGTTAACAGCCTTAAAAACAG 
 
